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Bariatric surgery has become an accepted, safe and durable method of weight loss for the 
obese patient. Despite this success, venous thromboembolism (VTE) continues to be one 
of the top two causes of mortality in bariatric surgery. Most bariatric surgeons today use a 
combination of non-invasive and pharmacologic techniques, including sequential 
compression devices, anti-embolic stockings, anticoagulation, and early ambulation, to 
prevent VTE. Despite these interventions, the incidence of VTE after bariatric surgery 
has been reported to be widely variable ranging from 0.3 to 3.8%. (1-11) The most recent 
study published to date reported an incidence of pulmonary emboli (PE) of 0.9%, deep 
venous thrombosis (DVT) without PE to be 1.3% and VTE (DVT + PE) to be 2.2% 
within the perioperative period. (12) Little data has been collected to evaluate the long 
term risk (greater than 30 days post-op) of VTE following bariatric surgery. Furthermore, 
the prevalence of asymptomatic deep venous thrombosis (DVT) in this population is 
unknown and is sure to be higher.  
Our main goal for this thesis was to study the effectiveness of current and future practices 
of venous thromboembolism prophylaxis in the bariatric surgical population. To do so, 
we first completed a narrative summary of the current agents and techniques used to 
prevent VTE in this population (Chapter one). We then analyzed a large administrative 
database to determine the long term risk and predictors for VTE in patients undergoing 
bariatric surgery using current VTE prophylaxis (Chapter two). We identified a history of 
previous VTE events as being the strongest predictor of development of a VTE post-
surgery.  This high rate of recurrence has led to the recommendation that patients with 
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prior VTE or other high risk groups should be considered for prophylactic vena cava 
filter insertion before surgery. This finding motivated us to specifically assess the 
efficacy and risks of IVC filters in the bariatric surgery population. We completed a 
retrospective analysis of a large administrative database to determine these risks and 
benefits (Chapter three). The body habitus of a bariatric surgical patient presents 
technical challenges in the detection of VTE, especially asymptomatic DVT in the pelvis 
and lower limbs. Because of the limited sensitivity and specificity of ultrasound in the 
detection of DVT in the obese patient, we performed a systematic review and meta-
analysis to determine the diagnostic accuracy of magnetic resonance venography in the 
detection of DVT in the obese (Chapter four). Based on these results above, we then 
designed a randomized double blinded controlled trial (RCT) to study the incidence of 
asymptomatic deep venous thrombosis in this special population. We compared two 
different anticoagulation regimens in the prevention of VTE in bariatric surgical 
patients:enoxaparin 40 mg subcutaneously twice daily (our standard regimen), and 
fondaparinux 5 mg subcutaneously once daily (a non-standard dose in the obese 
population, used under an IND obtained by Dr. Steele). We used MRV as a novel non-
invasive diagnostic tool to detect asymptomatic DVT in our patient population (Chapter 
five). In the final chapter, Chapter six, we discuss public health-based approaches and 
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Chapter 1 Introduction 
1.1 Defining Venous Thromboembolism  
VTE includes both deep vein thrombosis (DVT), blood clots that form in the deep veins 
of the body, and pulmonary emboli (PE), blood clots that form in the deep veins of the 
body and then break free and enter the arteries of the lungs. VTE affects all races, 
ethnicities, both genders and all age groups.(13) 
There is a fine balance between clot formation and fibrinolysis. Normally these two 
physiologic states are in dynamic equilibrium preventing patients from bleeding or 
clotting excessively. Numerous factors affect this delicate balance. These factors can be 
grouped into three broad categories, also known as Virchow’s triad (after the German 
physician Rudolf Virchow) (14):  
1. Vascular injury (endothelial damage) 
2. Activation of blood coagulation (hypercoagulability) 
3. Venous stasis 
Figure 1 Virchow’s Triad 
 
1.2 Burden of Venous Thromboembolism in the Bariatric Surgical Patient 
VTE and its sequelae constitute one of the most significant causes of morbidity and 
mortality in hospitalized and post-operative surgical patients. In the United States alone, 
an estimated 300,000 to 600,000 (1 to 2 per 1,000) patients each year are diagnosed with 
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VTE, and 60,000 to 100,000 die of VTE. (15) Among people who have had a DVT, one-
half will have long-term complications such as swelling, pain, discoloration, and scaling 
in the affected limb (post-thrombotic syndrome). (15, 16) Spyrpoulos et al completed a 
healthcare claims analysis on the economic burden of VTE and found that the cost of 
VTE ranges from $7594 to $16, 644 per patient.(17) This equates to a total annual cost of 
2 to 10 billion dollars. VTE is one of the top two causes of morbidity and mortality in the 
bariatric surgical patient. In the ninth edition of the Antithrombotic Therapy and 
Prevention of Thrombosis guideline published by the American College of Chest 
Physicians (2012), it is reported that virtually all bariatric surgical patients have at least a 
moderate risk of VTE, with many patients at high risk. (18, 19) Despite these impressive 
figures, there exists no FDA-approved or universally accepted protocol for 
pharmacologic VTE prophylaxis in morbidly obese patients. 
1.3 Etiology and Risk Factors for Developing Venous Thromboembolism 
As with many conditions, VTE is a multifactorial condition that involves genetic factors 
as well as acquired risk factors. Genetic factors include family history, factor V Leiden, 
protein C, S, and antithrombin deficiencies, prothrombin G20210A, and sickle cell trait. 
Acquired risk factors may be transient, such as pregnancy, use of birth control pills or 
hormonal therapy, trauma, immobilization, or surgery. Acquired risk factors may also be 
relatively immutable, such as advanced age, cancer, chronic disease, or obesity. (13) 
Patients undergoing bariatric surgery for the treatment of morbid obesity often have three 
or more risk factors (20, 21) and are therefore at high risk for a VTE event. In our 
retrospective analysis we identified male sex, advanced age, previous VTE, smoking, and 
long length of stay (>5 days) as risk factors for VTE. In a systematic review of venous 
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thromboembolism prophylaxis in obese patients, the authors concluded that “obese 
patients undergoing bariatric surgery have an increased risk for VTE that is greater than 
the risk of surgical procedure itself.”(22)  
The choice of open versus laparoscopic approach to bariatric surgery also affects the risk 
of VTE. Characteristics of the laparoscopic approach that increase the risk of VTE 
includes increased intra-abdominal pressure and decreased femoral venous flow, and 
characteristics that decrease the risk include milder derangement of the coagulation 
pathways, early ambulation, and faster recovery. (23) 
1.4 Prophylaxis of Venous Thromboembolism in Bariatric Surgical Patients 
To date, there remains no consensus as to the optimal regimen for prevention of VTE in 
the bariatric surgical patient. The approach to VTE prophylaxis used by most bariatric 
surgeons today is a combination of non-invasive and pharmacologic techniques, 
including sequential compression devices, anti-embolic stockings, anticoagulation, and 
early ambulation. In 2000, Wu and colleagues surveyed members of the American 
Society of Metabolic and Bariatric Surgery (ASMBS) and found that while virtually all 
of those who completed the survey practiced some form of DVT prophylaxis, nearly half 
nonetheless experienced patient mortality due to PE. They found considerable variation 
among surgeons with respect to preferred means of prophylaxis, and because of the 
relative infrequency of VTE they concluded that a multi-center, randomized trial would 
be needed to settle the issue. Unfortunately, such a trial would be very expensive, 
requiring a very large number of subjects. Furthermore, the existing protocol required by 
the FDA to assess the efficacy of prophylactic anticoagulation requires the use of lower 
extremity venography, which is very difficult to perform on morbidly obese patients due 
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to the difficulty of obtaining venous access in the lower extremities. Various investigators 
have attempted to use duplex ultrasound in place of venography to document adequacy of 
DVT prophylaxis. However, the sensitivity of duplex ultrasound in the general 
population is only 43% (with 97% specificity) and it is likely that the performance of this 
test is worse in the morbidly obese due to the technical challenges presented by the large 
lower extremities and abdominal pannus overlying the inguinal region. (24) 
In April 2004, a roundtable meeting sponsored by The Johns Hopkins University School 
of Medicine, in conjunction with Princeton Media Associates, was held to discuss the 
state of the art in prevention of VTE. This meeting involved 5 experts in the field 
including Dr. Michael Schweitzer, Johns Hopkins, Dr. Giselle Hamad, University of 
Pittsburgh, Dr. Raul Rosenthal, Cleveland Clinic, Dr. Eric DeMaria, Duke University, 
and Dr. Julio Teixeira, St. Luke’s Roosevelt Hospital. (25) A review of the meeting 
demonstrated significant inter-institution variability in the approach to VTE prophylaxis. 
Four out of the five surgeons used sequential compression devices plus anticoagulation. 
Two out of the five administered the first dose of anticoagulation before the start of the 
case. All five were in agreement that VTE prophylaxis should be continued in all patients 
at least until hospital discharge. The use of inferior vena cava filters (IVC filters) was 
also assessed, and four of the five surgeons strongly believed that a history of PE 
warranted the use of an IVC filter, while three of the five would also consider the device 
in patients with a history of DVT, obesity hypoventilation syndrome, severe leg edema, 
severe chronic venous stasis disease, or wheelchair bound status.  
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Because of this, best practices for VTE prophylaxis in bariatric surgical patients are 
unfortunately based not on evidence but on the experience and opinion of experts in the 
field. 
1.5 Narrative Summary of Methods of VTE Prophylaxis  
1.5.1 Non-pharmacologic VTE Prophylaxis 
According to the American College of Chest Physicians VTE guideline for non-
orthopedic surgical patients, non-pharmacologic prophylaxis includes early and frequent 
ambulation or mobilization, and mechanical prophylaxis such as graduated compression 
stockings (GCS), intermittent pneumatic compression (IPC), or sequential compression 
devices (SCDs). (26) IPC devices are designed to decrease venous stasis, improve blood 
flow, and increase the level of circulating fibrinolysins (proteolytic enzymes derived from 
blood plasminogen that cause breakdown of the fibrin in blood clots). The advantage of 
IPC devices over chemoprophylaxis is that there is no monitoring involved, with no 
increase in bleeding and they are in general well tolerated. (27) The disadvantage of IPC 
devices is that one size does not fit all and in patients with extremely large lower limbs 
there may not be an IPC device that fits correctly. In addition, their use is contraindicated 
in patients with lower limb DVT or injury.  
Most studies of bariatric surgical patients in the literature recommend some form of 
mechanical prophylaxis in combination with chemoprophylaxis. When there is an 
increased risk of bleeding complications, most would favor the use of mechanical 
prophylaxis, preferably IPC, over no prophylaxis until the risk of bleeding decreases and 
pharmacologic prophylaxis may be resumed. Several studies have questioned the need for 
chemoprophylaxis at all when mechanical prophylaxis has been used properly. Gagner et 
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al. completed a prospective observational study utilizing the Longitudinal Assessment of 
Bariatric Surgery (LABS) data which includes a cohort of 10 clinical sites within the 
United States between 2005 and 2007. (28) The authors compared bariatric surgical 
patients who received anticoagulation therapy during their index hospitalization to those 
who received only mechanical prophylaxis. Of the 4416 patients, 396 received SCDs 
alone, and the remaining 4020 received anticoagulation therapy. Interestingly, the 
incidence of VTE within 30 days was higher in the anticoagulation group than in the 
mechanical prophylaxis group.(28) Clements et al. had similar outcomes in their 
prospective study of 957 consecutive patients undergoing laparoscopic Roux-en Y gastric 
bypass by a single surgeon. The authors concluded that adequate VTE prophylaxis can be 
achieved using calf-length IPC devices with early ambulation and short operative times. 
They further went on to state that pharmacologic anticoagulation is not mandatory when 
the above conditions are met and the patient has no previous history of VTE.(7) While 
these studies have promoted the use of mechanical prophylaxis alone, it should be noted 
that both of these studies did not include high-risk bariatric surgical patients and there are 
far more studies with stronger evidence that recommend the use of mechanical 
prophylaxis in conjunction with chemoprophylaxis. 
1.5.2 Chemoprophylactic VTE Prevention 
To date there remains no class 1 evidence to formulate specific recommendations 
regarding the use of anticoagulation medication. The American College of Chest 
Physicians recognizes three main drug classes: heparin, including low-dose 
unfractionated heparin (UFH) and low-molecular weight heparin (LMWH), fondaparinux 
(anti-factor Xa inhibitor), and aspirin. 
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Aspirin acts as an effective platelet inhibitor at low doses (50-100mg daily). It acts on 
the cyclooxygenase-1 and prevents thrombosis. Scientists and physicians have considered 
aspirin for possible VTE prophylaxis. Unfortunately, the results have not measured up 
(29) and the American College of Chest and Physicians Guidelines do not recommend 
the use of aspirin alone as prophylaxis for VTE for any patient population.(26) 
Unfractionated Heparin (UFH) was first discovered by Mclean (a second year medical 
student at Johns Hopkins University) in 1916. (30) It is a naturally occurring 
polysaccharide and is derived from either porcine intestine or bovine lung. UFH binds to 
antithrombin (AT) III and enhances AT to inactivate factors IIa, Xa, IXa, and XIIa. This 
then prevents the conversion of prothrombin to thrombin and fibrinogen to fibrin. (31) 
UFH consists of polysaccharide molecular chains of varying lengths (5000 to 40,000 
Daltons). Heparin is administered intravenously or subcutaneously but is inactivated in 
the GI tract. It binds non-specifically to various plasma proteins and therefore causes an 
unreliable dose-response. It has a rapid onset of action and a short half-life. Intravenous 
administered heparin is measured by the activated partial thromboplastin time (aPTT).  
Low Molecular Weight Heparins (LMWH) are obtained by fractionating or 
depolymerizing unfractionated heparin through various chemical or enzymatic processes 
creating short chains of polysaccharides that have an average molecular weight of less 
than 8000 Daltons (32). LMWH also binds to and enhances the activity of AT, but has a 
preferential and longer lasting effect on factor Xa and does not selectively bind to 
specific proteins like heparin. As a result this drug is more predictable and has less inter-
patient variability, and has a longer duration of action when compared to heparin and the 
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risk of developing DVT is significantly reduced. (33-35) LMWHs do not require 
monitoring of either aPTT or INR. 
There are numerous varieties of LMWH based on their molecular weight and include 
Enoxaparin, Dalteparin, Nadroparin, Parnaparin, Certoparin. Bemiparin, Reviparin and 
Tinzaparin. Enoxaparin is the most commonly used and studied LMWH in the bariatric 
literature. It is derived from the intestinal mucosa of pigs.  
Fondaparinux is a synthetic pentasaccharide factor Xa inhibitor. Fondaparinux inhibits 
factor Xa by selectively binding to antithrombin III (AT), a blood protein responsible for 
inactivating enzymes in the clotting cascade. When fondaparinux sodium is introduced 
into the circulatory system it binds to AT and effectively neutralizes its activity. This in 
turn disrupts the blood coagulation cascade and prevents thrombin formation. (36) 
Fondaparinux has no direct effect on thrombin. It is administered subcutaneously and has 
a long half-life. While this medication cannot be used in patients with renal impairment, a 
potential advantage of fondaparinux over LMWH or unfractionated heparin is a greatly 
reduced risk for heparin-induced thrombocytopenia (HIT).(37) 
Whereas fondaparinux directly prevents DVT formation by selective binding to a specific 
protein, enoxaparin indirectly prevents DVT formation by prolonging the natural lag 
phase of thrombin formation in the body. (38) 
New Oral Anticoagulants (NOACs) are currently available for prophylaxis against 
venous thromboembolism in patients undergoing total hip or knee replacement surgery. 
Dabigatran etexilate (Pradaxa) is a direct thrombin inhibitor which inhibits both free and 
fibrin-bound thrombin. Randomized controlled trials have shown that dabigatran is as 
effective in the prevention of VTE in total hip replacement.(39) Rivaroxaban (Xarelto) is 
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an orally activated direct factor Xa inhibitor (4 hours after the dose is taken and the factor 
Xa activity does not return to normal for 24 hours thus once daily dosing is possible). 
(40) This drug has FDA approval for the initial treatment of DVT and PE and for the 
prevention of recurrent DVT and PE. Apixaban (Elquis): Like Rivaroxaban, Apixaban is 
a direct factor Xa inhibitor. Apixaban first became available in Europe in 2011 and is 
used there for preventing venous thromboembolism in hip and knee surgery. This drug is 
used in the United States presently for reducing the risk of stroke and PE in patients with 
atrial fibrillation. (41) 
A recent review and meta-analysis of these new oral anticoagulants has concluded that 
they were equally as good as enoxaparin but did have a higher bleeding tendency. The 
drugs did not differ significantly for efficacy and safety.(42) NOACs do not require 
routine coagulation monitoring and seem to be the way of the future for ease of 
administration efficacy and tolerability. Additional research is needed to determine how 
these new oral anticoagulants should be used in special populations such as the obese 
medical or surgical patient. (See Chapter 6 for future projects proposed) 
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Figure 2 Mechanism of Action of Anticoagulants 
*Derived from Dwek et al 2012 (43) 
The most widely used agents for the prevention of VTE in the bariatric surgical 
population include UFH and LMWH, more specifically enoxaparin.(21, 22, 44, 45) 
Currently, there are no direct comparative studies (RCTs) to evaluate these anticoagulants 
in the prophylaxis of bariatric surgical patients. There is one recent RCT which 
randomized 258 patients to two different doses (4250 vs. 6400 IU subcutaneous daily) of 
parnarparin (a drug not used within the United States). They concluded that 4250 IU 
daily was preferable for use in the prevention of VTE in bariatric patients, as the higher 
dose caused excessive bleeding.(46) Several cohort studies have compared heparin to 
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enoxaparin.(47, 48) Kothari et al compared enoxaparin 40 mg twice daily to UFH 5000 
units every 8 hours. One PE event occurred in the UFH group and none in the LMWH 
group. However, there was significantly more bleeding within the LMWH group, and the 
authors concluded that heparin was the safer choice. Birkmeyer et al used a state-wide 
registry and found similar results (48) but concluded that enoxaparin was safe and 
effective for use of VTE prevention. The ASMBS has recommended either UFH or 
LMWH as suitable choices for VTE prevention. (11) 
A large systematic review, which included 30 published papers that reported various 
combinations of UFH, LMWH and mechanical prophylaxis, concluded that the most 
effective regimen in the bariatric surgical population was either UFH 5000 IU every 8 
hours or enoxaparin 30 to 40 mg every 12 hours, and that the dosing should start pre-
operatively in combination with sequential compression devices. (49) 
Controversy exists regarding the use of anti-factor Xa levels in obese patients, as varying 
doses and frequencies of administration of enoxaparin, including 0.5 mg/kg once-daily 
(3), 60 mg twice daily vs. 40 mg twice daily (4), and 40 mg twice daily, have yielded 
inconsistent results.(50) These discrepancies may be due to the indirect nature of 
enoxaparin on thrombin activity. The inter-subject variability of factor Xa and platelet 
levels in obese patients may affect the mechanism of action of enoxaparin, as more or 
less drug may be needed to achieve prolongation of the lag phase of thrombin production. 
With this in mind the general consensus at this time is that weight-adjusted dosing of 
UFH or LMWH provides no clear advantage with respect to VTE prevention and may 
increase the incidence of bleeding. (51, 52)  
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Limited data have been published on extended prophylaxis in the bariatric population. In 
2008, Raftopoulos et al. reported a 4.5 % VTE rate in patients receiving perioperative 
VTE prophylaxis only, vs. with no VTE observed in patients who received extended 
prophylaxis. (53) In 2010, a study carried out in England reported a 0% VTE rate in 
patients who received extended prophylaxis with dalteparin (LMWH).(54) The question 
as to what the long term risk of VTE is in the bariatric population had not been 
determined and this is what motivated the aims for Chapter 2.  
1.5.3 Inferior Vena Cava Filters 
The first IVC filters to be used were permanent and included the Mobin Udin filter. (55) 
In the 1980s, Dr. Lazar Greenfield and engineers developed the Greenfield IVC filter. 
(56) Today, technically better filters are available that are retrievable, and are deployed 
by interventional radiologists and vascular surgeons to prevent life threatening PEs in 
high risk patients. The American College of Chest Physicians recommends the use of 
retrievable filters for patients in whom anticoagulation is contraindicated. There remains 
great controversy in the bariatric surgical literature and with the ASMBS as to the 
indications for IVC filter use in the bariatric surgical patient. This was a motivations for 
our research described in Chapter 3. 
1.6 Duration of Prophylaxis 
The optimal duration of anticoagulation has been addressed in a clinical trial: the 
ENOXACAN II study. (57) This was not a study in bariatric patients but was conducted 
in patients with cancer undergoing abdominal or pelvic surgery. Using venography, the 
study found that 6 to 10 days of enoxaparin therapy resulted in a VTE rate of 12 percent, 
while an additional 21 days of therapy reduced the rate to 4.8 percent. While this study 
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was both randomized and blinded, it is of questionable applicability as the patients 
studied had cancer and were not morbidly obese.  
1.7 Summary 
Currently there is no high level of evidence to guide our management of perioperative 
venous thromboembolism prophylaxis in the morbidly obese patient population. There is 
a general consensus among experts in the field that some form of anticoagulation therapy 
should be given for the duration of the hospital stay. However, the specific agents and 
dosing vary depending on the surgeon, the institution, and his or her experience. Special 
considerations should be given to patients with additional risk factors. In 2013, the 
ASMBS issued a consensus statement with recommendations for VTE prophylaxis. This 
included: 1) all bariatric patients are at moderate risk for VTE and prophylaxis should be 
used, 2) factors that place patients into a high risk category include high BMI, advanced 
age, immobility, prior VTE, known hypercoagulable conditions, obesity hypoventilation 
syndrome, pulmonary hypertension, venous stasis disease, hormonal therapy, expected 
long operative time or open approach and male gender, 3) individual practices should 
adhere to a standard VTE protocol, 4) mechanical prophylaxis is recommended for all 
bariatric patients, 5) early ambulation is recommended, 6) the combination of mechanical 
and chemoprophylaxis should be considered based on clinical judgment and risk of 
bleeding, 7) there is conflicting data regarding the type of chemoprophylaxis, though the 
highest level of evidence available suggests that low molecular weight heparin (LMWH) 
offers better VTE prophylaxis than unfractionated heparin (UFH) without increased 
bleeding risk, 8) most postdischarge VTE events occur within the first 30 days after 
surgery, so extended VTE prophylaxis should be considered despite insufficient data to 
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recommend a specific dose or duration, and 9) the use of IVC filters as the only method 
of prophylaxis before bariatric surgery is not recommended, though filter placement may 
be considered in combination with chemical and mechanical prophylaxis for selected 
high risk patients in whom the risks of VTE are determined to be greater than the risks of 
filter-related complications. (11) 
1.8 Specific Aims and Outline of Thesis Content  
Chapter 2 
1. To estimate the risk of late VTE, defined as greater than 30 days post-operatively in 
bariatric surgical patients.  
2. To identify specific characteristics that predicts an increased risk of VTE in bariatric 
surgical patients. 
Hypothesis: The risk of VTE in bariatric surgical patients will remain significantly 
elevated beyond the 30 day post-operative period. Certain demographic characteristics 
and pre-existing medical conditions will predict an increased risk of VTE in the bariatric 
surgical patient. 
Brief Methodology: We will perform a retrospective analysis based on a large 
administrative data base to determine the long term risk of VTE and predictors for VTE 




1. To determine the incidence of post-operative complications related to the use of IVC 
filter placement in the bariatric surgical patient.  
Hypothesis: Patients who undergo IVC filter placement prior to having bariatric surgery 
will have an increased risk of post-operative complications including post-operative 
bleeding and extended length of stay. 
Brief Methodology: To perform a retrospective analysis based on a large administrative 
data base to determine the incidence of post-operative complications related to the use of 
IVC filter placement in the bariatric surgical patient.  
Chapter 4 
1. To determine whether MRV is an effective diagnostic tool in the detection of 
suspected (symptomatic or asymptomatic) lower limb and pelvic DVT. 
Hypothesis: MRV is an underutilized non-invasive diagnostic tool for the detection of 
DVT. It should be considered for use in special populations such as the obese patient. 
Brief Methodology: We performed a systematic review and meta-analysis of all 
previously published observational studies that compared MRV to modalities used in the 
detection of VTE utilizing the Cochrane guidelines. 
Chapter 5 
1. To compare the effectiveness and safety of enoxaparin versus fondaparinux in the 
prevention of perioperative VTE in the bariatric surgical patient. 
2. To conduct a pilot study using magnetic resonance venography to estimate the 
incidence of asymptomatic DVT in bariatric surgical patients receiving enoxaparin versus 
fondaparinux during their perioperative hospitalization.  
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Hypothesis: Once daily dosing of fondaparinux will be as effective and safe to use as 
twice daily enoxaparin in the peri-operative prevention of VTE in the bariatric surgical 
patient. The incidence of asymptomatic DVT, especially within the pelvis of bariatric 
surgical patients (obese patients) will be higher than previous recorded studies have 
revealed.  
Brief Methodology: We performed a randomized double blinded controlled trial 
comparing 40 mg of subcutaneous enoxaparin twice daily with 5mg of subcutaneous 
fondaparinux sodium once daily during bariatric surgical patient's initial hospitalization. 
Two weeks following surgery the bariatric surgical patient underwent MRV to detect the 
presence of absence of asymptomatic DVT.  
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Chapter 2 Long Term Risk of Venous Thromboembolism in the Bariatric Surgical 
Patient 
2.1 Abstract 
Background: Venous thromboembolism (VTE) is a leading cause of morbidity and 
mortality following bariatric surgery. The exact duration and magnitude of post-surgery 
risk for VTE, however, is unclear. We analyzed a large administrative database to 
determine the long term risk and predictors for VTE in patients undergoing bariatric 
surgery. 
Methods: A private insurance claims database was used to identify 17,434 patients who 
underwent bariatric surgery. Longitudinal data were available for each patient for up to 
12 months post-surgery. We used logistic regression to identify independent predictors 
for VTE events. 
Results: The incidence of VTE during the index surgical hospitalization was .88%. This 
rate rose to 2.17% at one month and 2.99% by 6 months post-surgery. Over 74% of VTE 
events occurred after discharge. Risk factors identified for VTE developing by 6 months 
post-surgery included male sex (odds ratio (OR) = 1.68; confidence limits (CL) = 1.37-
2.07), age > 55 years (OR = 2.18; CL =1.56-3.03), smoking (OR = 1.86; CL = 1.06-3.27), 
and previous VTE (OR = 7.48; CL = 5.78-9.67). The laparoscopic adjustable gastric band 
(LAGB) was less likely to result in VTE compared to open or laparoscopic gastric bypass 
(OR = .31; CL = .13-.75). 
Conclusions: The period of increased risk for VTE following bariatric surgery extends 
well beyond the initial hospital discharge and 30 days post-surgery. The high frequency 
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of VTE up to 6 months following bariatric surgery suggests that more aggressive 
extended prophylaxis should be considered in patients at higher risk for VTE. 
2.2 Introduction 
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and 
pulmonary embolus (PE) is a significant cause of morbidity and mortality in hospitalized 
and postoperative patients (20). An estimated 900,000 fatal and nonfatal VTE events 
occur in the United States per year, representing a leading cause of preventable death in 
hospitalized patients (58). An increasing awareness of the public health implications of 
VTE has led to numerous initiatives aimed at primary prevention. In 2008, the Acting 
Surgeon General of the United States issued a “Call to Action to Prevent Deep Vein 
Thrombosis and Pulmonary Embolism”(59). The Surgical Care Improvement Project 
(SCIP), a nationwide initiative to improve perioperative outcomes, includes appropriate 
VTE prophylaxis and routine VTE risk stratification as key quality of care indicators 
(60). Traditional risk factors for VTE in patients undergoing surgery include previous 
VTE, advancing age (> 40 years old), general anesthesia/major surgery, relative 
immobility, malignancy, tobacco use, oral contraceptive agents, and coagulation 
disorders (20). 
Obesity has also been noted to be an independent risk factor for venous thrombosis. 
Accordingly, patients undergoing bariatric surgery for the treatment of morbid obesity 
often have three or more risk factors (20, 21) and are considered to be at high risk for a 
VTE event. The clinical significance of VTE is underscored by several reports suggesting 
that pulmonary embolus is the leading cause of death after bariatric surgery (61-63). The 
incidence of VTE after bariatric surgery has been reported to range from 0.2 to 3.8 
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percent (1-6, 8-10, 39, 44, 53, 64). This wide variation in rates may be due to the fact that 
most studies represent single institution series with relatively small study populations and 
with variable follow up and study design. Large population based studies using 
administrative data sets have reported overall VTE rates of less than one percent (1, 2, 
64). Most of these reports, however, lack longitudinal follow up and focus only on the 
surgical admission or a short time period after discharge. Several investigators (3, 21, 44, 
53) have noted that the majority of VTE events may occur after the initial hospital 
discharge and therefore may not be accounted for in studies that lack or have variable 
extended follow up. Understanding the timing of VTE events after surgery and duration 
of risk is critical to help guide measures to prevent VTE occurrence. 
We hypothesized that the risk for VTE after bariatric surgery extends well beyond the 
initial hospitalization and traditional thirty day postoperative window. Using a large 
administrative database, our aim was to define the prevalence and timing of VTE events 
after bariatric surgery and identify risk factors for VTE events. 
2.3 Materials and Methods  
2.3.1 Study Design 
We performed a retrospective cohort study in which we measured the cumulative 
incidence of VTE occurring over a one year period after bariatric surgery utilizing a 
private insurance claims database. 
2.3.2 Dataset 
The data were provided by Blue Cross/ Blue Shield (BCBS) of Tennessee, Highmark, 
Inc.(of Pennsylvania), BCBS of Michigan, BCBS of North Carolina, Independence Blue 
Cross (of Pennsylvania), Wellmark BCBS of Iowa, Wellmark BCBS of South Dakota, 
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and BCBS of Hawaii. All individuals with one of these seven plans as their primary 
insurer were eligible for inclusion in the dataset. The claims data used in this study were 
de-identified in accordance with the Health Information Portability and Accountability 
Act definition of a limited dataset. The dataset includes approximately 3.4 million insured 
lives over a five year period (2002-2006) and includes information on enrollee age, sex, 
enrollment dates, and inpatient and outpatient claims for reimbursement for billable 
health care services. These data include patient diagnoses as identified by ICD-9 codes 
and Diagnosis Related Groups, and medical procedures classified by CPT and ICD-9 
procedure codes.  
2.3.3 Study Cohort 
All patients in the dataset who had gastric bypass or LAGB surgery from 2002-2005 were 
eligible for inclusion in the study, as identified by diagnostic and procedural codes. 
Additional criteria for inclusion were patient age 18-65 years and continuous insurance 
coverage for at least 6 months prior to and 6 months after bariatric surgery. Prior to 2005, 
no specific CPT code for laparoscopic gastric bypass was available. Laparoscopic cases 
were identified by the appropriate bariatric surgery code as well as an associated 
laparoscopic procedure code and diagnostic code for morbid obesity. Patients were 
excluded if they had a diagnosis of gastrointestinal or pancreatic malignancy in the 
setting of a bariatric procedure code since these operations were more likely performed 
for the treatment of cancer rather than obesity. 
2.3.4 Statistical Analysis 
Our main outcome measure was the occurrence of VTE at various time points after 
bariatric surgery (during the index surgical admission as well as 1, 6, and 12 months after 
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surgery). The ICD-9 codes utilized for PE included 415.1-.19 and codes for DVT 
included 453, 453.0-.9. At 6 months after surgery, various demographic and surgical 
variables were evaluated as potential risk factors for VTE including age, sex, type of 
bariatric procedure, previous history of VTE, preoperative history of smoking or oral 
contraceptive use, and length of stay (LOS) during the index surgical admission. Data 
were compared using chi-square analysis and multivariate logistic regression analysis.  
All statistical analyses were performed using SAS Software version 9.1 (SAS Inc., Cary, 
North Carolina). 
2.4 Results 
A total of 17,434 patients were identified who had gastric bypass or LAGB surgery and 
met all inclusion criteria for the study.  These patients make up the study cohort.  A 
subset of this group (16,929 patients) also had continuous insurance coverage up to 12 
months after surgery and was used for data analysis at this time point.  The overall group 
was predominately female (82%) with a mean age of 43 years and an average LOS for 
the index surgical admission of 2.91 days. Open gastric bypass was the most common 
procedure (n=11,123), followed by laparoscopic bypass (n=5695) and LAGB (n=616). 
Cumulative rates for VTE as well as the subgroup of patients developing a PE are 
presented in Table 2.  During the index surgical admission, 153 patients (0.88 %) 
developed a VTE event.  When analyzed by type of VTE, 91 patients developed DVT 
only, 55 developed PE only, and 7 developed both DVT and PE by the time of hospital 
discharge.  By 6 months after surgery, a total of 522 patients (2.99%) were coded as 
having had a VTE event (DVT only = 324; PE only = 127; DVT and PE = 71).  Of the 
579 patients developing a VTE event in the first year after surgery, only 26% occurred 
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during the index surgical admission. The majority of VTEs occurred after hospital 
discharge with 64% developing by one month and 88% by 6 months after surgery. 
Risk factors for a VTE occurring by 6 months post-surgery are presented in Table 3. 
Patients experiencing a VTE were significantly more likely to be male, age 55 years or 
older, have had a previous VTE, smoke, or have a long length of stay after surgery 
compared to patients without a VTE event. Oral contraceptive agent use among female 
patients was similar in the VTE and no-VTE groups; data on post-menopausal estrogen 
replacement were not available.  
We also analyzed the data by looking at the incidence of VTE for each risk factor. By 6 
months after surgery, men were significantly more likely to develop a VTE compared to 
women (4.7% vs. 2.6%; p<.001). Advancing age was also a risk factor for VTE (Fig. 3) 
with a VTE rate in patients 55 years or older of 4.7% (<55 years=2.7%; p<.001). All age 
groups had significantly higher VTE rates compared to the <24-year old group (p<.05). 
Long length of stay during the index admission (5 days or greater = 5.6% vs. <5 
days=2.5%) and a history of previous VTE (previous VTE=21% vs. no previous 
VTE=2.4%) were also significantly associated with VTE occurrence after surgery 
(p<.001). Although relatively few patients were coded as smoking tobacco, this was 
associated with higher rates of VTE at 6 months (5.1% vs. 2.9%; p<.05). 
Type of bariatric procedure also appeared to impact the rate of VTE (Table 4).  LAGB 
surgery was associated with a lower rate of VTE (0.8%) compared to laparoscopic (2.7%) 
and open (3.3%) gastric bypass (p< .01).  No significant difference in VTE rates was 
found when open and laparoscopic gastric bypass procedures were compared. 
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On multivariate logistic regression analysis, the likelihood of a VTE by 6 months after 
surgery was associated with male sex (odds ratio (OR) = 1.69; 95% confidence interval 
(CI) = 1.37-2.07), long LOS (OR = 1.82; CI = 1.51-2.18), previous VTE (OR = 7.48; CI 
=5.78-9.67), smoking (OR = 1.86; CI = 1.06-3.27), and advancing age (OR = 2.18; CI = 
1.56-3.03).  Patients undergoing LAGB were less likely to develop a VTE (OR = .31; CI 
= .13-.75). 
2.5 Discussion 
In this study, utilizing a large insurance claims database we demonstrated that the risk for 
VTE after bariatric surgery extends well beyond the initial hospitalization.  Only 26% of 
VTE events occurring in the first 12 months after surgery were evident by the time of 
hospital discharge.  Over one third of VTEs occurred after 30 days post-bariatric surgery, 
a traditional time point for reporting perioperative complications.  We identified male 
sex, advancing age, previous VTE, smoking, and long length of stay as risk factors 
increasing the likelihood of VTE.  LAGB appeared to lower the likelihood of VTE when 
compared to gastric bypass. 
Previous studies examining the incidence of VTE post-bariatric surgery have reported 
rates ranging from .2 to 3.8 percent (1-6, 8-10, 39, 44, 53, 64).  Our observed incidence 
of VTE by 6 months (2.99%) and 12 months (3.42%) after surgery is similar to rates 
reported by others (3, 8, 10) of 3.4 - 3.8%.  Many studies, however, have reported VTE 
rates of less than 1%.  The reason for this wide variation may be related to relatively 
small patient numbers in some single institution series as well as incomplete follow up.  
Studies utilizing large administrative datasets such as the National Inpatient Sample 
(NIS) (1), University Health Consortium (UHC) (2), and National Surgical Quality 
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Improvement Program (NSQIP) (64) have reported VTE rates of .35%, .43%, and .59% 
respectively.  These studies, however, lack longitudinal follow up beyond the index 
surgical admission (NIS and UHC) or 30 days post-surgery (NSQIP) and therefore fail to 
account for VTE events after these short time periods.  The strengths of our study include 
a large study cohort of over 17,000 patients and complete longitudinal follow up of each 
patient for at least 6 months post-surgery.  Interestingly, a recent study by Encinosa et al 
(4) using a similar insurance claims based dataset involving 7060 patients reported a VTE 
rate at 6 months post-bariatric surgery of  2.5%, similar to our observed rate.  
Our finding that the majority of VTE events occur after hospital discharge has important 
clinical implications.  Pharmacologic thromboprophylaxis with low-molecular-weight or 
unfractionated heparin has been recommended during the index hospitalization after 
bariatric surgery in order to prevent VTE (20, 65). In a survey of members of the 
American Society for Metabolic and Bariatric Surgery, Barba et al (66) found that 95% 
of surgeons used some form of pharmacologic prophylaxis perioperatively during the 
initial hospital admission. There is little consensus, however, on the role of extended 
thromboprophylaxis after discharge. Our observation of the continued risk for VTE after 
discharge has been reported by others. In a study by Hamad and Choban (21), seven of 
668 patients undergoing bariatric surgery developed a VTE, all occurring post discharge.  
Other studies have also noted that the majority of thrombotic events after bariatric 
surgery occurred post discharge (once pharmacologic prophylaxis had been stopped).(3, 
6, 44, 53) These findings suggest that extended pharmacologic thromboprophylaxis for 
up to 4 weeks after discharge may be warranted in certain high risk patients undergoing 
bariatric surgery.  Randomized controlled trials in other high risk groups for VTE such as 
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patients undergoing cancer surgery (57) suggest that 30 days of extended 
thromboprohylaxis can significantly reduce VTE events.  
We identified several risk factors impacting the likelihood of VTE after bariatric surgery.  
Males were at significantly higher risk for VTE, a finding which has been noted by 
others.(6) This may be related, in part, to the relative increased central and intra-
abdominal deposition of fat in males which may lead to venous stasis and impaired 
venous return. Advancing age was also noted to be a risk factor for VTE. This was 
evident in all age groups compared to patients less than 24 years old. Age greater than 40 
years is a traditional risk factor for VTE and our data suggest this relative risk extends to 
patients age 30 to 40 years as well. Because estrogen use has been associated with VTE 
risk (20), we examined the risk of VTE in subjects reporting and not reporting oral 
contraceptive use. While no difference in risk was found, we were unable to determine 
whether contraceptive agents had been stopped prior to surgery. Furthermore, we were 
unable to obtain data on postmenopausal estrogen use.  
The type of bariatric surgery performed also appeared to influence VTE risk, with LAGB 
lowering the odds of VTE compared to gastric bypass. This was not surprising since the 
LAGB is in general a less invasive procedure with shorter operating times, shorter length 
of stay, and quicker return to full activity. We found no difference in VTE rates 
comparing laparoscopic and open gastric bypass.  Some investigators have noted less 
VTE risk with laparoscopic bypass (2, 67), while others have found no difference 
between the open and laparoscopic techniques.(5, 21, 64)  The laparoscopic approach 
involves steep reverse trendelenburg positioning and pneumoperitoneum, both of which 
may impede venous return and increase the potential for venous thrombosis. This may be 
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offset, however, by the association of open surgery with increased tissue trauma and 
inflammatory cytokine production as well as slower return to full activity, potentially 
increasing the risk for VTE.(2) 
In the present study, we identified a history of a previous VTE event as being the 
strongest predictor of development of a VTE post-surgery. Patients with a history of a 
prior VTE were over eight times more likely to develop another VTE (21%) compared to 
those with no prior VTE events (2.5%). Consistent with our findings, Prystowsky et al (3) 
and Gonzalez et al (8) reported VTE rates of 33% and 19%, respectively following 
bariatric surgery in patients with a previous history of VTE. This high rate of recurrence 
has led to the recommendation that patients with prior VTE or other high risk groups 
should be considered for prophylactic vena cava filter insertion before surgery. (68) It is 
unclear, however, whether vena cava filters provide adequate protection against PE and 
DVT. It is also unclear how long such filters should be kept in place to maximize anti-
embolic benefit. Lower extremity venous duplex screening prior to discharge has been 
proposed to better select those patients most likely to benefit from extended 
thromboprophylaxis or vena cava filter placement. However, most clinical VTE events 
occurring after discharge appear to arise from clots that occurred de novo following 
discharge.(3)  
Our study is one of the largest to date reporting on VTE rates after bariatric surgery with 
longitudinal post-surgery follow up of 12 months.  We recognize, however, several 
important limitations. This was a retrospective review utilizing an insurance claims 
database with the potential for errors in diagnostic and procedural coding. We were 
unable to account for potential variations in the use, duration, and type of 
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thromboprophylaxis after surgery, which could impact VTE occurrence. The number of 
laparoscopic gastric bypass procedures is likely underestimated in this study due to the 
lack of a specific procedural code prior to 2005. In addition, body mass index (BMI) data 
were not reliably available in the database and therefore we are unable to comment if 
increasing BMI above 40 is an independent risk factor for VTE. Previous studies have 
reported that increasing BMI or “super obesity” increases the likelihood of VTE (5, 6), 
while others have not found this relationship. (8) Finally, our data did not show whether 
the VTE events in our population resulted in clinically significant outcomes, such as 
death or prolonged disability. Nonetheless, we feel that the morbidity accompanying 
VTE is sufficiently well established that such events can be assumed to have significant 
consequences for many patients.  
2.6 Significance 
Patients undergoing bariatric surgery are at significant risk for VTE. Previous studies 
may have underestimated this risk by focusing primarily on the immediate perioperative 
period. We have found that the risk of VTE extends well beyond the initial 
hospitalization with the majority of VTE events occurring after discharge, with over one-
third occurring more than four weeks post-surgery. Risk factors identified on multivariate 
analysis for VTE after bariatric surgery include male sex, advancing age, smoking, long 
length of stay and history of prior VTE. LAGB was associated with lower incidence of 
VTE compared to gastric bypass. Extended post discharge thromboprophylaxis or vena 























Figure 3 Incidence of VTE at 6 Months Post-op Grouped by Age 
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Chapter 3 Prophylactic Inferior Vena Cava Filters in Patients Undergoing Bariatric 
Surgery: Does the Benefit Outweigh The Risk? 
3.1 Abstract 
Background: Pulmonary embolism remains a major risk after bariatric surgery. Current 
practice is to identify patients who are at high risk for VTE and place an inferior vena 
cava (IVC) filter preoperatively to prevent postoperative pulmonary embolism. The 
purpose of this study is to analyze postoperative complications in bariatric surgical 
patients receiving a preoperative IVC filter. 
Methods: Retrospective data from 2002 to 2008 was queried from the national BC/BS 
bariatric surgery database.  972 patients were identified as having an IVC filter placed 
prior to bariatric surgery.  These patients were case-matched by age, gender, and type of 
surgery to non-IVC filter patients.  A multivariate logistic regression analysis was 
performed using the SAS statistical package. 
Results: Seven hundred and eighty-nine of the 972 IVC filter patients were case matched 
to 1,578 non-IVC filter patients. Seventy-one percent of all patients underwent open 
gastric bypass, 22% underwent laparoscopic gastric bypass, and 7% underwent 
laparoscopic adjustable band. Forty-two percent of patients who received a pre-operative 
IVC filter had a history of VTE within one year prior to bariatric surgery. The risk of 
postoperative VTE in the IVC filter group was 16.7% and in the non-IVC filter group 
was 10.7%. The length of stay for IVC filter patients was greater (3.12 days vs. 2.77 
days; p=0.0198). Post-operative bleeding (29% vs. 13.6%; p=0.0001) was significantly 
higher in the filter group. All postoperative complications combined were higher in the 
filter group (84% vs. 76.6%; p < 0.0002), but mortality within one year of surgery was 
statistically equivalent in the filter and non-filter groups (0.38% vs. 0.25%, p=1.0).  
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Conclusions: This study is one of the largest retrospective analyses to date of bariatric 
patients who underwent preoperative IVC filter placement. While complication rates 
were higher in those who underwent a preoperative IVC filter, mortality rates for both 
groups were nearly equivalent. Interestingly, the presence of an IVC filter is strongly 
associated with development of VTE within one year postoperatively.  
3.2 Introduction 
Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and laparoscopic adjustable 
gastric banding have become established as safe and effective surgical procedures for 
morbid obesity. The overall mortality rate is low at 1% or less in many series, with 
pulmonary embolism and anastomotic leak as the first and second leading causes of 
death.(69, 70) Despite widespread use of perioperative prophylaxis for venous 
thromboembolism with sequential compression devices, anti-embolic stockings, 
anticoagulation, and early ambulation, the incidence of symptomatic pulmonary 
embolism remains between 0% and 6.4%. (71, 72) A systematic review that included 19 
studies of VTE rates following bariatric surgery reported the incidence of pulmonary 
emboli to be 0.5%. (51)  Birkmeyer et al. and Finks et al. utilized the Michigan Bariatric 
Surgery Collaborative Database and reported VTE rates of less than 0.5% in average risk 
bariatric surgical patients. (48) While the incidence of symptomatic VTE appears to be 
low, a post-mortem study of gastric bypass patients showed that while only 20% had 
been clinically diagnosed with pulmonary emboli prior to death, 80% had evidence of 
pulmonary emboli that were thought to have contributed to their morbidity and 
mortality.(73) This finding suggests that venous thromboembolism remains an 
underappreciated complication. Patients undergoing bariatric surgery are classified as 
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moderate to high risk for having a thrombotic complication according to American Chest 
Physicians guidelines.(26) Despite its importance, to date there exists no consensus 
regarding agent, dose, and duration of chemoprophylaxis for the prevention of VTE.
 
To reduce rates of death from pulmonary embolism after bariatric surgery, other 
prophylactic modalities have been tried, including mechanical compression devices 
combined with early ambulation and chemoprophylaxis. A less commonly used modality 
is preoperative placement of an inferior vena cava filter those patients deemed at highest 
risk. Among trauma patients, a significant reduction in the incidence of pulmonary 
emboli from 17 to 2.5 % has been demonstrated with the use of prophylactic IVC filter 
placement in patients with three or more risk factors.(74) A recent systematic review in 
2013 confirmed these findings, supporting the association of IVC filter placement with a 
lower incidence of PE and fatal PE in trauma patients. (75) However, the evidence for 
benefit of inferior vena cava filters in the bariatric surgical population is less clear. 
Keeling et al reviewed their experience with IVC filter placement in 14 gastric bypass 
patients and reported no filter-related complications or pulmonary emboli. Based on this 
very small series, the authors recommended routine preoperative filter placement in all 
bariatric patients with prior pulmonary embolus, prior deep venous thrombosis, evidence 
of venous stasis, or a known hypercoagulable state. (76) More recent studies including a 
systematic review reported less favorable results with regards to using IVC filters in the 
bariatric surgical population.(52, 77)  The aim of this study was to determine the 
incidence of post-operative complications related to the use of IVC filter placement in the 




3.3.1 Study Design 
We performed a retrospective cohort study using administrative claims data.  
3.3.2 Data 
We accessed claims data from seven Blue Cross Blue Shield health plans providing 
coverage in Western Pennsylvania, Philadelphia, South Dakota, Iowa, Hawaii, Michigan, 
North Carolina, and Tennessee. All individuals with one of these seven plans as their 
primary insurer were eligible for inclusion in the dataset.  The claims data used in this 
study were de-identified in accordance with the Health Information Portability and 
Accountability Act (HIPAA) definition of a limited dataset, ensuring confidentiality of 
enrollee health information. The study was also approved by the Johns Hopkins 
Institutional Review Board. Patient diagnoses were identified by ICD-9 codes and 
Diagnosis Related Groups, and medical procedures by Current Procedural Terminology 
(CPT) and the International Classification of Diseases (ICD-9) procedure codes. We 
queried the data base for all bariatric surgical patients from 2002 to 2008 and identified 
seven hundred and eighty-nine patients as having an IVC filter placed prior to bariatric 
surgery. These patients were case-matched 1:1 by age group (18-24, 25-34, 35-44, 45-54 
and 55-65), gender, and type of surgery to non-IVC filter bariatric surgical patients. To 
control for seasonality of outcomes, IVC and non-IVC filter patients were also matched 
by date of surgery. 
 
3.3.3 Analytic cohort 
An analytic cohort was created by restricting the above data to persons between the ages 
of 18 to 64 years inclusive, based on the National Institutes of Health (NIH) adult criteria 
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for bariatric surgery, who had at least 6 months of continuous insurance coverage prior to 
the date of bariatric surgery. Bariatric surgical patients were identified by the ICD-9 
procedure and CPT codes listed in Appendix A.2 using methods and codes from 
previously published literature. (78)  For four of the ICD-9 codes, we required that a code 
for morbid obesity (ICD-9-287.1) be present concurrently with the procedure. We 
excluded patients with a concurrent primary diagnosis of ulcer disease, as these patients 
were probably undergoing gastric bypass for ulcer disease and not obesity. Those with a 
diagnosis of cancer of the esophagus (ICD-9 150-150.9), stomach (ICD-9 151-151.9), 
small intestine (ICD-9 152-152.9) or pancreas (ICD-9 157-157.9), or malignant neoplasm 
without specification of site ICD-9 (199-199.2) were also excluded. We also excluded 
individuals with codes for gastric bypass revision procedures prior to the index bariatric 
surgery code (suggesting that this was not the first bariatric procedure and would put the 
patient at greater risk due to presumed increased operative time). (Appendix A.2) As 
well, we excluded patients undergoing biliopancreatic diversion with or without duodenal 
switch and sleeve gastrectomy procedures because of the relative infrequency of these 
procedures during this time period from 2002 to 2008 (<2% and <3% respectively). 
Laparoscopic cases were identified by the appropriate bariatric surgery code as well as an 
associated laparoscopic procedure code and diagnostic code for morbid obesity. Prior to 
2005, no specific CPT code for laparoscopic gastric bypass was available. Patients were 
excluded if they had a diagnosis of gastrointestinal or pancreatic malignancy in the 
setting of a bariatric procedure code since these operations were more likely performed 
for the treatment of cancer rather than obesity.
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3.3.4 Data Collection and Outcomes 
Patient characteristics collected included 1) enrollment files with administrative data 
(date of birth, gender, state and enrollment periods); 2) benefits information that included 
pharmacy and medical coverage; and 3) claims records containing International 
Classification of Disease (ICD-9) diagnoses, and ICD-9 procedure codes. The claims 
were used to identify bariatric surgery cases, types of surgery, obesity related diagnoses 
and complications.  
Our main outcome measure was post-operative VTE, defined as pulmonary embolism or 
deep venous thrombosis, at two time points after bariatric surgery (during the index 
surgical admission and up to 12 months after surgery).  The ICD-9 codes utilized for PE 
were 415.1-415.19, and for DVT were 453 and 453.0-.9. Secondary outcome measures 
included other post-operative complications: bleeding (requiring > 2 units of blood), 
surgical site infection (wound and port site infections or wound dehiscence), 
cardiovascular events (myocardial infarction, arrhythmia, or stroke), respiratory events 
(pneumonia requiring antibiotic treatment or respiratory failure requiring 2 or more days 
of intubation), reoperation, and death. Various demographic and surgical variables were 
evaluated as potential risk factors for VTE including age, sex, type of bariatric procedure, 
previous history of VTE, preoperative history of diabetes, hypertension, use of 
anticoagulation and length of stay (LOS) during the index surgical admission.  
3.3.5 Statistical Analysis 
All complications were treated as binary events. Data were compared using chi-square 
analysis. Additionally, we used multivariate logistic regression to estimate the relative 
odds of the occurrence of each complication in the IVC filter group relative to the non-
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IVC filter group. Models were adjusted for baseline characteristics including age, gender, 
type of surgery, length of stay, use of anticoagulation pre-operatively, previous VTE, and 
comorbidities including diabetes, hypertension and sleep apnea.  All statistical analyses 
were performed using SAS Software version 9.1 (SAS Inc., Cary, North Carolina). 
3.4 Results 
From 2002 to 2008, we initially found 972 IVC filter patients. Of these, 789 had 
complete data and were case matched to non-IVC filter patients (n=789). Matching 
within the cohort resulted in fairly well balanced groups on all baseline characteristics 
(Table 5). The mean age of the cohort was 46.5 (IVC=46.7 and non-IVC=46.3. The 
majority of the cohort was female (74.4%). Seventy-one percent of patients underwent 
open gastric bypass, 23% underwent laparoscopic gastric bypass, and 7% underwent 
laparoscopic adjustable band. The length of stay for IVC filter patients was greater (3.12 
days vs. 2.77 days; p=0.0198). Extended length of stay, defined as greater than 5 days for 
gastric bypass patients and greater than one day for band patients, was significantly more 
common among IVC filter patients (21.2% vs 16.5%; p=0.017). There were more patients 
with a diagnosis of diabetes (39% vs. 31%; p=.003), hypertension (68% vs. 62%; 
p=0.009) and sleep apnea (39% vs. 35%; p=0.118) in the IVC filter patients than in the 
non-IVC patients. Ten percent of patients who received a pre-operative IVC filter had a 
history of PE within one year prior to bariatric surgery (p=.002).  There was no difference 
in the number of patients who were on anticoagulation therapy (warfarin) prior to surgery 
(p=0.81) 
With regards to outcomes (Table 6) IVC filter patients had significantly higher rates of 
post-operative VTE (16.7% vs. 10.7%; p=0.0006) and DVT (13.9% vs. 8.4%; p=0.0004) 
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than matched controls (non-IVC filter patients).  While rates of pulmonary embolism 
post-operatively were higher among IVC filter patients, this was not statistically 
significant (4.4% vs. 3.8%; p=0.08).  The rates of postoperative VTE among the IVC 
filter and non-IVC filter groups were 16.7% and 10.7%, respectively.  The occurrence of 
any postoperative complication was higher in the filter group than the non-filter group 
(84.03% vs. 76.6%; p < 0.0002), but mortality within one year of surgery was statistically 
equivalent in the two groups (0.38% vs. 0.25%, p=1.0).  Bleeding post-operatively was 
significantly higher among IVC filter patients (29% vs. 13.6%; p < 0.0001). Wound 
infection (20.4% vs. 17.5%; p=0.157), re-operation (7.9% vs. 6.6%; p=0.33), and 
respiratory complications (29.9% vs. 27%; p=0.29) were also higher in the IVC filter 
group, but this was not statistically significant. After adjusting for patient characteristics 
including demographics (age, gender, type of surgery, length of stay) and medical 
comorbidities (diabetes, hypertension, sleep apnea, anticoagulation use, previous VTE 
history), patients who had an IVC filter placed prior to bariatric surgery had 2 times 
increased risk of developing a post-operative DVT (OR 2.01, CI 1.4-2.5; p=0.0001) and 
almost 3 times the increased risk of bleeding (OR 2.97, CI 2.3-2.9; p=0.0001). (Table 7) 
3.5 Discussion 
Bariatric surgical patients are classified as moderate to high risk for VTE by the 
American College of Chest Surgeons (AMCS). As such, bariatric surgeons have a low 
threshold when considering the approach to very high risk patients who are scheduled to 
undergo bariatric surgery. While there is no consensus as to the definition of a high risk 
patient, most of the published literature are in general agreement and include patients 
with a body mass index (BMI) greater than 55 kg/m
2
, obesity hypoventilation syndrome, 
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pulmonary hypertension, venous stasis, severe lymphedema and leg swelling, history of 
previous VTE, hypercoagulable state (Sickle Cell anemia, Protein C, S and Factor V 
Leiden Deficiencies), and immobility. (79-83)  The American Society for Metabolic and 
Bariatric Surgery (ASMBS) has recommended in their latest position statement that filter 
placement may be considered in combination with chemical and mechanical prophylaxis 
for selected high risk patients only when the risk of VTE is thought to be greater than the 
risk of filter related complications. (11) 
3.5.1 Clinical Motivation for Study Topic 
Our current study was prompted by our own Bariatric Center’s experience with IVC 
filters. The following case in particular stands out, suggesting that further studies are 
needed to help form standard guidelines on VTE prophylaxis in the high risk bariatric 
surgical patient, more specifically on the indications for IVC filter placement.(84) 
A morbidly obese 63 year old white female presented to our center for laparoscopic roux-
en-Y gastric bypass. Her past medical history was significant for gastroesophageal reflux 
disease with Barrett’s esophagus, hypertension, hypothyroidism, degenerative joint 
disease, urinary stress incontinence, hiatal hernia, and history of previous pulmonary 
embolism.  At the time of her pulmonary embolus, nine years prior to the operation, an 
evaluation for hypercoagulability was performed and no abnormalities were found. The 
etiology of her pulmonary embolus was thought to be due to hormone replacement 
therapy and obesity.  
She weighed 284 lbs and had a calculated body mass index (BMI) of 45 kg/m
2
. Her 
cardiac and pulmonary examinations were normal, and her abdomen was notable only for 
obesity. Her lower extremities were warm with palpable pulses and no edema or evidence 
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of venous stasis.  Preoperative evaluation, including laboratory investigations, 
electrocardiogram, and nocturnal polysomnography were all within normal limits.  Her 
only risk factor for placement of a retrievable inferior vena cava (IVC) filter was history 
of previous PE. The filter was placed by our vascular surgery team on the day prior to 
surgery. As recommended by the ASMBS position statement, she also received 
chemoprophylaxis of enoxaparin 40 mg subcutaneously 2 hours prior to the procedure. 
Anti-embolism (TED) stockings and sequential compression devices (SCDs) were placed 
on her lower extremities. A laparoscopic Roux-en-Y gastric bypass and hiatal hernia 
repair were performed uneventfully. Postoperatively, the patient received enoxaparin 40 
mg subcutaneously twice a day. TED stockings and SCDs were continued. She was 
encouraged to ambulate on the day of surgery. On postoperative day 2, a screening lower 
extremity duplex ultrasonography was completed revealing no evidence of thrombosis, 
and the patient was discharged to home on ursodiol 300 mg twice daily,  ranitidine 150 
mg orally twice daily, and levothyroxine 0.125 mg once daily. 
Two weeks postoperatively the patient presented to clinic with a complaint of weakness 
and left lower extremity pain. Vital signs were within normal limits and physical exam 
revealed a benign abdomen and no lower extremity swelling nor tenderness.  Laboratory 
studies revealed a normal chemistry panel and a hematocrit of 40.7. The patient was 
admitted to hospital with a working diagnosis of dehydration and possible deep venous 
thrombosis. Lower extremity and pelvic duplex ultrasonography was negative for 
thrombosis. The patient received only intravenous hydration. The following day she was 
feeling better and tolerating her gastric bypass diet, and she was discharged to home. 
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Two days following discharge the patient had a witnessed syncopal episode at home. She 
was found unconscious by paramedics, with a heart rate of 130 and had a systolic blood 
pressure of 154. On arrival to the emergency department, she was found to be 
bradycardic and hypotensive, and progressed to cardiac arrest. She was intubated and the 
Advance Cardiac Life Support protocol was initiated with atropine and epinephrine. 
Intravenous access could not be established, and the patient expired. Laboratory studies 
obtained during resuscitation were notable for a hematocrit of 29.2, creatinine of 1.5 
mg/dl, and bicarbonate of 8 mEq/L. Postmortem examination revealed an IVC filter 
completely occluded by thrombus. Small bilateral pulmonary emboli were present but 
there was no saddle embolism and these emboli were too small to cause hemodynamic 
instability. A retroperitoneal hematoma was present, with one leg of the IVC filter 
protruding 1 mm through the wall of the inferior vena cava. The duplex ultrasound 
obtained on the previous admission was reviewed, and again no evidence of thrombosis 
was seen.  
The above case represents the trials and tribulations that a bariatric surgeon faces when 
making decisions on the risk/benefit ratio of various VTE prophylactic methods. Despite 
the ever increasing use of IVC filters in high risk populations there is little scientific 
evidence to date on their safety and effectiveness. Our study assessed the incidence of 
post-operative complications that occur when comparing patients who had an IVC filter 
placed prior to bariatric surgery with those who were matched 1:1 and did not have an 
IVC filter pre-operatively placed. We found that patients who had an IVC filter had 
significantly worse outcomes (any complication, post-op DVT, and bleeding) when 
compared to their matched control. However, mortality was not significantly different 
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between the two groups. These findings were similar to those of Birkmeyer et al 
published in 2013. Completing a propensity-matched cohort study, the authors used the 
clinical registry of the Michigan Bariatric Surgery Collaborative and reported on the 
complications associated with 1077 bariatric surgical patients who had had a pre-
operative IVC filter placed. The authors found that patients with IVC filters had 
significantly higher rates of VTE and DVT.(85) As in our study, rates of PE and death 
were higher in the filter patients but this was not statistically significant. The only 
systematic review published on this topic was carried out in 2010 and concluded that the 
evidence was insufficient to recommend IVC filters in patients undergoing bariatric 
surgery.(86) 
Several limitations need to be defined as one interprets the findings in this study. First, 
this study is observational and thus is subject to confounding. While our patients were 
well-matched with respect to age, sex, and type of surgery, and we did control for patient 
risk factors such as previous VTE, diabetes, hypertension and sleep apnea, other 
important variables including smoking history, use of birth control pills or estrogen 
containing medications, hypercoagulable states, and immobility were not analyzed, as the 
data were missing or unable to be accessed. Second, our data also lacked height and 
weight data and therefore we were unable to account for BMI, which is a known 
increased risk factor in the development of VTE. To Birkmeyer’s credit, the author used a 
propensity score to ensure that the IVC filter group and non-IVC filter group were better 
matched, and in so doing they controlled for confounding by indication. Despite our 
inability to account for BMI and lack of a propensity score our findings were consistent 
with Birkmeyer’s study.(85)  Thirdly, the study was limited by the use of administrative 
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data and the accuracy of the ICD-9 codes used to determine the exposures and outcomes. 
Fourth, our population was mainly female, relatively young (mean age 46.5), and well-
insured and therefore may not be generalizable to males, older patients, and those with 
lower socioeconomic status. Fifth, the period of time in which the data was accessed 
(2002 to 2008) is several years old and may not accurately reflect current surgical case 
mix and clinical care. Today, bariatric surgeons are increasingly turning to laparoscopic 
procedures, and are performing fewer laparoscopic adjustable gastric bands and more 
vertical sleeve gastrectomies. (87, 88)  As well, the safety of bariatric surgery continues 
to improve as techniques become ever more advanced. There is better awareness in the 
prevention of VTE and more standardized approaches including risk-stratified 
preventative measures and patient education. Finally, our data does not include specifics 
on the types of filters that were used in this cohort, for example retrievable vs. permanent 
filters. This lack of knowledge could very well influence the outcomes that were 
documented. In 2010, the FDA issued a warning with regard to the use of IVC filters. 
They cited 921 device adverse event reports including 328 occurrences of device 
migration, 146 device embolizations, 70 perforations into the IVC, and 56 filter fractures. 
The FDA recommended close surveillance, use of retrievable filters only, and removal of 
filters as soon as the risk of PE was gone. (89) 
Strengths of this paper include the access to a large dataset, with one of the largest 
reported number of bariatric patients with IVC filter placement before bariatric surgery. 
Demographically the data drawn from the Blue Cross/Blue Shield plans closely 
resembles the US population and the results should be generalizable. And importantly, 
unlike other studies in the literature who have reported on the risks and benefits of the 
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IVC filters up to 30 days post bariatric surgery, our study captures events up until one 
year post bariatric surgery. This is a key factor to take into consideration, as venous 
thromboembolism and other complications that may be directly related to IVC filters 
have been known to occur 30 days following bariatric surgery. (90) 
This study adds knowledge to the literature and provides further evidence that IVC filter 
use in the high risk bariatric surgical patient should be considered on an individual case 
basis with an understanding of the risks and benefits to their use.  
3.6 Conclusion 
We concur with the findings from other published literature including Birkmeyer et al 
(85, 91, 92) that IVC filter placement in bariatric surgical patients does not reduce the 
risk of PE in high risk bariatric surgical patients and may even cause more complications 
post-operatively. The use of IVC filter placement in high risk bariatric surgical patients 
should be used cautiously. 
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Table 5 Baseline Characteristics of the Analytic Cohort 
Characteristics for 
















    
Mean (SE) age, in years 46.68 (0.35) 46.34 (0.35) 46.51 (0.25) p=0.45 
Age Categories, years 
18 to 24 
24 to 34 
35 to 44 
45 to 54 






















Gender, % female 587 (74.4%) 202 (25.6%) 1174 (74.4%) p=0.05 
Type of Surgery 
Open Gastric Bypass 
Laparoscopic Gastric 
Bypass 















Comorbidities     
*Hypertension 540 (68.4%) 491 (62.2%) 1031 (65.3%) p=0.01 
*Diabetes 305 (38.6%) 248 (31.4%) 553 (35%) p=0.003 
*Sleep Apnea 308 (39.0%) 278 (35.2%) 586 (37.1%) p=0.13 
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*Diagnosis or treatment within one year of bariatric surgery 
DVT = Deep venous thrombosis 
PE = Pulmonary Emboli 
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Table 6 Primary and Secondary Outcomes 
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Any Complication 663 (84) 604 (76.6) 1267 (80.3) 0.0002 
*Long length of stay = 5+ days for gastric bypass, 1+ days for laparoscopic adjustable gastric band 
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Table 7 Relationship between Inferior Vena Cava Filter Use and Outcomes in the 
Matched Analysis 






Primary Outcome    
Post-op VTE 
 
1.87 1.4-2.5 0.0001 
Post-op DVT (%) 
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Odd Ratio = Adjusted odds ratio controlled for age, sex, type of surgery, length of stay, diabetes, 
hypertension, sleep apnea 
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Chapter 4 The Diagnostic Accuracy of Magnetic Resonance Venography in the 
Detection of Deep Venous Thrombosis: A systematic review and meta-analysis 
4.1 Abstract 
Background: Previous studies have reported on the use of magnetic resonance 
venography as a possible alternative non-invasive modality in the detection of deep 
venous thrombosis. However, the majority of these studies have a small sample size and 
magnetic resonance venography’s (MRV) potential significance is debated. One 
systematic review and meta-analysis on this topic has been published in literature in 
2007. We plan to use this as our index paper and search the literature for further evidence 
for or against the use of MRV in the detection of DVT. In particular, we would like to 
consider the use of MRV in special populations for example, the morbidly obese where 
contrast venography may not be feasible or safe. 
Objective:  The aim of our systematic review and meta-analysis is to re-evaluate the 
accuracy of MRV in the detection of suspected (symptomatic and asymptomatic) DVT in 
light of recent additional data. 
Methods: Pubmed, Embase, Scopus, Cochrane and Web of Science were searched to 
identify observational studies (case-control studies (CC) and cohort studies (CS)). We 
excluded case series, cross-sectional and non-human and non-English studies. Study 
quality and the risk of bias were evaluated using the Quality Assessment for Diagnostic 
Accuracy Studies tool (QUADAS 2). A random meta-analysis including subgroup and 
sensitivity analyses were performed.  
Results: Our search resulted in 23 observational cohort studies all from academic 
centers. The total number of cases was 1121. Sixteen articles were included in the meta-
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analysis. The summary estimates for MRV as a diagnostic non-invasive tool revealed a 
sensitivity of 93% [95% CI: 89% to 95%] and specificity of 96% [95% CI: 94% to 97%]. 
The heterogeneity of the studies was found to be high for both sensitivity and specificity. 
Inconsistency (I
2
) for sensitivity and specificity was 80.7% and 77.9% respectively.  
Conclusions: Further studies investigating the use of MRV in the detection of suspected 
DVT did not offer any further evidence to support the replacement of ultrasound with 
MRV as a first line investigation for DVT. However, MRV may offer physicians an 
alternative tool in the detection/diagnosis of DVT in patients for whom ultrasound is 
inadequate or not feasible (such as in the obese patient). 
4.2 Introduction 
Venous thromboembolism (VTE) is a serious condition, leading to over 50,000 deaths a 
year in the United States. (93-95) Venous thrombosis is defined as a blood clot 
(thrombus) that originates in any vein of the human venous system. These can occur in 
the deep veins of pelvis, thighs or legs (DVT) or part of the thrombus could detach as an 
embolus and lodge in the pulmonary vessels, leading to PE. (96, 97)  Early detection is 
essential for immediate treatment to avoid significant morbidity and mortality 
accompanied with DVT and pulmonary emboli (PE). (98) 
The clinical presentation of VTE may vary widely from being completely asymptomatic 
to having a lethal outcome such as PE; moreover, a diagnosis of DVT may lead to long 
term comorbidity such as chronic venous insufficiency. (99) One of the known risk 
factors for VTE is obesity.(100) Excessive abdominal fat limits the venous return and 
chronically raises the intra-abdominal pressure, leading to decrease in the blood velocity 
in the femoral veins. (100, 101)  In addition to these mechanical factors, obese patients 
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have high levels of leptin, decreased fibrinolysis and a high activity of the coagulation 
cascade, which contributes to more venous thrombosis, especially in the lower 
limbs.(100) Other risk factors for VTE,  include pregnancy, smoking, heart failure, 
previous DVT or PE, increased age, cancer, nephrotic syndrome, medications; including 
birth control pills, hormone replacement therapy and tamoxifen, surgical procedures, 
especially those involving the hip and pelvis, prolonged postoperative recumbency and 
inherited thrombophilia; such as factor V Leiden, anti-thrombin deficiency, protein C or 
protein S deficiency. (102) 
Recently the mortality of PE caused by DVT increased in the USA, reaching 40,000–
200,000 deaths annually.(103) Therefore, early detection of DVT and especially 
asymptomatic DVT is necessary to avoid hazardous and devastating results due to PE.  
The gold standard for the detection of DVT is contrast venography.  While this modality 
is considered to be ideal it comes not without risk and comorbidity to the patient.  These 
risks include contrast nephropathy, systemic reactions to the contrast dye, tissue necrosis 
due to extravasation of the contrast medium, venous thrombosis at the catheter site and 
pulmonary emboli as sequelae.(104) In addition, contrast venography is not ideal for 
pelvic originated DVT because of the wash-out effect of the contrast medium in 
tributaries of the deep pelvic veins. (104) Because of these obvious limitations to 
venography other non-invasive modalities have been developed and include duplex 
ultrasound (U/S), contrast enhanced computed tomography (CT) venography, and 
magnetic resonance venography (MRV).  Each modality brings with it its own 
advantages and disadvantages.  
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Duplex U/S is a non-invasive and relatively inexpensive tool for the detection of DVT. 
However, it is operator dependent, with a poor anatomical view especially in the 
morbidly obese and might not be helpful in some situations, such as a limited available 
acoustic window. (99, 105)  It is also not useful for pelvic veins and as such this limits its 
applicability to extremities only.  
Unlike duplex U/S, contrast  enhanced CT venography has a better anatomical view, but 
has high risk of ionizing radiation, in addition to the contrast material used, which makes 
the patient more vulnerable to allergic reactions and nephrotoxicity. (99, 105)  X-ray 
venography is rarely used anymore, not only because it has similar limitations as contrast 
enhanced CT venography, including  ionizing radiation and contrast material, but also 
because it only evaluates a single draining venous system with each acupuncture, which 
makes it impractical.(105, 106)   
Alternatively magnetic resonance venography (MRV) has been suggested as a non-
invasive diagnostic tool for confirming the presence of absence of DVT. This may be of 
important benefit in special populations such as uremic patients and those with 
inadequate venous access, as in the morbidly obese patient.(107-109)  MRV has lower 
operator dependence and provides better venous anatomy, (98) especially in the pelvic 
region, allowing better visualization of the inferior vena cava and external iliac veins. 
This is crucial in the diagnosis of DVT for the obese patient, where thicker lower limbs 
and excessive fat tissue, obscuring the view of pelvic veins makes duplex ultrasound non-
diagnostic. (106, 108, 109)  Sampson et al. explored the accuracy and benefits of MRV in 
a systematic review and meta-analysis in 2007. To our knowledge this is the only 
literature review that has been conducted on this specific topic to date. The authors 
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concluded that MRV will not replace ultrasound as the first-line modality for DVT 
detection. However, they did suggest that MRV may offer an alternative in special 
populations such as the obese patient where ultrasound is not feasible or yields 
inconclusive results.(110)  Since the systematic review and meta-analysis by Sampson 
and colleagues, additional studies have been published reporting the experience with 
MRV as compared to other non-invasive modalities and the gold standard contrast 
venography.  
Given the limited options of non-invasive modalities available for the detection of DVT 
especially in special populations and the unclear benefit described in the literature, we set 
out to compare MRV with other non-invasive modalities (duplex ultrasound and 
computed tomography venography) with the gold standard contrast venography in the 
detection of DVT of the lower limbs.   
4.3 Objective of the Review 
The objective of this review is to assess whether the diagnostic accuracy of MRV for 
clinically suspected and asymptomatic DVT is high enough to justify its use in clinical 
practice and to evaluate if MRV can replace venography particularly in special 
populations such as the obese. Similar to our index systematic review, our hypothesis is 
that MRV may be very useful in special populations such as in the obese, offering an 
alternative modality to be used when ultrasound is not feasible or yields inconclusive 
results. We formulated our research question using the acronym PECO, where “E” stands 
for exposure, i.e.  In patients with suspected DVT (symptomatic or asymptomatic) of the 
lower limbs does MRV when compared to other non-invasive modalities such as duplex 
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ultrasound and computed tomography venography accurately detect blood clots within 
the pelvis and lower limbs using contrast venography as the gold standard? 
P In patients with suspected DVT (symptomatic or asymptomatic) of the lower limbs 
E does MRV  
C when compared to other non-invasive modalities such as duplex ultrasound and 
computed tomography venography 
O accurately detect blood clots within the pelvis and lower limbs using contrast 
venography as the gold standard 
4.4 Methods 
Inclusion and exclusion criteria for studies 
We included prospective and retrospective cohort studies, cross-sectional studies and 
case-control studies. We did not include any case series, case reports or animal studies. 
4.4.1 Definition of Exposure  
Adults or children who were suspected of having a DVT (symptomatic or asymptomatic) 
who underwent MRV for the diagnosis of blood clot in the pelvis or lower limbs were 
included. These same patients should have undergone another diagnostic study (duplex 
ultrasound, compute tomography venography and/or contrast venography) to compare the 
diagnostic accuracy of the MRV. We included only studies that evaluated the pelvis and 
lower extremities and excluded studies that only included upper extremity MRV or chest 
MRV. We did not exclude subjects based on age, race, ethnicity, gender geographical 
location, health care setting or method of MRV used. 
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4.4.2 Primary Outcome 
The primary outcome for this review and meta-analysis was the accurate detection of 
blood clots in the lower limb and pelvis as compared to contrast venography (the gold 
standard). 
4.4.3 Search Strategy 
We searched MEDLINE (via PUBMED), COCHRANE, EMBASE, SCOPUS and WEB 
OF SCIENCE for papers containing the synonyms for both terms “deep vein thrombosis” 
and “magnetic resonance imaging”. Synonyms were compiled using both controlled 
vocabulary and free text concepts. We also searched systematic reviews and meta-
analyses using the clinical queries tool in Pubmed. The specific search strings are listed 
in Appendix A.4.1. 
Hand-searching was performed by compiling a list of the top 40 journals based on the 
2013 impact factor in 3 major areas radiology (pertinent to MRV imaging), 
surgery/medicine and orthopedic surgery. From the list we chose the 4 most pertinent 
journals: Radiology, Investigative Radiology, Journal of Magnetic Resonance Imaging, 
JAMA surgery and Clinical Orthopedics and Related Research. Each of these journals 
was searched back six months for articles that were not identified in our database search. 
Conference proceedings were not searched for unpublished and ongoing studies. Finally, 
we examined the 14 articles from the Sampson review and meta-analysis (110) to ensure 
that they were included in our review. 
The initial list of articles derived above was aggregated into EndNote X6 software. 
Duplicates were removed based on author, year, title, journal, volume, issue and page. 
Articles from Pubmed were kept in preference to those in Embase and Scopus.  
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4.4.4 Selection of Studies  
We compiled a list of all articles identified from the search strategies outlined above.  
These results were merged into a common file and duplicates were deleted (as above). 
The articles were then divided evenly among two reviewers (KS and GA).  The reviewers 
independently examined their assigned articles for inclusion and classified each article as 
“exclude” “include” or “unsure.”  Initial article screening began with a title screen.  To be 
included articles needed to include the words DVT, MRV or contrast venography. Our 
initial title criteria were very broad in order to sufficiently capture potential studies.  
After title screening, abstracts were retrieved and screened to determine eligibility.  
Finally, full text articles were retrieved and screened for inclusion.  Any discrepancy 
between title, abstract and text review was adjudicated by a third reviewer.  
4.4.5 Data Extraction and Management  
To avoid bias in the distribution of articles, we randomly shuffled the titles and abstracts 
using EndNote X6 and then assigned half of the articles to each reviewer (KS and GA). 
Titles and abstracts were then reviewed, summarized and abstracted with any relevant 
data compared, and any dissension was adjudicated by a third reviewer (VV). Articles 
were excluded if they were poster presentations, case series, case reports, review articles 
or editorials, animal studies or published in a language other than English. See the 
adapted MOOSE guidelines flow chart in Figure 4 for a numeric description of the 
process. 
The full text of articles selected by the above procedure was retrieved. A standardized 
data extraction form was developed, which was pilot tested on two full text articles. 
(Appendix A4.2)  Each team member independently reviewed the full text article, 
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extracted study and patients characteristics, including type of study, country of origin, 
origin of patients recruitment, number of cases recruited, patients status (symptomatic or 
asymptomatic), patients mean age, patients gender, prevalence of DVT, MRI technique 
used in each study, the reference standard used, MRV and the reference standard 
interpreted blindly, and reference standard done independently from MRV. If sensitivity 
and specificity were not calculated within the individual paper a 2 × 2 table was 
constructed to extract the number of true positives, false positives, true negatives, false 
negatives, for MRV study results. We also confirmed given sensitivity and specificity 
values of each individual study by recreating 2 x 2 tables. Any values that we found to be 
incorrect were corrected and used for our quantitative analysis.  
The extracted data was entered in duplicate into Microsoft Excel and then transferred to 
our data analysis software package. We did not impute any missing values though to 
complete the analysis, we did correct for values of zero for sensitivity and specificity of 
reported for any of the individual studies Data reporting conformed to the Meta-analysis 
of Observational Studies in Epidemiology (MOOSE) group guidelines. (111) 
4.4.6 Assessment of Methodological Quality of Included Studies 
In 2003, QUADAS a validated assessment tool was developed for systematic reviews to 
determine the quality of primary diagnostic accuracy studies and risk of bias. QUADAS 
has since been modified and QUADAS-2 was developed. The QUADAS-2 tool is 
composed of four main domains that consider patient selection, index test, reference 
standard and flow of patients through the study and timing of the index tests and 
reference standard. (112)  The tool was piloted with two reviewers (KS and GA) 
extracting data on 2 individual papers included in this review and agreement was found to 
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be good. Therefore the tool was used to rate all included studies. Two reviewers (KS and 
GA) independently extracted study characteristics using standardized Quadas-2 forms. 
(Appendix A4.3)  Any disagreements were solved by consensus and if necessary, by 
involving a third reviewer (VV). The study was then labeled either “low bias,” “high 
bias” or “unclear” based on each category. 
4.4.7 Data Synthesis and Analysis 
The unit of analysis for this study was either thrombus of the lower limb and/or pelvis or 
the patient. A bivariate random effects approach was used to obtain joint summary 
estimates of sensitivity (the proportion of patients with positive DVT, as established by 
contrast venography or other non-invasive modality, who have a positive MRV) and 
specificity (the proportion of patients who are negative for DVT by contrast venography 
or other non-invasive modality, who have a negative result by MRV). We used Meta-
Disc (Version 1.4) dedicated and comprehensive software for meta-analysis of diagnostic 
data. (113) A continuity correction of 0.5 was set for any sensitivity or specificity value 
reported as zero. This was to ensure that we could define the calculation of sensitivity and 
specificity within the statistical software. Significance was set at p < 0.05 for all analyses. 
We planned to conduct stratified analyses to explore the effects of differences in the 
reference standard, symptomatic versus asymptomatic cohorts, and other factors that 
might be affecting heterogeneity.  
4.4.8 Assessment of Heterogeneity 
Heterogeneity was assessed qualitatively based on the individual characteristics of the 
studies, their methodological quality and their individual risk of bias.  Specific attention 
was paid to participant characteristics (age, sex, hospital setting, symptomatic or 
60 
asymptomatic DVT), the type of MRV, protocol used and whether contrast or no contrast 
was used, criteria used to diagnose a lower limb or pelvic DVT for the index test and the 
reference standard. Effect size was compared using Chi-square test (Q), and by visual 
assessment of the point estimates of effect and degree of overlap of the confidence 
intervals in the forest plot. The impact of heterogeneity on the meta-analysis was 
quantified using I statistic (I
2
). Cochran Handbook guidelines were followed with 0 to 
40% defined as low heterogeneity, 30 to 60% as moderate heterogeneity, 50 to 90% as 
substantial heterogeneity and 75 to 100% as considerable heterogeneity. (114) To assess 
clinical and methodological heterogeneity we considered performing subgroup analyses 
of our studies according to type of reference standard performed, patient symptoms 
(asymptomatic versus asymptomatic), index and reference standard blinded or not, age 
and geographic location. 
4.4.9 Qualitative Synthesis 
A narrative summary of our review was completed by our two team members. This 
summary included a description of the quality of the studies included in our review and 
the degree to which individual study design might impact the quantitative results. We 
attempted to document and control for all potential biases that may arise while 
undertaking this review. We documented our reasons for exclusion of studies. 
4.4.10 Subgroup Analysis 
We defined our subgroup analysis a priori so as to reduce bias. These subgroups 
included: 
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1. Stratifying studies into those which included the gold standard: contrast venography as 
the reference standard versus those which included other reference standards such as 
duplex ultrasound, computed tomography venography or X-ray venography. 
2. Stratifying patients as presenting with asymptomatic or symptomatic VTE. 
3. Stratifying the index test as being read blindly and by two or more radiologists 
independently. 
4.5 Sensitivity Analysis 
Sensitivity analyses were performed by excluding studies that were found to have 
unusual variability or low methodological quality. Specifically, the following sensitivity 
analyses were performed:  
1. Dropping individual studies that may be affecting heterogeneity (ex. those studies 
that extremely low sensitivities and specificities). 
4.6 Results of the search 
Records identified by an extensive electronic database search yielded 1062 records using 
the following search engines: Pubmed 228, Embase 517, Scopus 177, Cochrane Review 
15 and Web of science 125. (Appendix A4.1) Two records were identified individually 
by hand search. All records were combined and transferred to EndNote X6. Duplicates 
were purged leaving 658 records for title and abstract screening. The search found all 
articles included in the most recent systematic review and meta-analysis; Sampson et al. 
2007 (our reference article) except Pope et al. 1989 (Sampson reference 24), which was 
one of the two records identified by hand search. The other paper was Montgomery et al. 
1994, which was found through hand searching in the reference section of Aschauer et al. 
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2003. We excluded 492 records based on our exclusion criteria and 166 full text articles 
were assessed for eligibility. Of the 166 articles, 143 articles were excluded: 85 articles 
did not meet our inclusion criteria, 21 were case reports, 28 were observational and 
systematic reviews, 8 were in foreign language; including German, Italian, Chinese and 
Japanese, and 1study was still pending from Weldoc. Our final date for including studies 
in our systematic review was March 10, 2014. After reviewing these full text articles, 23 
were included in our qualitative study. All were cohort studies. Sixteen studies were 
included in our meta-analysis.  Seven studies (Akhtar, Alnoldussen, Spuentrup, 
Aschauer, Evans 1996, Ono and Stover) were excluded from the meta-analysis and 
quantitative analysis, to be included only in qualitative analysis of the systematic review. 
These 7 studies were excluded because they failed to use contrast venography as the 
reference standard to be compared to MRV. Twenty-one out of the 23 eligible studies 
evaluated their cohort in a prospective fashion while the 2 remaining studies 
(Arnoldussen, Spritzer).were retrospective.  
4.6.1 Qualitative analysis 
The characteristics of these studies are summarized in Table 6. The 23 studies were 
performed among 3 continents, including Europe, North America and Asia. The majority 
(91%) of the eligible studies were done in Europe and North America. From Europe there 
were eleven studies, four of which were conducted in England (Fraser 2002, Fraser 2003, 
Montgomery, and Moody) and the remaining studies originated in seven different 
countries, including the Netherlands (Arnoldussen), Austria (Aschauer), Ireland 
(Cantwell), Italy (Catalano), Denmark (Jensen), France (Laissy) and Germany 
(Spuentrup). Ten studies were carried out in North America; all of which were done in 
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USA (Carpenter, Erdman, Evans 1996, Evans 1992, Larcom, Pope, Sica, Spritzer, 
Vukov, Stover). Two studies represented Asia; one was carried out in the Kingdom of 
Saudi Arabia (Akhtar) and one in Japan (Ono). All 23 eligible studies were conducted in 
an academic setting. The number of patients included in the studies ranged from 10 to 
203. There were a total of 1121 cases included among all of our eligible studies. These 
patients were recruited from different settings that varied from either hospital inpatients 
(Akhtar, Arnoldussen, Erdman, Larcom, Jensen, Montgomery), a mix between inpatients 
and outpatients (Fraser 2003, Fraser2002, Sica, Ono, Stover)  or via the Emergency 
Department(Cantwell, Vukov). Ten studies did not report the setting in which patients 
were recruited (Aschauer, Carpenter, Catalano, Evans1992, Evans1996, Laissy, 
Pope,Spritzer, Spuentrup, Moody). All of the 23 studies investigated suspected DVT. 
Fifteen of the studies recruited patients with symptomatic DVT ( Akhtar , Arnoldussen, 
Aschauer, Cantwell, Carpenter,Catalano,Evans 1993,Evans1996,Fraser 2003,Fraser 
2002,Pope,Sica,Spritzer,Vukov,Moody) (98, 105, 115-126), Laissy et al. recruited 
patients that had symptoms of either DVT, PE, or both. (107)  Four of the studies 
recruited asymptomatic patients (Jensen, Larcom, Montgomery and Stover) (104, 127-
129) and 2 studies recruited a mixture of both symptomatic and asymptomatic patients 
(Erdman,Ono). (130, 131) Spuentrup et al. did not distinguish between symptomatic or 
asymptomatic patients nor were any demographic or clinical details given regarding the 
patients recruited in their study.(132) 
Fifteen of the 23 eligible studies interpreted DVT utilizing a double blinded system for 
both MRV and the reference standard (Akhtar, Cantwell, Carpenter, Erdman, evans1992, 
Evans1996, Fraser 2002,Fraser 2003, Jensen, Larcom, Laissy, Montgomery, Sica, Vukov, 
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Ono), while 3 of the studies did not assess DVT in a double blinded way, either for MRV 
or the reference standard(Arnoldussen,Aschauer, Moody). It was unclear in the remaining 
four studies whether the radiologic assessment of DVT was double blinded or not 
(Catalano, Pope, Spritzer, Spuentrup). Stover et al. interpreted DVT blinded for MRV 
only, while it was not clear whether it was blinded for the reference standard. The 
reference standard was performed independent to the results of MRV in all 23 studies, 
except for Ono et al. and Stover et al., for which the reference standard was only 
performed on patients found to be positive on MRV. All studies used non-contrast MRV, 
except for Aschauer et al. and Fraser et al. 2003, these studies utilized contrast enhanced 
MRV in the detection of DVT. In both of Evans papers (1992 and 1996) contrast 
enhanced MRV was used only when the non-contrast MRV studies were equivocal.  
The majority of the studies used the gold standard for the detection of DVT - contrast 
venography (Cantwell, Catalano, Erdman, Evans 1992, Fraser 2002, Fraser 2003, Jensen, 
Larcom, Montgomery, Pope, Vukov, Moody). Three studies used Duplex US (Akhtar, 
Arnoldussen, Evans 1996), 2 studies used X ray venography (Aschauer, Ono), and 4 
studies used a combination of both contrast venography and Duplex US (Carpenter, 
Laissy,Sica, Spritzer). Two studies incorporated computed tomography venography with 
other modalities: Stover et al. used computed tomography venography with contrast 
venography, while Spuentrup et al. used 3 imaging modalities, including computed 
tomography venography, X-ray venography and Duplex US. 
4.6.2 Risk of Bias 
We utilized predetermined criteria based on QUADAS 2 (a validated risk of bias 
assessment tool for diagnostic accuracy described in the methods section) to determine 
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the risk of bias and applicability concerns of the individual studies included in our 
review. These results are summarized in Table 7 and plotted in Figure 5. 
In general, the studies included in this review performed well with regards to 
applicability. We found that the majority of the included studies were at low risk for two 
categories with respect to applicability, including the patient selection and index test, 
with an average rating of 82.6% and 78.3%, respectively. While the reference standard 
scored an average rating of 43.5% for low risk, 21.7% for unclear risk and 21.7% as high 
risk. Overall, 19 of the 23 eligible studies were rated with an average acceptable 
applicability of concerns, except for 3 studies (Catalano, Spritzer, Spuentrup) that were 
found to be unclear and 2 studies (Aschauer and Pope) were determined to be of poor 
quality (high risk) for applicability. 
With respect to the methodological quality and risk of bias: In 14 of 23 studies, the 
protocol for the MRV was clearly defined, leading to low risk of bias in the index 
domain, with 3 studies (Aschauer, Catalano and Spuentrup) having an unclear MRV 
protocol and 6 studies (Arnoldussen, Jensen, Pope, Spritzer, Vukov, Moody) with MRV 
protocols that were ill defined and at high risk of bias. With regards to the flow and 
timing domain, acceptable time intervals between the index test and reference standard 
were found in 52.2% (12 out of 23) of the studies. Four studies (Akhtar, Catalano, 
Larcom, Spuentrup) were assessed as having an unclear flow and timing between the 
reference and index tests while 7 studies (Arnoldussen, Laissy, Montogomery, Pope, 
Spritzer, Ono, Stover) were found to be at high risk with time intervals between reference 
and index tests approaching greater than 1 week. The areas of most concern when 
evaluating the risk of bias in our 23 included studies were the patient selection (over 60% 
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of the studies were unclear or at high risk for bias because of lack of detail with respect to 
patient selection) and reference standard chosen (over 61% of the studies used a 
diagnostic modality other than the gold standard – contrast venography). Added to this, 
diagnostic bias (unclear whether the study included prevalent cases instead of incident 
cases) and confounding bias (study did not account for age, weight, race, social history 
(tobacco use) or patient past medical history, medications (estrogen, anticoagulants) and 
associated medical comorbidities such as COPD, obesity, previous VTE or predisposing 
risk factors of VTE) were common among the studies.  
4.6.3 Quantitative analysis 
Meta-analysis was performed for 16 out of the 23 eligible studies. The forest plots for 
sensitivity and specificity of the 16 studies using contrast venography as their reference 
standard are summarized in Figure 6 & 7. Sensitivities and specificities for individual 
studies ranged from 0 to 100% and 43% to 100% respectively. We found significant 
heterogeneity for both estimates (p<0.001). This must be considered when evaluating the 
pooled estimates. The pooled sensitivity was 93% [95% CI: 89% to 95%], while the 
pooled specificity was 96% [95% CI: 94% to 97%]. There was a large amount of 
heterogeneity demonstrated among the studies with regards to sensitivity (Chi-square= 
77.10, I2=81.8%, p value=0.0001) and specificity (Chi-square= 59.72, I2=76.6%, p 
value=0.0001). 
Visually, the forest plots showed that the majority of the studies tended to cluster around 
high estimates of sensitivity and specificity, representing a positive association between 
MRV and the detection of DVT in pelvis and lower limbs. (Figure 6&7) 
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4.6.4 Subgroup analysis 
After our overall quantitative analysis was complete, we carried out our subgroup 
analyses to assess methodological and clinical heterogeneity. There were three planned 
subgroup analyses:  
1. Stratifying studies into those which included the gold standard – contrast venography 
as the reference standard versus those which included other reference standards such as 
duplex ultrasound, computed tomography venography or X-ray venography. 
2. Stratifying patients as presenting with asymptomatic or symptomatic VTE. 
3. Stratifying the index test as being read blindly and by two or more radiologists 
independently. 
We did not complete the third subgroup analysis. We felt that this was not necessary as 
the majority of the studies were blinded to the index test and were read by two or more 
radiologists independently. 
We chose as our main meta-analysis the forest plots of sensitivity and specificity for 
those studies which used contrast venography as the reference standard. Contrast 
venography, an invasive diagnostic tool is the known gold standard for detection of DVT 
in the pelvis and lower limbs. Our main aim of this review was to determine if MRV, a 
non-invasive diagnostic tool could replace contrast venography for the detection of DVT 
in pelvis and lower limbs. Furthermore, we wanted to determine if MRV could be used in 
special populations where contrast venography is contraindicated. 
The pooled sensitivity and specificity estimates of all studies in the meta-analysis: 93% 
[95% CI= 91 to 96%] and 96% [95% CI=95to 97%] respectively (Figure 8 & 9) was 
comparable to the pooled sensitivity and sensitivities of only those studies which 
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included contrast venography as the reference standard:  93% [95% CI=89% to 95%] and 
96% [95% CI=94% to 97%] respectively (Figure 6 & 7). However, as predicted there was 
more heterogeneity demonstrated when all studies were included in the meta-analysis 
versus only studies that used contrast venography as their reference standard: sensitivity 
[Chi-square= 87.83 (p=0.0001), I
2
=78.4%] and specificity [Chi-square= 94.48 p=0.0001), 
I
2
=79.9%], in comparison to the studies that used contrast venography as their reference 
standard . [Chi-square= 77.10 (p=0.0001), I
2




We chose to stratify studies which reported symptomatic versus asymptomatic DVT as 
we felt that this may bias the interpretation of the MRV results and only 3 of the studies 
recruited asymptomatic only patients. We excluded Erdman et al. from this subgroup 
analysis because they included both asymptomatic and symptomatic patients in their 
recruitment. We found the pooled sensitivity of symptomatic only patients to be 97% 
[95% CI: 94% to 99%] versus asymptomatic only patients sensitivity pooled estimate 
61% [95% CI: 41% to 78%] with an unaffected pooled specificity, symptomatic 96% 
[95% CI: 94% to 98%] and asymptomatic 95% [95% CI=91 to 97%]. The heterogeneity 
of these estimates showed a significant decrease with respect to the sensitivity estimates 
for the symptomatic cohort [chi-square=30.17 (p=0.0008) and I
2
=66.9%] versus all 
patient cohorts that included symptomatic, asymptomatic and mixed cohorts [chi-square 
= 77.10 (p=00001) and I
2
=81.8%] and pooled specificity for symptomatic cohort [chi-
square=33.07 (p=0.0003) and I
2
=69.8%] versus all patient cohorts that included 
symptomatic, asymptomatic and mixed cohorts [chi-square = 59.2 (p=00001) and 
I
2
=76.6%] . This was not the case for the heterogeneity estimates of the asymptomatic 
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cohort. Heterogeneity remained high regardless of the subgroup analysis. The forest plots 
for sensitivity and specificity of the symptomatic and asymptomatic studies using 
contrast venography as their reference standard are summarized in Figure 10, Figure 11, 
Figure 12, and Figure 13.  
4.7 Sensitivity Analysis 
During our analysis, we noted several studies with measures of extreme variation and low 
methodological quality. We examined each individual study’s effect by removing them 
one at a time to see if this changed the effect measures. We therefore performed 
sensitivity analyses: 
First, on visual inspection of our index forest plot (all studies that included contrast 
venography as a reference standard) Jensen et al. yielded results that were markedly 
different then all of the other included studies and therefore we regarded this study as an 
obvious outlier. For this reason, we performed a sensitivity analysis by removing Jensen 
et al. from the main analysis. We found the results of the dropping Jensen et al. to have a 
slight improvement on the pooled sensitivity being 95% [95% CI= 91 to 97%], while the 
pooled specificity was 96% [95% CI=94to 97%], which is similar to the pooled 
specificity before dropping Jensen et al. However, there was a significant decrease in the 
heterogeneity demonstrated among the studies pooled sensitivity [Chi-square= 44.31 
(p=0.0001), I
2
=68.4%] and a slight decrease in the heterogeneity of the pooled specificity 
[Chi-square= 65.09 (p=0.0001), I
2
=78.5%], when compared to the pooled estimates of all 
included studies in our index meta-analysis. (Figure 16 & 17) 
Examining the overall forest plot of the main meta-analysis, two other studies were also 
found to be outliers while the majority of the studies tended to have sensitivity and 
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specificity estimates greater than 80%. These studies included Sica et al. and 
Montgomery et al.  By dropping these studies one at a time we found very little change in 
the summary estimates for both sensitivity and specificity. However, there was an overall 
improvement in the I
2
 score. After dropping Montgomery et al. the I
2
=79.8%, then after 
dropping Sica et al. the I2=68.9% and finally by dropping Jensen the I
2
=68.4%. Finally, 
when all 3 studies were dropped we found a significant improvement in heterogeneity of 
I
2
=47.2%. (Figure 18, 19, 20, 21, 22 & 23) 
For our second sensitivity analysis, we chose to exclude Jensen et al. from the 
asymptomatic only analysis as this study performed poorly with respect to the index test 
and may be a cause of the lowered sensitivity amongst the asymptomatic cohort. We 
found an improved pooled sensitivity of the asymptomatic cohort 77% [95% CI=55% to 
92%]. The pooled specificity remained comparable at 96% (95% CI=92 to 98%). 
However, there was a significant decrease in the heterogeneity demonstrated among the 
studies with respect to pooled sensitivity [Chi-square= 2.46 (p=0.0001), I
2
=59.3%] and 
only slight decrease in heterogeneity with respect to the pooled specificity [Chi-square= 
22.85 (p=0.0001)] when compared to the pooled estimates of all asymptomatic cohort 
studies. The inconsistency (I
2
) for specificity of MRV for the asymptomatic cohort after 
removing Jensen was actually higher than with all asymptomatic studies included. 
(Figure 14 & 15) 
4.8 Discussion 
4.8.1 Clinical Heterogeneity 
The studies were conducted in developed countries from around the world with diverse 
populations including France, Germany, Italy, Denmark, The Netherlands, England, 
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Ireland, Japan, Austria, Saudi Arabia and several studies in the United States. Publication 
ranged widely from 1990 to 2012. All studies were cohort studies, were conducted at 
academic institutions and evaluated MRV as a diagnostic tool in the detection of DVT. 
Thus, none of the studies were excluded based on applicability. However, there were 
significant differences in the geographic location, sample size, range in patient age and 
almost all of the studies lacked detail with respect to patient demographics and VTE risk 
factors.  
4.8.2 Methodological Heterogeneity 
Confounding 
We judged the most important confounders to be age, gender, number of cases recruited, 
patients status (symptomatic or asymptomatic), blind interpretation of both MRV and the 
reference standard in a double blinded manner, type of MRV protocol, timing and flow 
between studies and type of reference standard used in each study. The majority of 
studies accounted for sex and age, but there was great variation in the way each study 
recorded the patient demographics. As such, the heterogeneity we observed may be due 
to variations in the comorbidities. However it is impossible to control for these variations 
because the populations were not well described in any of the 23 included studies. Five 
studies (Carpenter, Catalano, Pope, Spritzer, Vukov) did not report age at all, while two 
studies (Jensen, Akhtar) recorded the median age of the patients rather than the mean age, 
three studies (Cantwell, Spuentrup, Erdman) recorded only the range without the mean 
ages, and two studies (Ono, Evans 1993) recorded the mean ages without the range of 
ages of cases. In addition, six studies (Carpenter, Catalano, Fraser 2002, Spritzer, Vukov, 
Spuentrup) failed to report the gender of their recruited cases.  
72 
Another confounding factor that could have affected the heterogeneity among the studies 
was the defined unit of analysis for each individual study. Some studies reported DVT on 
a patient level while others chose the unit of analysis to be on the vein level. Montgomery 
et al. reported DVT on both a patient level and a venous level. As well, the studies varied 
with regards to the anatomical areas examined. Some studies examined the entire venous 
system of the pelvis and lower limbs, while other studies studied only a single anatomical 
area. The technique and protocols used for MRV varied amongst the studies. The 
majority of the included studies used non-contrast MRV except for one study (Fraser 
2003) which used contrast. The strength of the MRV magnet varied with the majority of 
the studies using 1.5 Tesla, except 3 studies [Erdman (0.35T), Laissy (1.0T) and Ono 
(0.5T)] which used different ranges of smaller Tesla units for the MRV. Finally, there 
was variation in the way images were reviewed. Some studies used maximum intensity 
projection images, while other studies viewed source axial images.  
Information Bias 
Eighteen of the twenty-three cohort studies did specify the radiological diagnostic criteria 
of a thrombus in the deep veins, either in lower limbs or pelvis. Five studies 
(Arnoldussen, Jensen, Pope, Vukov, and Moody) did not mention the radiological criteria 
used to diagnose DVT. This could have contributed to the heterogeneity, especially given 
that four (Jensen, Pope, Vukov, Moody) out these five studies were included in the meta-
analysis.    
Selection Bias 
Patient selection was assessed as being high risk for bias in majority of the studies 
because they either did not recruit their patients consecutively or randomly, or they were 
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found to have inappropriate exclusions. Only a handful of studies (Cantwell, Evans 1992, 
Fraser 2002, Jensen, Laissy, Montgomery, and Ono) were noted to have conducted their 
patient selection in an appropriate fashion.  
Recall Bias  
Several factors related to interpreting the results of the MRV by the radiologists involved 
in each study contributed to the wide heterogeneity among the studies. The majority of 
the studies assigned only one reviewer to interpret the presence of DVT by imagine, only 
8 studies (Carpetner, Cantwell, Fraser 2002, Laissy, Vukov,Ono, and Spuentrup) 
interpreted the results via two independent reviewers. While Catalano et al. used three 
reviewers to read the results of the index and reference standard, it was not clear from 
their methods as to whether the index test or reference standard tests were read in a 
double blinded manner. All studies described the independent interpretation of both the 
reference standard and the MRV results, except for 2 studies (Ono, and Stover) and these 
were already excluded from the meta-analysis because of the inability to create 2 x 2 
tables. 
Experimenter’s bias 
Seven of the studies (Arnoldussen, Aschauer, Moody, Catalano, Pope, Spritzer, and 
Spuentrup) were unclear or did not assess the diagnosis of DVT in a double blinded 
manner, either for MRV or the reference standard.  Stover et al. interpreted DVT blinded 
for MRV only, while it was not clear whether it radiologists were blinded for the 
reference standard. From the details of the studies above four of our 16 studies included 
in our meta-analysis (Moody, Catalano, Pope and Spritzer) were found to have 
experimenter’s bias because of questionable blinding practices.  
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4.8.3 Quantitative Analysis 
Overall, MRV- a non-invasive diagnostic tool for DVT appears to perform well when 
compared to contrast venography - an invasive diagnostic tool for DVT. Moreover, MRV 
was found to be highly sensitive and specific for the detection of clinically suspected 
(symptomatic) DVTs. According to the results of our meta-analysis, summary estimates 
of sensitivity and specificity were 93% and 95%, respectively.  
Statistical Heterogeneity 
Individually the included studies in our meta-analysis had significant heterogeneity. Four 
studies (Jensen, Sica, Montgomery, and Vukov) deviated from the other studies with 
respect to their lower sensitivity estimates. While 3 studies (Sica, Moody, and 
Montgomery) had lower than average specificity estimates when compared to the other 
included studies. Factors that may have led to these inconsistencies include: a) the studies 
lack of description with regards to the criteria used for DVT detection (Vukov and 
Jensen) b) studies  had a small sample size [Vukov (n=10), Sica (n=14), Jensen (n=27)] 
c) studies lacked a standardized protocol for interpreting the radiographic results (ex. 
Montgomery had only one reviewer/radiologist only) d) studies had different units of 
analysis (i.e. some studies analyzed patients while others analyzed at the level of the 
veins) e) two of the outlier studies recruited asymptomatic patients. Finally, Moody et al. 
may have had a lower specificity given that they recruited only a small number of 
symptomatic cases and more importantly radiographic criteria of DVT was not reported 
and the interpretation of MRV and contrast venography results were not blinded. 
Subgroup Analysis 
1. Studies including any imaging modality as a reference standard 
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In comparison to our reference index article (Sampson 2007), we chose to include in our 
main meta-analysis only studies that considered contrast venography as the reference 
standard. We then completed a subgroup analysis to see how this would affect our 
summary estimates by including other diagnostic modalities such as X- ray venography, 
duplex ultrasound and CT venography. We felt that this was necessary given that contrast 
venography is the gold standard for diagnosis of DVT in pelvis and lower limbs. 
Interestingly, we found that the pooled sensitivity and specificity of all studies including 
any imaging modality as a reference standard to be comparable to the contrast 
venography only studies, recording a sensitivity and specificity of 94% and 96%, 
respectively. However, the level of heterogeneity was much higher in meta-analysis that 
included any imaging modality as a reference standard, in comparison to the contrast 
venography studies. To complete our main meta-analysis, four studies (Ono, Stover, 
Aschauer, and Evans 1996) were excluded.. Ono et al. and Stover et al. were noted to 
have selection bias (only patients who had a positive MRV then underwent the reference 
standard –contrast venography). As well, it was unclear if Stover et al. insisted on a 
blinded and independent interpretation of the reference standard. In Aschauer and 
colleagues study the reviewers were blinded only to the location of thrombus, but were 
informed about the presence of thrombus in at least one venous segment, increasing bias 
in their study. 
2. Symptomatic versus Asymptomatic DVT 
Although the study by Erdman et al. was found to be of overall excellent clinical and 
methodological quality with low risk of bias and applicability, we chose to exclude it 
from this symptomatic versus asymptomatic subgroup analysis because they recruited 
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both symptomatic and asymptomatic patients and did not distinguish between them. In 
the subgroup analysis, the symptomatic only group recorded a significantly higher 
sensitivity (97%) in comparison to the asymptomatic patients (61%). Running this 
subgroup analysis did show a slight improvement in the sensitivity in comparison to the 
sensitivity of including all patients (both symptomatic and asymptomatic) (93%). In 
addition we found a lower heterogeneity associated with symptomatic patients in 
comparison to all patients setting. As for the specificity estimate, both symptomatic and 
asymptomatic DVT were nearly equal and didn’t differ from the all patients setting.  
 
Sensitivity analysis 
On visual inspection of the main forest plot for sensitivity there were several outliers, the 
most obvious being Jensen et al with Sica et al and Montgomery also having lower 
individual sensitivities. The study by Jensen et al. had several limiting factors that may 
have contributed to its individual sensitivity estimates being so much lower when 
compared to the other included studies. These factors included a small number of cases, 
and no defining radiologic criteria for DVT diagnosis. By dropping Jensen et al. from the 
meta-analysis, we found a slight improvement on the pooled sensitivity of 95%, while the 
pooled specificity of 95%, stayed the same. A significant decrease in the heterogeneity 
for sensitivity was observed (I
2




4.9 Language bias: Exclusion of studies not published in English 
Due to time constraints, studies not published in English were excluded. It is possible 
such studies differ systematically from those published in English. However, given that 
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only 8 of 166 studies were excluded on this basis, we believe that it is unlikely that 
inclusion of these studies would materially affect our results. 
4.10 Publication Bias 
In general, Funnel Plots to assess publication bias for diagnostic test are of little value 
and so therefore we chose that examine this type of bias. (133) 
4.11 Limitations of the study 
There were several limitations in our systematic review. First, the nature of data 
collection used in this systematic review was done in a retrospective manner. Second, the 
unit of analysis used for each individual study was not standardized. Many studies, 
reported the unit of analysis as the patient (thrombus detected per patient) while others 
documented their unit of analysis as the vein (thrombus detected per vein in a lower limb 
and/or pelvis). This was a clear cause of the methodological heterogeneity and 
inconsistency seen in this meta-analysis (sensitivity and specificity estimates and I
2
 
scores). Thirdly, we were unable to use all of the 23 studies included in our qualitative 
review for the quantitative review as we were unable to abstract the needed data. As well, 
during our analysis, the statistical values extracted from the 2 x 2 tables in Moody et al. 
was rejected by the software used for meta-analysis for unknown reasons. We therefore, 
were unable to use all of the given data and only considered the results obtained for 
pelvic DVT from this paper. Finally, our motivation to perform this SRMA was to 
identify MRV as a possible non-invasive diagnostic tool to be used in special populations 
such as the obese. Unfortunately, none of the studies that we found in our literature 
search or that were included in our SRMA specifically studied the use of MRV in special 
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populations. We therefore, cannot make any conclusions as to the whether MRV is a 
useful diagnostic tool for detection of DVT in the obese patient.  
4.12 Strengths of the study 
 The value of performing a systematic review and meta-analysis (SRMA) on 
observational studies has been questioned. However, SRMA of observational studies can 
provide valuable information and summarize diagnostic test accuracy.  (Cochrane 
Handbook page 393-395). By pooling the breadth of information that exists on the topic 
and using strict criteria as noted in the Cochrane Handbook (pages 391-448), 
observational studies can make an important contribution to the literature with respect to 
questions regarding the diagnostic accuracy of specific tests. Despite the listed 
limitations, we believe that this review embraced the rigorous expectations as set forth by 
the Cochrane Review.  
Strengths of our study include enlisting the help of our institutions expert librarians to 
perform a rigorous and thorough search of the literature using the index test and target 
condition as key terms, developing strict inclusion criteria that defined the target 
condition, reference standard, intended patient group, and the test under evaluation, 
careful assessment of the risk of bias and study applicability by utilizing the QUADAS-2 
quality assessment tool. We completed 2 x 2 tables for each of our 23 studies and 
corrected for any discrepancies. For example in our reference article we found different 
sensitivities and specificities reported for Fraser 2002 et al, a different sensitivity for 
Larcom et al. and different specificities for Catalano and Carpenter. In the individual 
studies that were added to our review we found a different sensitivity and specificity 
reported for Evans 1996 & Spritzer and a different specificity for Jensen & Carpenter. 
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We accounted for the large heterogeneity in our studies by using a random effects model, 
and by completing subgroup and sensitivity analyses. The populations were very 
heterogeneous representing adults from around the world with a wide range of ages, of 
both sexes, and were both from inpatient and outpatient settings and as such made this 
study fairly generalizable to the general adult population. We also considered 
confounding within individual studies and assessed various forms of bias. (134) Finally, 
if a new test is to replace the existing test, it is important to compare the accuracy of both 
tests on the same population and with the same reference standard. (135) We did just that 
by performing our meta-analysis only on studies that used contrast venography as the 
gold standard.  
4.13 Differences from the index study  
We did a very thorough and extensive search that included the databases that were 
searched in our index reference article by Sampson et al.: Pubmed, Embase, Scopus, Web 
of Science and Cochrane. We also completed a hand search. Our final qualitative review 
included 23 studies, 9 more than our index reference study (Sampson 2007). Of the nine 
new included studies, 3 studies (Akhtar, Arnoldussen, and Ono) were published after 
2007, the year of Sampson et al. publication. Additionally, we found 5 other studies 
(Aschauer, Montgomery, Stover, Spuentrup, and Moody) that were published before 
2007, but that were not included in Sampson’s review. Unlike Sampson et al. we only 
included studies using contrast venography as the reference standard for our main meta-
analysis, whereas Sampson’s review included studies which used X-ray venography, CT 
venography and duplex ultrasound as reference standards. As well, to account for the 
large amount of heterogeneity in the included studies we conducted subgroup analyses 
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including stratifying symptomatic versus asymptomatic DVTs and performed several 
sensitivity analyses for outliers. Sampson et al. used Meta-Disc software for running their 
meta-analysis. We also used this software but had the good fortune to use an updated 
version, which provided us with the value of inconsistency (I
2)
, an additional value that 
helps assess heterogeneity within a pooled estimate. Finally, we performed a rigorous 
assessment of the risk of bias and applicability of each study of the 23 studies included in 
our review using the most recent and validated tool QUADAS-2 recommended by the 
Cochrane Review.  
4.14 Implications for research and practice 
Presently, the gold standard to detect DVT is an invasive study – contrast venography. 
While there are other diagnostic modalities to detect DVT, to date none have been shown 
to be comparable to contrast venography. Duplex U/S is a non-invasive and relatively 
inexpensive tool for the detection of DVT. It is limited by the poor anatomical view 
especially in the morbidly obese (not useful for pelvic DVT). (99, 105) Contrast 
enhanced CT venography has a better anatomical view, but has high risk of ionizing 
radiation and requires contrast material increasing the risk of allergic reactions and 
nephrotoxicity.(106) Alternatively MRV has been suggested as a non-invasive diagnostic 
tool. MRV provides better venous anatomy especially in the pelvic region. (98) This is 
essential in the diagnosis of DVT in special populations such as the obese, where thicker 
lower limbs and excessive fat tissue, obscuring the view of pelvic veins makes duplex 
ultrasound non-diagnostic. Since the systematic review and meta-analysis by Sampson 
and colleagues, additional studies have been published reporting the experience with 
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MRV as compared to other non-invasive modalities and the gold standard contrast 
venography.  
We completed an exhaustive search of the literature and rigorous methods as set out by 
the Cochrane review in hopes of shedding more light on this subject. From our results we 
believe that while MRV may not replace ultrasound as the first-line modality for DVT 
detection, it should be considered as an alternative especially in special populations such 
as the obese where other diagnostic tools are not feasible.  However, given the vast 
amount of heterogeneity found amongst the studies, larger patient cohorts are needed to 
validate the accuracy of this technique in a broader clinical setting (125) and a 
standardized unit value for analysis may yield a more consistent estimate and therefore 
provide better evidence. Also, further studies should be conducted to compare the 
diagnostic accuracy of MRV in patients for whom ultrasound is not feasible as a 
screening tool for DVT, such as the obese. Finally, a cost analysis study should be 
considered to compare MRV with other diagnostic modalities.  
4.15 Author’s conclusion 
Our systematic review and meta-analysis did show significant sensitivity and specificity 
results of MRV comparable to contrast venography for detection of DVT. MRV is an 
underutilized, non-invasive diagnostic tool for the detection of DVT. It should be further 
considered for use in special populations such as the obese patient. 
However, given the large amount of heterogeneity in the studies, it would be wise to 
continue investigating this comparison using improved study designs and more 
appropriate patient populations. 
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Figure 4: MOOSE Diagram 
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Table 8 Characteristics of Included Studies 


























40 Inpt Symptomatic  46 
(32-73) 
19/21 71 1.5 T 
(-) 
Duplex US No/No  Yes  






31 Inpt Symptomatic * 
(18-85) 
10/21 71 1.5 T 
(-) 
Duplex US Yes/Yes Yes   




32 Mixed Mixed 69 8/24 20 0.5 T  
(-) 
X ray venography Yes/Yes No  
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12 NR Symptomatic 55 
(21-75) 
6/6 30 1.5 T  
(+) 
X ray venography No/No Yes  
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20 NR NR (14-88) NR 58 1.5 T 
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(26-89) 
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75 NR Symptomatic 58 
(20-85) 
34/41 35 ** 
1.5 T 
(-) 
Duplex US Yes/Yes Yes  
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203 Inpt Asymptomatic  66 
(28-86) 




Yes/Yes Yes  




45 Inpt Asymptomatic   41 
(14-87) 




Yes/Yes Yes  









Yes/Yes Yes  








Yes/Yes Yes  
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Yes/Yes Yes  
*Median age was used instead of mean age. ** Contrast enhanced MRV was used only when the non-contrast MRV studies were equivocal. 
Inpt=Inpatient  ED=Emergency Department  US=Ultrasound  T-Tesla  NR=not reported 
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Table 9: Bias and applicability 
 Study                     Risk of Bias                                                                Applicability Concerns 
                                      Patient      Index Test     Reference    Flow and                      Patient              Index Test       Reference 
                                     Selection                          Standard      Timing                          Selection                                    Standard 
1 Akhtar 2009     
 
   
2 Arnoldussen 2012        
3 Aschauer 2003        
4 Cantwell 2006        
5 Carpenter 1993        
6 Catalano 1997        
7 Erdman 1990        
8 Evans 1992        
9 Evans 1996        
10 Fraser 2002        
11 Fraser 2003        
12 Jensen 2001        
13 Laissy 1996        
14 Larcom 1996        
15 Montgomery 1994        
16 Pope 1990        
17 Sica 2001        
18 Spritzer 1991        
19 Vukov 1990        
20 Ono 2010        
21 Stover 2001        
22 Spuentrup 2001        









Proportion of studies with low, high or unclear  














0% 20% 40% 60% 80% 100%
Proportion of studies with low, high, or unclear 
 CONCERNS regarding APPLICABILITY 
Low High Unclear
Figure 5: Graphic representation of bias and applicability 
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Figure 6: Forest plot for sensitivity of studies using CV as the reference 
 
Figure 7: Forest plot for specificity of studies using CV as the reference 
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Jensen 2001 0.00    (0.00 - 0.46)
Sica 2001 0.57    (0.18 - 0.90)
Moody 1998 1.00    (0.29 - 1.00)
Catalano 1997 1.00    (0.86 - 1.00)
Laissy 1996 1.00    (0.84 - 1.00)
Larcom 1996 0.91    (0.59 - 1.00)
Montgomery 1995 0.64    (0.31 - 0.89)
Carpenter 1993 1.00    (0.96 - 1.00)
Evans 1993 1.00    (0.66 - 1.00)
Spri tzer 1993 1.00    (0.88 - 1.00)
Pope 1991 1.00    (0.66 - 1.00)
Vukov 1991 0.80    (0.28 - 0.99)
Erdman 1990 0.90    (0.73 - 0.98)
Sensitiv ity (95% CI)
Pooled Sensi tivi ty = 0.93 (0.89 to 0.95)
Chi-square = 77.55; df =  15 (p = 0.0000)
Inconsistency (I-square) = 80.7 %
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Cantwell 2006 0.97    (0.94 - 0.99)
Fraser 2003 0.98    (0.87 - 1.00)
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Sica 2001 0.43    (0.10 - 0.82)
Moody 1998 0.73    (0.45 - 0.92)
Catalano 1997 0.94    (0.73 - 1.00)
Laissy 1996 1.00    (0.79 - 1.00)
Larcom 1996 0.99    (0.96 - 1.00)
Montgomery 1995 0.76    (0.59 - 0.89)
Carpenter 1993 0.82    (0.57 - 0.96)
Evans 1993 0.95    (0.85 - 0.99)
Spritzer 1993 0.92    (0.75 - 0.99)
Pope 1991 1.00    (0.63 - 1.00)
Vukov 1991 1.00    (0.48 - 1.00)
Erdman 1990 1.00    (0.54 - 1.00)
Specificity (95% CI)
Pooled Specificity = 0.95 (0.93 to 0.97)
Chi-square = 67.91; df =  15 (p = 0.0000)
Inconsistency (I-square) = 77.9 %
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Figure 8 Forest plot for sensitivity of all included studies 
 
Figure 9 Forest plot for specificity of all included studies 
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Figure 10 Forest plot for sensitivity of symptomatic DVT 
 
Figure 11 Forest plot for specificity of symptomatic DVT 
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Laissy  1996 1.00    (0.79 - 1.00)
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Evans 1993 0.95    (0.85 - 0.99)
Spritzer 1993 0.92    (0.75 - 0.99)
Pope 1991 1.00    (0.63 - 1.00)
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Specificity (95% CI)
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Inconsistency  (I-square) = 73.6 %
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Figure 12 Forest plot for sensitivity of asymptomatic DVT 
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Figure 17 Sensitivity Analysis: Forest plot for specificity of main meta-analysis without 
the outliers (Jensen) 
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Figure 20 Sensitivity Analysis: Forest plot for sensitivity of main meta-analysis without 
outliers (Montgomery) 
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Figure 22 Sensitivity Analysis: Forest plot for sensitivity of main meta-analysis without 
the outliers (Jensen/Sica/Montgomery) 
 
Figure 23 Sensitivity Analysis: Forest plot for specificity of main meta-analysis without 
the outliers (Jensen/Sica/ Montgomery) 
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Chapter 5 The EFFORT Trial 
Enoxaparin versus Fondaparinux For Thromboprohylaxis in Bariatric Surgical Patients: 
A randomized double-blinded pilot trial 
5.1 Abstract.  
Context: Prophylaxis for venous thromboembolism (VTE) is routinely performed for all 
patients undergoing bariatric surgery. However, there is disagreement regarding the 
optimal dosing and duration of anticoagulant therapy. Furthermore, there is little data 
regarding the incidence of asymptomatic deep venous thrombosis (DVT) in this 
population.   
Objective: To conduct a pilot study using magnetic resonance venography (MRV) to 
estimate the incidence of asymptomatic deep venous thrombosis (DVT) in bariatric 
surgical patients receiving enoxaparin or fondaparinux sodium during their perioperative 
hospitalization. 
Design, Setting and Patients: From July 2010 to August 2013, one hundred and ninety-
eight consecutive bariatric surgical patients from an academic institution were 
randomized in a double blinded manner to receive either enoxaparin 40 mg twice daily or 
fondaparinux sodium 5 mg once daily. Two weeks following surgery the patients 
returned to clinic to undergo magnetic resonance venography to detect the presence or 
absence of asymptomatic deep venous thrombosis.  
Main Outcome Measures: The primary outcome was asymptomatic DVT. Secondary 
outcomes were attainment of therapeutic anticoagulation and symptomatic DVT. Safety 
outcomes were perioperative bleeding, perioperative complications, and death. 
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Results: Four of 175 patients evaluated developed DVT, two in each arm of the study.  
Nearly half (47.4%) of patients did not attain target prophylactic anti-factor Xa levels. 
Adequate anti-factor Xa levels were associated with fondaparinux use and elevated 
preoperative D-dimer level. No major adverse events occurred in either arm. 
Conclusion:  Both regimens appear to be equally effective at reducing the risk of DVT. 
Fondaparinux was much more likely to produce target prophylactic anti-factor Xa levels 
than enoxaparin. Further prospective studies are needed to determine the optimal DVT 
prophylaxis regimen in the bariatric surgical population. 
5.2 Introduction 
Morbid obesity has become epidemic in the United States in the 21st century. It is a 
major cause of chronic illness and disability, and an important risk factor for diabetes, 
cardiovascular disease, sleep apnea, and osteoarthritis. Treatment of obesity with lifestyle 
modification and pharmacologic therapy has yielded disappointing results (136). In 
contrast, bariatric surgical procedures—Roux-en-Y gastric bypass, laparoscopic sleeve 
gastrectomy, and laparoscopic adjustable gastric band—have been highly successful in 
producing sustained weight loss, and in reversing obesity-related co-morbidities (137, 
138).  
Despite a generally good safety record, bariatric surgery does carry a risk of 
complications, the two most important of which are anastomotic leak and venous 
thromboembolism (VTE) (90). Anastomotic leak is usually treated with percutaneous 
drainage or reoperation, while VTE, which includes deep venous thrombosis (DVT) of 
the pelvis and lower extremities and pulmonary embolism (PE), is treated with 
anticoagulation and/or placement of a vena cava filter (84, 139, 140). Anastomotic leak 
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and VTE prolong hospital stay and are the most common causes of postoperative 
mortality. In an era of increasing emphasis on patient safety, prevention of these adverse 
outcomes has taken on great importance. To that end, the American College of Surgeons 
and the American Society of Metabolic and Bariatric Surgeons have developed a 
certification program for Centers of Excellence in bariatric surgery, which specifies best 
practices in patient care. However, a standard dosing regimen for the chemoprevention of 
VTE in the obese bariatric population has yet to be established. 
The usual approach to prevention of perioperative VTE involves early ambulation of the 
patient, use of pressure stockings, and administration of unfractionated or low molecular 
weight heparin anticoagulation. While these measures have been widely adopted in the 
bariatric surgical population, there remains disagreement regarding the optimal 
administration of pharmacologic VTE prophylaxis. Specifically, the choice of 
anticoagulant, dose, and duration of therapy remain to be established. 
In order to assess the effects of different anticoagulation regimens, it is important to 
know the baseline frequency of perioperative VTE. Estimates of clinically apparent VTE 
following bariatric surgery range from 0.2% to 3.8% (3, 7, 71, 90); and symptomatic 
perioperative pulmonary embolism occurs at a rate of 0.7% to 2.4% (61). The prevalence 
of asymptomatic VTE in the bariatric surgical population is unknown. However, a post-
mortem study by Melinek et al 2002 found that while only 20% of gastric bypass patients 
had been clinically diagnosed with pulmonary emboli prior to death, 80% had 
microscopic evidence of pulmonary emboli that likely contributed to their mortality (73). 
At present, there are no trials comparing prophylactic anticoagulation regimens in the 
bariatric surgical population. However, the Enoxican II trial evaluated the use of 
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enoxaparin in patients with cancer undergoing pelvic or abdominal surgery, and found 
that 6-10 days of enoxaparin therapy at 40 mg daily resulted in a VTE rate of 12%. An 
additional 21 days of therapy at 40 mg daily reduced the rate to 4.8% (141).
 
Even though 
the Enoxican II study was a randomized, blinded trial, the cancer patients were not 
morbidly obese and the applicability to bariatric patients is questionable. A retrospective 
study by Hamad, et al, reviewed the outcomes of 668 bariatric patients at five centers 
who received one of five different enoxaparin dosing regimens, ranging from a single 30 
mg preoperative dose to 30 mg/day postoperatively for 10 days (21). The authors 
concluded that these dosing regimens were safe, yet no definitive conclusions were 
drawn regarding optimal dosing or duration. Further work by Hamad et al demonstrated 
that 40 mg twice daily of enoxaparin does not achieve adequate anti-factor Xa levels for 
prophylaxis of VTE in over half of postoperative gastric bypass patients (142). However; 
60 mg twice daily has been shown to increase bleeding risk during the perioperative 
period (52, 143).
 
A clinical trial assessing the adequacy of perioperative anticoagulation for DVT 
prophylaxis requires an accurate means of detecting VTE. Most trials have used 
conventional invasive venography due to its excellent sensitivity and specificity. Indeed, 
venography is mandated in all trials submitted to the U.S. Food and Drug Administration 
for the indication of VTE prophylaxis. However, morbidly obese patients cannot undergo 
conventional venography due to the difficulty of obtaining venous access of the lower 
extremities. To avoid this problem, investigators have usually employed duplex 
ultrasound in place of venography. Unfortunately, the sensitivity of duplex ultrasound in 
the asymptomatic general population is poor (38 to 62%) (108, 109), and is likely worse 
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in the morbidly obese due to large lower extremities and the pannus that may overlie the 
inguinal region and obscure the view of the pelvic veins. Thus an alternative approach is 
needed. Magnetic resonance venography (MRV) has been performed using an open MRI 
scanner, and a recent prospective study reported a high sensitivity (92-98%) and 
specificity (90-100%) compared to standard venography (107, 120).  
Our study compares two anticoagulation regimens, enoxaparin 40 mg twice daily and 
fondaparinux 5 mg once daily, for the prevention of perioperative VTE in the bariatric 
surgical patient. Enoxaparin and fondaparinux were chosen due to their different 
pharmacology, which may be expected to produce differences in efficacy and adverse 
events. In contrast to enoxaparin, fondaparinux is a synthetic molecule that specifically 
inhibits factor Xa via antithrombin. In addition, fondaparinux is 100% bioavailable, does 
not undergo metabolism, and may be dosed once daily. Our objectives were to determine 
(i) the incidence of asymptomatic DVT in each regimen, (ii) the feasibility of using MRV 
in the bariatric population, and (iii) the adequacy of anticoagulant dosing by measuring 
anti-factor Xa levels. 
5.3 Materials and Methods. 
5.3.1 Setting and Subjects 
The study was conducted at an academic institution that is accredited by the American 
College of Surgeons Bariatric Surgery Network. From July 2010 to August 2013, patients 
were recruited and consented after meeting a standard set of preoperative requirements, 
including meeting with a bariatric dietitian and assessment by a clinical psychologist. 
Patients were eligible for the study if they were 18 years or older with a BMI of 35-59 
kg/m
2 
, and were undergoing laparoscopic vertical sleeve gastrectomy (VSG) or 
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laparoscopic Roux-en Y gastric bypass (LRYGB). Patients with contraindications to low 
molecular weight heparin or selective antithrombin III agonists, previous history of DVT 
or pulmonary emboli (PE), documented clotting/coagulation disorders, history of 
treatment for cancer within the last year, history of venous stasis or superficial 
thrombophlebitis, vein stripping or ligation, obesity hypoventilation syndrome, recent 
history of smoking (within the last year), and BMI>60 (who may have required extended 
DVT prophylaxis) were excluded. Other exclusion criteria were conditions that would be 
considered predispositions to increased bleeding including severe hepatic impairment, 
creatinine clearance of less than 30 ml per minute and a platelet count of less than 
100,000 per cubic millimeter. Finally, women of childbearing age were excluded if they 
were pregnant or were taking estrogen based birth control medication up until less than 
one month prior to surgery. 
The study received investigational review board approval at our institution and written 
informed consent was obtained from all patients before they underwent randomization. 
An Investigational New Drug (IND) application was submitted by the principal 
investigator to study fondaparinux (an approved product) at a once daily dosing of 5mg in 
the bariatric perioperative surgical patient. This proposal was approved by the United 
States Food and Drug Administration. A Data Safety and Monitoring Board met 
quarterly.  
5.3.2 Study Design 
Patients approved for either VSG or LRYGB underwent a thorough history and physical 
exam by the patient’s primary care physician on a standard intake form. Demographics 
including age, sex, height, weight and body mass index (BMI), and medical 
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comorbidities including hypertension, hyperlipidemia, type II diabetes mellitus, sleep 
apnea, GERD and cancer were documented. All patients were contacted by the pre-
operative evaluation clinic nurses, and were required to discontinue any non-steroidal 
anti-inflammatory drugs and other antiplatelet agents 14 days prior to surgery.  
5.3.3 Randomization 
After providing informed consent, consecutive patients were randomly assigned on the 
day of surgery in a 1:1 ratio to either enoxaparin or fondaparinux, using a computer-
generated randomization scheme (Microsoft Excel 2007 data analysis tool pack). 
Uniform distribution was utilized. Variables were drawn with equal probability from all 
values in the range of 0 to 1. Each block of 4 contained equal number of enoxaparin and 
fondaparinux treatment assignments. Each successive study participant was randomized 
by selecting the next available treatment assignment in the random code. 
5.3.4 Blinding 
Investigational product was obtained as commercial syringes of enoxaparin 40 mg/0.4mL 
and fondaparinux 5 mg/0.4mL. At the time of dispensing contents of commercial 
syringes were transferred into a 1 milliliter syringe made by Becton Dickinson for 
blinding purposes. Due to the different dosing schedules of enoxaparin and fondaparinux, 
placebo doses were prepared to maintain the blind. Active and placebo syringes were 
prepared by our inpatient pharmacy and were not identifiable by external appearance.  
In accordance with current practice, the enoxaparin group received a dose of enoxaparin 
40 mg subcutaneously on call to the operating room. To maintain blinding, patients 
randomized to enoxaparin received placebo (saline) injection six hours following surgery 
stop time. Beginning on post-operative day one, 40 mg of enoxaparin was administered 
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subcutaneously twice daily for the duration of the patients hospital stay. The 
fondaparinux group received a placebo on call to the operating room. Six hours following 
surgery stop time, the patients were given 5mg of fondaparinux subcutaneously. 
Beginning on post-operative day one, patients received 5 mg of fondaparinux 
subcutaneously once daily in the morning and placebo (saline) injection subcutaneously 
once daily in the evening for the duration of their hospital stay.  
All patients had sequential compression devices and anti-embolic stockings placed prior 
to induction of anesthesia. Four to six hours following the surgery stop time; patients 
were ambulated in the hallways. Sequential compression devices were removed during 
ambulation. The use of aspirin, non-steroidal anti-inflammatory drugs, and other 
antiplatelet agents were prohibited during the patients hospital stay. Study drugs, 
enoxaparin and fondaparinux were discontinued at the time of patient discharge (average 
length of hospital stay = 2.5 days). Patients were educated on the importance of 
ambulation and exercise, and were encouraged to get up and move around at least every 
30 minutes while recuperating at home.  
5.3.5 Effectiveness of the treatment 
Patients underwent outpatient magnetic resonance venography (MRV) of the pelvis and 
lower extremities between postoperative days 10 and 14. The studies were interpreted by 
two qualified radiologists independently. Each radiologist was blinded to the type of 
anticoagulation therapy the participant received, and reviewed the coronal reformatted 
multiple intensity projections and source axial images. If there was a discrepancy 
between the interpretations, the radiologists reviewed the studies together and came to a 
final consensus regarding the presence or absence of clot. If the MRV revealed an 
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asymptomatic DVT, the patient was immediately evaluated and treated appropriately. 
Incidental findings aside from asymptomatic or symptomatic DVT were also reported to 
the patient and their primary care physician. 
5.3.6 Efficacy of the drug dose 
Anti-factor Xa levels were drawn on all patients in both study arms, three hours after the 
first dose on post-operative day zero, immediately prior to the second dose on post-
operative day one, and three hours after the second dose. All blood draws were performed 
according to the study schedule (Appendix A.5). The blood was collected in a sodium 
citrate tube, and analyzed using the standard hematology protocols of the Johns Hopkins 
clinical laboratory. Laboratory personnel were blinded to the source of the samples. Anti-
factor Xa levels were determined using the Siemens Berichrom Heparin Assay to 
measure both the enoxaparin and the fondaparinux levels. Different calibrators were used 
for each assay thus allowing the lab to measure both drugs using the same reagent and 
accounting for the different target prophylactic ranges for the two treatment groups 
(enoxaparin: 0.2-0.6 IU/ml and fondaparinux:  0.39-0.50 mg/L) (143-145) . 
5.3.7 Outcome Measures 
The primary outcome was asymptomatic DVT, defined as a positive MRV within two 
weeks following surgery. The secondary outcomes were attainment of a target 
prophylactic anti-factor Xa level on the study drug, and symptomatic DVT. Attainment of 
a target anti-factor Xa level was determined based on blood samples drawn 6 hours after 
receiving the drug on post-operative day one. This cutoff was the standard for adequate 
prophylaxis used by the Johns Hopkins Hematology Lab: ≥0.20 IU/mL for enoxaparin 
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and ≥0.39 mg/L for fondaparinux. Safety outcomes included perioperative bleeding, 
perioperative complications and death.  
5.3.8 Statistical Analysis 
Statistical analysis was performed by intention-to-treat. Thus, all patients who were 
randomized were analyzed. Descriptive analysis included calculations of the means, 
medians and standard deviations for continuous variables and proportions for categorical 
variables. Univariable analyses comparing patient characteristics between treatment arms 
were conducted using Student t- tests for continuous variables and chi-square test or 
Fisher exact test for categorical variables as appropriate.  A similar analysis was 
performed to evaluate the association of various risk factors with the incidence of DVT 
and with inadequate anti-factor Xa levels. 
For statistical testing, p<0.05 (2-tailed) was considered significant.  All statistical 
analyses were performed using Stata statistical software (version 12.1, StataCorp, 
College Station, Texas). 
5.4 Results 
5.4.1 Randomization 
Three hundred and twenty bariatric surgical patients were screened for eligibility. One 
hundred and ninety-eight were randomized. Of the 122 patients who were not 
randomized, 19 refused to participate and 103 were not eligible. Of the 198 patients 
enrolled in the study, 184 (92.9%) were treated according to the protocol. Of the 14 
patients that were not treated according to protocol, three were due to medication errors 
(one in the enoxaparin treatment arm and two in the fondaparinux treatment arm), and 11 
were due to events that necessitated a modification of the treatment protocol (six in the 
108 
enoxaparin treatment arm and five in the fondaparinux treatment arm). There were 21 
patients (15 in the enoxaparin treatment arm and 6 in the fondaparinux treatment arm) 
who were not evaluated for asymptomatic DVT because of inability to tolerate the MRV 
or because they missed the 10-14 day follow-up visit. While these patients did not 
undergo MRV they were evaluated by a qualified surgeon or nurse practitioner for 
symptomatic VTE during the standard of care two week post-operative check-up. No 
symptomatic VTEs were reported amongst any of the patients enrolled in this study. All 
198 patients were followed up to two weeks post-operatively (Figure 24). 
5.4.2 Baseline Characteristics 
The two treatment arms were very homogenous with regard to gender, age, race, weight, 
height, and co-morbidities (all p>0.05). The majority of the patients were female 
(83.8%), with a mean age of 41.1 (SD ±9.6) and a mean pre-operative BMI of 45.4 (SD± 
5.4). Seventy-five patients (37.9%) underwent laparoscopic vertical sleeve gastrectomy 
and 123 (62.1%) underwent laparoscopic Roux-en Y gastric bypass. The mean operative 
time for LRYGB and VSG was 202 (SD± 46) minutes and 156 (SD± 41) minutes 
respectively. The average length of stay (LOS) for the post-operative bariatric surgical 
patient was 2.4 (SD± 0.6) days. The patient’s medical comorbidities associated with 
obesity included hypertension (52.5%), hyperlipidemia (30.8%), type II diabetes mellitus 
(27.8%), gastroesophageal reflux (30.8%), cancer (1.5%) and sleep apnea (37.9%). The 
pre-operative D-dimer (a marker for thrombotic potential) was elevated (≥0.88 mg/L) in 
18.1% of patients (Table 10).  
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5.4.3 Primary Outcome 
Of the 175 patients evaluated for asymptomatic DVT by MRV, there were four positive 
DVTs (2.3%) diagnosed and treated. Two DVTs occurred in the enoxaparin treatment 
arm and two in the fondaparinux arm (2.4% versus 2.2%, p=1.00). All four DVTs were 
large, and were located in the left iliac vein. (Figure 25) There were three patients (one in 
the enoxaparin treatment arm and two in the fondaparinux arm) that were diagnosed with 
DVT by one reader but not confirmed by the second reader.  Even if these are added into 
the analysis, the resulting DVT incidence is not significantly different between the two 
treatment arms (3.6% for the enoxaparin treatment arm and 4.3% for the fondaparinux 
treatment arm; p=1.00).  
In general the number of patients with DVT was too low to be able to assess possible risk 
factors. Patients with a DVT had a higher mean pre-operative BMI than patients without 
DVT (51.0 kg/m
2
 versus 45.3 kg/m
2
; p=0.04). Other factors that seemed to be associated 
with DVT incidence but which did not attain statistical significance included older age 
(49.5 years versus 40.6 years; p=0.06), Type II diabetes (75.0% versus 25.7%; p=0.06), 
and hypertension (100.0% versus 52.0%; p=0.12). Univariate analyses of the association 
between DVT and patient baseline characteristics are summarized in Table 11. 
5.4.4 Secondary Outcome 
Of the 198 patients in the study, 137 had valid anti-factor Xa data from the post-operative 
day one blood draw. Almost half of the patients (47.4%) were found to have inadequate 
anti-factor Xa activity as evaluated on post-operative day 1 at 6 hours after administration 
of drug. Furthermore, more patients reached target prophylactic anti-factor Xa levels on 
fondaparinux than on enoxaparin (74.2% versus 32.4%, p<0.001). The only baseline 
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variables that were found to be associated with attainment of target prophylactic anti-
factor Xa level were an elevated pre-operative D-dimer level (>0.88 mg/L) and bariatric 
surgery procedure. Among patients who attained target anti-factor Xa levels, 25.0% had 
an elevated D-dimer versus 9.4% for those who were non-therapeutic (p=0.017). Among 
patients who were therapeutic, 52.8% underwent Vertical Sleeve Gastrectomy, versus 
32.3% for those who were non-therapeutic (p=0.016). No symptomatic DVTs were found 
in our study. Univariable analyses of key clinical characteristics are summarized in Table 
12. 
5.4.5 Safety Outcomes 
Eight patients experienced minor perioperative bleeding, three patients experienced atrial 
fibrillation, one patient had elevated creatinine and one patient had thrombocytopenia. Of 
the eight patients with bleeding none required transfusion, five had increased 
intraoperative bleeding, one had bright red blood per rectum on postoperative day one, 
one had melena on postoperative day one and one had an incidental finding of a rectus 
sheath hematoma that did not lead to dose adjustment. 
There were no deaths in either treatment arm. Three patients (two in the enoxaparin and 
one in the fondaparinux treatment arm) experienced rapid atrial fibrillation post-
operatively, which was controlled with medical intervention and eventually resolved. All 
three patients had a pre-operative history of intermittent atrial fibrillation that was not 
reported prior to screening and randomization. Minor bleeding, elevated creatinine, and 
thrombocytopenia were infrequent (Table 13).  
Four patients (two in each treatment arm) were re-admitted for nausea, vomiting, and/or 
dehydration. Two patients (one in each treatment arm) experienced a post-operative rash. 
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These patients were evaluated by the inpatient dermatology service, who felt the rash was 
most likely secondary to perioperative antibiotics. One fondaparinux patient had high 
blood sugar, one fondaparinux patient had a low platelet count, and one enoxaparin 
patient had post-operative chest pain and shortness of breath. This patient was evaluated 
for VTE by duplex ultrasound and chest CT, which were both negative. A summary of 
adverse events can be found in Table 14. 
5.4.6 Discussion and Summary  
This is the first reported randomized double blinded study comparing two different 
chemoprophylactic agents for the prevention of VTE following bariatric surgery. We 
compared high dose fondaparInux (5 mg daily) with enoxaparin (40 mg twice daily). 
While previous studies in non-obese patients have used a 2.5 mg dose of fondaparinux 
for prophylaxis, we chose a 5 mg dose based on work suggesting that this dose would 
achieve target anti-factor Xa concentrations in morbidly obese patients more consistently 
than the 2.5-mg dose (146). Enoxaparin was dosed at 40 mg twice daily based on a 
previous study by Scholten et al (50). 
Our study evaluated all patients for asymptomatic DVT post-operatively. Four patients 
(2.3%) were identified by MRV to have an asymptomatic DVT two weeks after 
undergoing uncomplicated bariatric surgery. This is similar to findings in the existing 
literature for perioperative bariatric patients (0.2 to 3.8%) (52, 90). However, given the 
potentially serious consequences of asymptomatic DVT, especially iliac vein thrombosis 
seen in this study, continued investigation of this phenomenon is warranted. 
No difference in the rates of DVT was seen between enoxaparin and fondaparinux. 
However, the small sample size precludes any firm conclusions about the relative 
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efficacy of these medications. A surprising finding was the high prevalence of inadequate 
anticoagulation. More patients did not reach target anti-factor Xa levels in the enoxaparin 
group, a finding that has been suggested by other studies that have examined the dose-
response relation of enoxaparin in bariatric surgical patients (147). An elevated 
preoperative D-dimer level was strongly associated with adequate levels of anti-factor 
Xa; the meaning of this interesting finding is unclear. 
The strength of this study is that it is a double blinded randomized trial using a novel 
means of detecting DVT. There was homogeneity of both treatment arms allowing for 
precise comparisons between both study drugs. The population was fairly representative 
of a typical academic bariatric surgical center in the United States. There are several 
limitations to this study. First, we treated all cases as incident or new cases. However, we 
did not obtain baseline ultrasound data on all patients so that we cannot exclude the 
possibility that some of the clots may have existed prior to the study. Second, this study 
has a small sample size which made it impossible to draw any causal inferences. Larger 
trials are needed to confirm whether the two agents are equivalently efficacious at 
preventing DVT, or whether the striking difference in anti-factor Xa levels seen in our 
study will result in better clinical efficacy with fondaparinux. 
As obesity becomes increasingly prevalent and the numbers of people undergoing 
bariatric surgery continues to increase, the need for effective and convenient 
anticoagulation dosing is essential. The American Society for Metabolic and Bariatric 
Surgery recently issued a position statement on VTE prophylaxis, which states that 
chemoprophylaxis should be considered in bariatric patients, but which does not specify a 
preferred regimen.(11) Results of this pilot study suggest that further trials need to be 
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conducted to determine the optimal agent and dosing for prevention of DVT in the obese 
population. Additional studies utilizing MRV should be conducted to demonstrate its 














103 not eligible by 
inclusion and exclusion 
criteria 
19 patients did not wish to 
participate  
14 deviations from 
protocol: 
3 nursing/medication error 
7 with bleeding only 
2 with atrial fibrillation 
1 with bleeding and atrial 
fibrillation 
1 with elevated creatinine 
n=100 assigned 
to fondarparinux 
n=98 assigned to 
enoxaparin 
 Analyzed with 






Analysis 2 asymptomatic 
DVTs assessed by 
MRV 
2 asymptomatic 
DVTs assessed by 
MRV 
Figure 24 Trial Profile: Enrollment, Randomization and Follow-up of Study Patients 
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Table 10 Baseline Characteristics of Patients Treated with enoxaparin or fondaparinux 







Gender (%)     
   Female 82(84.7) 84(84.0) 166(83.8) 0.95 
     
Race (%)     
   White, non-Hispanic 63(64.3) 65(65.0) 128(64.6)  
   Black, non-Hispanic 31(31.6) 33(33.0) 64(32.3)  
   Hispanic 3(3.1) 1(1.0) 4(2.0) 0.78 
     
     
Age-years (range) 18-65 19-68 18-68  
   (Mean ±SD) 41.8±9.0 40.4±10.2 41.1±9.6 0.30 
     
Hospitalization 
 
    
Bariatric Procedure (%)     
  Vertical Sleeve Gastrectomy               37(37.8) 38(38.0) 75(37.9)  
  Roux-en Y Gastric Bypass 
    
61(62.2) 62(62.0) 123(62.1) 0.97 
     
Surgical Time-minutes (Mean ±SD) 183±51 187±49 185±50 0.63 
Length of Stay (Mean ±SD) 2.4±0.8 2.5±0.8 2.4±0.8 0.21 
Pre-op BMI (Mean ±SD) * 45.7±5.2 45.1±5.5 45.4±5.4 0.44 
Pre-op D-dimer  0.9±3.7 1.5±4.4 1.2±4.1 0.30 
     
Medical Comorbidities ∞     
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   Hypertension 55(56.1) 49(49.0) 104(52.5) 0.32 
   Hyperlipidemia 29(29.6) 32(32.0) 61(30.8) 0.71 
   Type II Diabetes Mellitus 27(27.5) 28(28.0) 55(27.8) 0.94 
   GERD 33.33.7) 28(28.0) 61(30.8) 0.39 
   Cancer 1(1.0) 2(2.0) 3(1.5) 0.57 
   Sleep Apnea 
 
33(33.7) 42(42.0) 75(37.9) 0.23 
Other Risk Factors 
 
    
Smoking status †     
Ever smoked 14(16.9) 17(19.8) 31(18.3) 0.63 
     
Birth Control Pills 7(7.1) 8(8.1) 15(7.6) 0.80 
     
Therapeutic on Study Drug (%) ¥  2(2.8) 
 
49(49) 51(37.2) <0.001 
*BMI measured as kg/m
2
 
∞Medical comorbidities defined by patient’s primary care physician 
†Patients were all smoke free for at least two months prior to surgery as per standard protocol  
□Patients on estrogen based birth control pills one month prior to surgery. All patients were free of birth 
control pills one month prior to surgery as per protocol. 









Table 11 Risk Factors for Development of Deep Vein Thrombosis 







Gender (%)     
   Female 3(75.0) 143(83.6) 146(83.4) 0.52 
     
Race (%)     
   White, non-Hispanic 3(75.0) 111(64.9) 114(65.1)  
   Black, non-Hispanic  1(25.0) 55(32.2) 56(32.0)  
   Hispanic 0(0.0) 3(1.7) 3(1.7) 1.00 
     
     
Age-years (range) 43-56 18-65 18-65  
   (Mean ±SD) 49.5±5.4 40.6±9.5 40.8±9.5 0.06 
     
Hospitalization 
 
    
Bariatric Procedure (%)     
  Vertical Sleeve Gastrectomy               2(50.0) 65(38.0) 67(38.3)  
  Roux-en Y Gastric Bypass 
    
2(50.0) 106(62.0) 108(61.7) 0.64 
     
Surgical Time-minutes (Mean±SD) 150±27 187±50 196±50 0.14 
Length of Stay (Mean ±SD) 2.5±0.8 2.4±0.8 2.4±0.8 0.85 
Pre-op BMI (Mean ±SD) * 51.0±4.8 45.3±5.3 45.4±5.4 0.04 
Pre-op D-dimer  0.5±0.4 1.3±4.4 1.2±4.3 0.73 
     
Medical Comorbidities ∞     
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   Hypertension 4(100.0) 89(52.0) 93(53.1) 0.12 
   Hyperlipidemia 1(25.0) 53(31.0) 54(30.8) 1.00 
   Type II Diabetes Mellitus  3(75.0) 44(25.7) 47(26.9) 0.06 
   GERD 0(0.0) 49(28.6) 49(28.0) 0.58 
   Cancer 1(25.0) 1(0.6) 2(1.1)   0.045 
   Sleep Apnea 
 
2(50.0) 68(39.8) 70(40.0) 1.00 
Other Risk Factors 
 
    
Smoking status †     
   Ever smoked 1(25.0) 28(19.0) 29(19.2) 0.58 
     
Birth Control Pills 0(0.0) 13(7.6) 13(7.5) 1.00 
     
Fondaparinux Treatment Arm 2 (50.0) 96 (50.0) 98 (50.0) 1.00 
     
Therapeutic on Study Drug (%) ¥  1(33.3) 42(36.5) 43(36.4) 1.00 
*BMI measured as kg/m
2 
∞Medical comorbidities defined by patient’s primary care physician 
†Patients were all smoke free for at least two months prior to surgery as per standard protocol  
□Patients on estrogen based birth control pills one month prior to surgery. All patients were free of birth 
control pills one month prior to surgery as per protocol. 





Table 12 Baseline Characteristics of Patients with and without Therapeutic Dose 








Gender (%)     
   Female 44(86.3) 74(86.0) 118(86.1) 0.97 
     
Race (%)     
   White, non-Hispanic 36(70.6) 49(57.0) 85(62.0)  
   Black, non-Hispanic 13(25.5) 34(39.5) 47(34.3)  
   Hispanic 1(2.0) 2(2.3) 3(2.2) 0.40 
     
     
Age-years (range) 25-68 18-65 18-65  
   (Mean ±SD) 42.2±10.5 40.4±9.0 41.0±9.6 0.28 
     
Hospitalization 
 
    
Bariatric Procedure (%)     
  Vertical Sleeve Gastrectomy               24(47.1) 35(40.7) 59(43.1)  
  Roux-en Y Gastric Bypass 
    
27(52.9) 51(59.3) 78(56.9) 0.47 
     
Length of Stay (Mean ±SD) 2.4±0.7 2.4±0.9 2.4±0.8 0.78 
Pre-op BMI (Mean ±SD) * 45.4±5.9 46.3±5.4 45.9±5.6 0.36 
Pre-op D-dimer  1.4±4.7 0.9±3.9 1.1±4.2 0.52 
     
Medical Comorbidities ∞ 
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   Hypertension 21(41.2) 45(52.3) 66(48.2) 0.21 
   Hyperlipidemia 14(27.4) 21(24.4) 35(25.6) 0.69 
   Type II Diabetes Mellitus 13(25.5) 22(25.6) 35(25.6) 0.99 
   GERD 15(29.4) 29(33.7) 44(32.1) 0.60 
   Cancer 1(1.5) 1(1.4) 2(1.5) 0.94 
   Sleep Apnea 
 
23(45.1) 30(34.9) 53(38.7) 0.23 
Other Risk Factors 
 
    
Smoking status †     
   Ever smoked 10(25.6) 13(18.8) 23(21.3) 0.41 
     
Birth Control Pills 4(7.8) 5(5.8) 9(6.6) 0.64 
     
Pre-op D-dimer >0.88 25(29.4) 9(10.6) 24(17.6) 0.005 
     
Fondaparinux Treatment Arm 49(96.1) 17(19.8) 66(48.2) <0.001 
 
*BMI measured as kg/m
2
 
∞Medical comorbidities defined by patient’s primary care physician 
†Patients were all smoke free for at least two months prior to surgery as per standard protocol  
□Patients on estrogen based birth control pills one month prior to surgery. All patients were free of birth 
control pills one month prior to surgery as per protocol. 
¥ Therapeutic level for Enoxaparin ≥ 0.20 IU/L and for Fondaparinux ≥ 0.39 mg/L 
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Table 13 Primary, Secondary and Safety Outcomes 
 







exact p-value  
Primary Outcome n=83 n=92 n=175  
     
Asymptomatic DVT (%) 
 
2(2.4) 2(2.2) 4(2.3) 1.00 
Secondary Outcome 
 
n=71 n=66 n=137  


















0(0.0) 0(0.0) 0(0.0) 1.00 
Safety Outcomes 
 
n=98 n=100 n=198  
Minor Bleeding (%) 
 
5(5.1) 3(3.0) 8(4.0) 0.49 
Increased Creatinine (%) 
 
0(0.0) 1(1.0) 1(0.5) 1.00 
Rapid atrial fibrillation (%) 1(1.0) 1(1.0) 2(1.0) 1.00 
     






















Intra-operative bleeding 4 (4.1%) 2 (2.0%) 6 (6.1%) 
Rectus sheath hematoma 0 (0.0%) 1 (1.0%) 1 (0.05%) 
Melena 1 (1.0%) 0 (0.0%) 1 (0.05%)  
Bright red blood per rectum 1 (1.0%) 0 (0.0%) 1 (0.05%) 
Rapid atrial fibrillation 2 (1.0%) 1 (1.0%) 3 (1.5%) 
Elevated creatinine 0 (0.0%) 1 (1.0%) 1 (0.05%) 
Thrombocytopenia 0 (0.0%) 1 (1.0%) 1 (0.05%) 
Rash 1 (1.0%) 1 (1.0%) 2 (1.0%) 
Nausea and vomiting 2 (1.0%) 2 (2.0%) 4 (2.0%) 
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Chapter 6 Public health-based approaches and future work in the prevention of VTE in 
this special population. 
6.1 Public Health Relevance 
In recent years there has been a marked increase in the awareness of patient safety with special 
attention focused on VTE prevention at both the federal and national level. Programs have been 
implemented to raise public and healthcare awareness, increase surveillance and research efforts 
with specific goals to reduce VTE events and improve outcomes in the hospitalized patient. 
Moreover, it is well recognized that in certain special populations such as the obese surgical 
patient, the risk of VTE may be three times as high as the general population. (148) 
In 2011, a new program was developed by the U.S. Department of Health and Human Services 
(Partnership for Patient Better Care, Lower Costs) aimed at reducing the number of preventable 
VTE cases in the hospitalized patient. (15) Using the National Hospital Discharge Survey 
(NHDS) the CDC estimated that between 2007 to 2009 there were over 500,000 VTE events in 
hospitalized adult patients (>18yrs old) within the United States. (149) They recognized that the 
majority of DVT and PE events could be prevented and that there was opportunity to reduce 
disease burden via implementation of evidence-based prevention strategies within the hospital 
setting. Simply, this could be achieved by using appropriate administration of prophylaxis which 
may include pharmacologic agents or mechanical devices.  
Johns Hopkins Bayview Medical Center recognized that their VTE event rates were higher than 
the national average and therefore created a VTE task force committee with the main goal of 
reducing the VTE events in their hospital population.  
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6.2 Previous work 
6.2.1 Invited Presentations 
On March 10, 2010 I was invited to be a guest speaker at the Johns Hopkins Hospital 2
nd
 
Annual Symposium In Recognition Of DVT Awareness Month. My topic of discussion 
was the Prevention of VTE in the Bariatric Surgical Patient: Barriers specific to VTE 
prevention in bariatric surgical patients and, how to overcome these barriers. This 
presentation is now archived on the Johns Hopkins website under Educational Videos. 
http://webcast.jhu.edu/Mediasite/Play/12c7e4266bcb4a98b76b9b60605895c7 




Figure 27 Educational Video: Prevention of Venous Thromboembolism in the Bariatric 
Surgical Patient by Kimberley E. Steele, M.D. 
 
6.2.2 Invited Committees 
In 2011, I was honored to be asked to represent surgery, more specifically bariatric surgery to 
become a member of a task force/committee to work on improved ways to prevent VTE during a 
hospital admission. The Johns Hopkins Bayviwe Medical Center had a higher than national 
average of in hospital VTE rates and needed to address this problem. The committee included an 
orthopedic surgeon, an obstetric and gynecologic surgeon, a bariatric surgeon (this author), a 
hospitalist, a physical therapist and a pharmacist. We met once a week for 10 months reviewing 
hospital data, previous preventative measures, completing staff surveys and then finally making 
recommendations for improvement.  
Our recommendations included: 
1. We created education pamphlets for distribution to our patients during their hospital admission. 
(Figure 28) 
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2. Standard protocols that were part of order sets. (Figure 29) 
3. Mandatory questionnaires that a physician had to fill in while completing hospital admission 
orders. This questionnaire ascertained the VTE risk profile for the patient and then provided VTE 
recommendations. (Figure 30) 
4. Alerts while completing orders. Physicians are unable to finish hospital admission orders until 
the proper VTE prophylaxis was ordered.  
5. Creation of educational material for our patients including extended prophylaxis and Coumadin 
teaching. 

















Figure 30 Physician Order Entry VTE Prophylaxis Risk Guide and Standardization 
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6.4 Future Projects  
Project Name: APB study – Apixaban Pharmacokinetics in Bariatric Patients: A study to 
determine the pharmokinetics and pharmodynamics of apixaban in obese patients who 
undergo bariatric surgery. 
Type of support: Drug plus funding – submitted to Pfizer/Bristol Meyers December 
2013 
Study Rationale: Obesity is now the leading health problem of the 21
st
 century. Weight 
reduction by conservative methods including diet and exercise has had poor success rates. 
There has been a substantial increase in the use of bariatric surgery to provide sustained 
weight loss and thus a reduction in the medical comorbidities that are associated with 
obesity. However, because these procedures may alter the anatomical and physiological 
aspects of the gastrointestinal system, there is a possibility of altered pharmacokinetics to 
medications particularly when taken orally. Furthermore, patients typically lose anywhere 
from 50 to 75% of their estimated excess body mass approximately one to two years 
following surgery. This successful therapeutic outcome of the surgery may be causing 
long term changes in the pharmacokinetics that are independent of any direct anatomical 
or physiologic changes induced by the procedure.    
Physicians and surgeons are very interested in the oral anticoagulants for this special 
patient population. To date, there is no approved dosing for the obese patient (especially 
when considering surgical intervention such as bariatric surgery). 
Our Center for Bariatric Surgery is interested in conducting a pharmacokinetic study 
of apixaban in the obese adult population. More interesting would be to see how the dose 
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may change pre- vs. post-bariatric surgery (this will be important for physicians as more 
and more patients undergo this procedure worldwide and many may require 
anticoagulation in their future healthcare).  
Specific Aims and Hypotheses: 
Specific Aim 1: To determine the pharmacokinetics of apixaban in patients with a body 
mass index (BMI) of 35 kg/m2 or greater.  
Hypothesis 1a: Obese patients prior to bariatric surgical intervention, compared to 
normal weight historical controls, will have a decrease in both Cmax and AUC when 
given the standard dose of 5 mg of apixaban.  
Specific Aim 2: To determine the pharmacokinetics of apixaban in the bariatric surgical 
patient who has undergone Roux-en Y gastric bypass (RYGB) or Vertical Sleeve 
Gastrectomy (VSG) at 1, 6, 12 and 18 months post-op.  
Hypothesis 2a: Patients who have recently undergone RYGB surgery (1 month post-op) 
will have a decrease in both the Cmax and AUC when given the standard dose of 5 mg of 
apixaban.  
Hypothesis 2b: Patients who have recently undergone VSG surgery (1 month post-op) 
will have a decrease in both the Cmax and AUC when given the standard dose of 5 mg of 
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apixaban. The magnitude of the decrease in Cmax and AUC will be less than that seen in 
RYGB patients.  
Rationale: Anatomic alteration of the GI tract will immediately reduce absorption in all 
post-operative bariatric patients. In RYGB patients, the attenuated small bowel and 
altered bile acid composition will lead to decreased absorption of the drug, whereas in 
sleeve gastrectomy patients prolonged gastric emptying will affect pharmacokinetics.  
These findings will be important when considering the use of apixaban as an oral 
anticoagulation option for perioperative VTE prophylaxis in the bariatric population, both 
in the acute hospital setting and after discharge in patients requiring extended VTE 
prophylaxis or treatment.  
Hypothesis 2c: Patients who have undergone bariatric surgery (6, 12, and 18 months 
post-op) will have an increase in Cmax and AUC when given the standard dose of 5 mg 
of apixaban. 
Hypothesis 2d: Patients who have undergone RYGB (6, 12, and 18 months post-op) will 
have a greater increase in both Cmax and AUC than VSG patients when given the standard 
dose of 5 mg of apixaban. 
Rationale: Patients who are 6 to 18 months post-bariatric surgery generally have a 30-
40% decrease in excess body weight. This decrease in body weight reduces volume of 
distribution of drug, resulting in higher plasma levels.  
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The effect of RYGB vs sleeve gastrectomy on long-term pharmacokinetics is difficult to 
predict because of the opposing effects of greater weight loss with reduced absorption in 
the RYGB patient.  
These findings will be important when considering apixaban as an oral medication for 
long-term post-op bariatric patients that may require anticoagulation for stroke, 
myocardial infarction, atrial fibrillation or orthopedic procedures such as hip or knee 
replacements.  
Specific Aim 3: To measure the effect of apixaban on Factor Xa activity in bariatric 
surgical patients pre-operatively then at 1, 6, 12 and 18 months post-operatively. 
Hypothesis 3a:  In spite of the changes in pharmacokinetics, the pharmacodynamics 
response (measured with Factor Xa activity) will not differ by more than 10% in 
comparing pre-surgical response to that at 1, 6, 12 and 18 months after surgery. 
Rationale:  The changes in pharmacokinetics should not lead to a different dose-response 
relationship in the Factor Xa activity of individual patients following dosing with 
apixaban 5 mg.  Were there to be a significant change in pharmacodynamics, other 
factors due to the altered anatomy or substantial weight loss would need to be invoked to 




a. Primary objective: To determine the durability or change in pharmacokinetics and 
pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or 
greater who undergo one of two bariatric surgical procedures. 
b. Secondary objectives:  
1. To compare/contrast the pharmacokinetics and pharmacodynamics of apixaban in 
bariatric surgical patients who have undergone RYGB vs. VSG.   
2. To determine how the pharmacokinetics of the drug may differ when there is 
significant post-operative surgical weight loss (>40% estimated excess body weight) 12 
to 18 months following surgery. 
Treatment: Dose schedule, duration, and concurrent medications:  5 mg of apixaban 
given within one month before bariatric surgery, then 1, 6 and 12 months after bariatric 
surgery if patient loses at least 30% of body weight, and then again within 18 months of 
surgery if patient achieves 40% loss of body weight.  There will be no required 
concurrent medications.  Excluded medications are mentioned below. 
Study population: Obese patients with a body mass index (BMI) of 35 kg/m2 or greater 
that have been approved for bariatric surgery at the Johns Hopkins Center for Bariatric 
Surgery from Jan. 2014 until all patients recruited.    
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Sample size/sample size justification:  We propose to study 25 subjects in each arm 
(RYGB vs. VSG). We have accounted for loss to follow-up (even with a 36% (9 in each 
group) drop-out rate, we would have enough subjects (16 per group) to demonstrate a 25 
% change in AUC with an alpha error of 0.05 and a beta error of 0.2 (Power of 80%).  If 
there is no loss to follow-up and all patients remain in the study, this will allow us to 
demonstrate a 20% change in AUC with an alpha error of 0.05 and a beta error of 0.2. 
These calculations were calculated based on the following data: Ratio of geometric mean 
point estimated for high body weight (>120 kg) vs. normal body weight for Cmax = 0.692 




Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who are 





1. History of documented clotting/coagulation disorder. 
2. History of cancer (within the last year)  
3. Any diagnosis requiring anti-coagulation 
4. History of hypersensitivity reaction to apixaban 
5. Active clinically significant bleeding  
 
Study Assessments (and methodology):  Consenting subjects will be hospitalized 
overnight in the JHH Clinical Research Center.  A dose of 5 mg apixaban will be 
administered, and blood samples for apixaban concentration and Factor Xa activity will 
be collected before and at 1, 2, 3, 4, 6, 8 and 24 hours after dosing.  The apixaban 
concentrations will be measured at Pfizer, and the Xa activity measured at JHH. 
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Data and statistical Plan:  Routine pharmacokinetic data will be determined, including 
Cmax, Tmax and AUC for each subject at each dosing time, and compared within 
subjects and between subjects and between groups.  Factor Xa activity will be compared 














A.4.1 Search Strategy 
PUBMED 
 
(((("Phlebography"[Mesh]) AND "Magnetic Resonance Imaging"[Mesh] OR "magnetic 
resonance venography" OR mrv OR ("magnetic resonance" AND venography [tw]) OR 
"mr venography" OR ("mr" AND venography))) AND (("Venous Thrombosis"[Mesh] AND 








#3 #1 AND #2 517 
#2 'deep vein thrombosis'/exp OR ('venous 
thromboembolism'/exp AND deep:ab,ti) OR dvt:ab,ti OR 
('deep vein' NEAR/3 thrombos*):ab,ti 
44,243 
#1 'phlebography'/exp AND 'nuclear magnetic resonance 
imaging'/exp OR ('magnetic resonance' NEAR/3 
venography):ab,ti OR mrv:ab,ti OR (mr NEAR/3 






Search Name: Magnetic resonance venography for deep vein thrombosis 
Last Saved: 17/02/2014 18:33:53.042 
Description:   
 
ID Search  
#1 MeSH descriptor: [Phlebography] explode all trees 
#2 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 
#3 "magnetic resonance" near/3 venography or mrv or mr near/3 venography  
#4 (#1 and #2) or #3  
#5 MeSH descriptor: [Venous Thrombosis] explode all trees 
#6 #5 and deep  
#7 dvt or "deep vein" near/3 thrombos*  
#8 #6 or #7  
#9 #4 and #8 
143 
 
15 total citations retrieved 
3 Cochrane reviews 






((TITLE-ABS-KEY("magnetic resonance" W/3 venography) OR TITLE-ABS-KEY(mrv) OR 
TITLE-ABS-KEY(mr W/3 venography) OR TITLE-ABS-KEY("magnetic resonance 
venography"))) AND ((TITLE-ABS-KEY("deep vein thrombosis") OR TITLE-ABS-KEY("deep 
vein" W/3 thrombos*) OR TITLE-ABS-KEY(dvt OR dvts))) 
Searched 2/17/2014 
 
177 citations retrieved 
 
WEB OF SCIENCE 
 
TOPIC: (((("magnetic resonance" NEAR/3 venography) OR (mrv) OR (mr NEAR/3 
venography) OR ("magnetic resonance venography")))) AND TOPIC: (((("deep vein 
thrombosis") OR ("deep vein" NEAR/3 thrombos*) OR (dvt OR dvts))))  
Timespan=All years. Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, 
BKCI-SSH, CCR-EXPANDED, IC.  
Searched 2/17/2014 
 
125 citations retrieved 
 
Hand Search was performed on 4 of the top 40 impact journals: Radiology, Investigative 
Radiology, Journal of Magnetic Resonance Imaging, JAMA surgery and Clinical 




Total citations retrieved: 1062 
Duplicates removed:  406 




A.4.2 Cohort Data Extraction Form 
Characteristics of Cohort studies (can do the same for case-control studies if there 
are any) 
 
A. Review author 
B. Study ID  
C. Date completed 
D. Methods 
1. Total number of subjects recruited in the study (exclude studies with <10 patients), 
number of cases 
2. Exclusion criteria  
3. Diagnosis of DVT present prior to MV 
 
E. Participants 
6. Country of origin 
7. Setting (where cases recruited from)-specify Yes or no for options below 
(a) Healthcare setting (hospitals/clinics) 
(b) Academic (university hospitals) 
(c) Registry 
(d) Community 
(e) Other, please specify 
8. (a)Age (mean)                   (b) age (SD) 
9.  Gender                                 Female (N,%) 
10. Race N(%) 
(a) American Indian or Alaskan Native 
(b) Asian 
(c) Black/African American 
(d) Native Hawaiian/Pacific Islander 
(e) Spanish/Hispanic/Latino 
(f) White 
(g) Other, please specify 
 
F. Exposure 
11. Procedure type  
(a) MRV      
(d) Other-specify 
12. What type of MRV was used for the procedure? 
13. Was MRV done with or without contrast? 
14. Reference standard used? 
(a) ultrasound/duplex 
(b) CT  
 
G. Outcome 
19. No. of true positives 
20. No of. true negatives 
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21. No. of false positives 
22. No. of false negatives 
 
 
H. Other variables of interest 
 
I. Measures of association 
25. Which measure of association was reported? 
(a) Odds ratio                    (b) ln(Odds ratio) 
(c) Other measure of association, specify 
(d) ln(measure of association) 
27. SE of measure 
(a) ln(SE of measure) 
28. 95% CI of measure 
29. List variables adjusted for: 




A.4.3 Risk of Bias Assessment 
QUADAS-2 Quality of Study and Risk of Bias Data Collection Form 
Study Title and Date of 
Publication:___________________________________________ 
Author:___________________ 
Phase 1: State the review question: 
Patients (setting, intended use of index test, presentation, prior testing): Index test(s): 
Reference standard and target condition: 









Phase 3: Risk of bias and applicability judgments 
QUADAS-2 is structured so that 4 key domains are each rated in terms of the risk of bias 
and the concern regarding applicability to the research question (as defined above). Each 
key domain has a set of signalling questions to help reach the judgments regarding bias 
and applicability. 
DOMAIN 1: PATIENT SELECTION 
A. Risk of Bias 
Describe methods of patient selection: 
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1. Was a consecutive or random sample of patients enrolled? 
Yes/No/Unclear 
2.  Was a case-control design avoided? 
Yes/No/Unclear 
3. Did the study avoid inappropriate exclusions? 
Yes/No/Unclear 
Could the selection of patients have introduced bias? 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Is there concern that the included patients do not match the review question? 
CONCERN: LOW/HIGH/UNCLEAR 
DOMAIN 2: INDEX TEST(S) 
If more than one index test was used, please complete for each test. 
A. Risk of Bias 
Describe the index test and how it was conducted and interpreted: 
1. Were the index test results interpreted without knowledge of the results of the 
reference standard? 
Yes/No/Unclear 
2. If a threshold was used, was it pre-specified? 
Yes/No/Unclear 
Could the conduct or interpretation of the index test have introduced bias? 
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RISK: LOW /HIGH/UNCLEAR 
B. Concerns regarding applicability 
Is there concern that the index test, its conduct, or interpretation differ from the review 
question? 
CONCERN: LOW /HIGH/UNCLEAR 
 
DOMAIN 3: REFERENCE STANDARD 
A. Risk of Bias 
Describe the reference standard and how it was conducted and interpreted: 
1. Is the reference standard likely to correctly classify the target condition? 
Yes/No/Unclear 
2. Were the reference standard results interpreted without knowledge of the results of 
the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its interpretation have introduced bias? 
RISK: LOW /HIGH/UNCLEAR 
B. Concerns regarding applicability 
Is there concern that the target condition as defined by the reference standard does not 
match the review question? 
CONCERN: LOW /HIGH/UNCLEAR 
 
DOMAIN 4: FLOW AND TIMING 
A. Risk of Bias 
149 
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
1. Was there an appropriate interval between index test(s) and reference standard? 
Yes/No/Unclear 
2. Did all patients receive a reference standard? 
Yes/No/Unclear 
3. Did patients receive the same reference standard? 
Yes/No/Unclear 
4. Were all patients included in the analysis? 
Yes/No/Unclear 
Could the patient flow have introduced bias? 
RISK: LOW /HIGH/UNCLEAR 
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in obese adults with normal and impaired glucose metabolism. Cardiovascular 
Diabetology. 2010 Dec 1;9:83. 
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23. Pallayova M, Steele KE, Magnuson TH, Schweitzer MA, Smith PL, Patil SP, 
Bevans-Fonti S, Polotsky VY, Schwartz AR. Sleep Apnea Determines Soluble TNF-
alpha Response to Massive Weight Loss. Obesity Surgery.  2011 Sep;21(9):1413-23. 
 
24. Lin B, Hyndman ME, Steele KE, Feng Z, Trock BJ, Schweitzer MA, Pavlovich CP. 
Incidence and risk factors for inguinal and incisional hernia after laparoscopic radical 
prostatectomy. Urology. 2011 Apr;77(4):957-62. [Epub 2011 Feb 18.] 
 
25. Lidor AO, Chang DC, Feinberg RL, Steele KE, Schweitzer MA, Franco MM. 
Morbidity and mortality associated with antireflux surgery with or without paraesophageal 
hernia: a large ACS NSQIP analysis. Surgical Endoscopy. 2011 Sep;25(9):3101-8. Epub 
2011 Apr 22. 
 
26. Steele KE, Schweitzer M, Shore A, Makary M, Nguyen H, Lidor A, Prokopowicz G, 
Magnuson T. Long-term Risk of Venous Thromboembolism Following Bariatric Surgery. 
Obesity Surgery. 2011 Sep; 21(9):1371-6. 
  
27. Steele KE, Prokopowicz GP, Chang H, Richards T, Clark J, Weiner J, Bleich S, Wu 
A, Segal J. Risk of Complications after Bariatric Surgery Among Individuals With and 
Without Type 2 Diabetes Mellitus. Surgical Obesity and Related Diseases. 2012 May-
Jun;8(3):305-30. Epub 2011 Jun 15. 
 
28. Bleich S, Chang H, Steele KE, Segal J. Impact of Bariatric Surgery on Healthcare 
Utilization and Costs among Patients with Diabetes. Medical Care. 2012 Jan;50(1):58-
65. 
 
29. Steele KE, Lidor A, Magnuson T, Wong D, Schweitzer MA. Obesity and the Brain: 
Implications for the Surgeon. Bariatric Times. 2011;8(7):12–13. 
 
30. Eaton, LCB, Walsh CM, Magnuson TH, Schweitzer MA, Lidor AO, Nguyen HT, 
Steele, KE. An online bariatric surgery information session is as effective as an in-
person information session. Surgical Obesity and Related Diseases. 2012 Mar-
Apr;8(2):225-9; discussion 229. Epub 2011 Nov 7. 
 
31. Tymitz K, Steele KE, Schweitzer M. Laparoscopic single-incision repair of internal 
hernia defects using an intracorporeal suturing techniques. Surgical Obesity and Related 
Diseases, 20011; 7(6):778-80. 
 
32. Coughlin J, Guarda A, Clark J, Furtado M, Steele KE, Heinberg L. "A Screening Tool 
to Assess and Manage Behavioral Risk in the Postoperative Bariatric Surgery Patient: 
The WATCH". The Journal of Clinical Psychology in Medical Settings (J Clin Psychol 
Med Settings). 2013 Dec; 20(4):456-63. 
 
33. Chen, C, Colbert-Getz J, Green I, Steele KE, Lawson S, Chou B, Andersen D, Satin 
A. Warm-Up on a Simulator Improves Resident’s Performance in Laparoscopic Surgery: 
A Randomized Trial. Int Urogynecol J. 2013 Oct; 24(10):1615-22. 
 
34. Kawaji Q, Marohn M.,Stem M, Fleming R. M., Schweitzer M.A., Steele KE, Lidor 
A.O. Defining Recurrence After Paraesophageal Hernia Repair: Correlating Symptoms 
And Radiographic Findings. Surgery. 2013 Aug; 154(2):171-8. 
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35. Knoepp L., Semins MJ, Shore A, Wright J, Steele KE, Chen G, Matlaga B, Clark J, 






1. Steele KE, Makary MA, Eckhauser FE. Review of Postoperative Surveillance in 
Patients with Colorectal Cancer Who Have Undergone Curative Resection. 
American Journal of Oncology Review, 2006; 24(3): 386-394. 
 
2. Gupta A, Steele KE, Schweitzer M, Lidor A, Lyn-Sue J. Surgical Site Infection in 
the Morbidly Obese Patient: A Review. Bariatric Times 2008; 5: 30-33. 
 
3. Hyams E, Steele KE, Matlaga B. Bariatric Surgery and Risk of Stone Disease. 
American Urology Society. 2012 Update Series Volume 31 CME 
 
 
State of The Art Articles 
 
1. Steele KE, Schweitzer MA, Lidor AO. Prophylaxis of Venous Thromboembolism in 







1. Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. An Unusual Case of a 
Gastric Bezoar Causing Obstruction after Roux-en Y Gastric Bypass. Surgery for 
Obesity and Related Diseases, 2006;2:536-537. 
 
Invited Critique & Editorials 
 
1. Steele KE. Hospital Complication Rates with Bariatric Surgery in Michigan 
Centers of Excellence: The Emperor’s New Clothes? Archives of Surgery, Arch 
Surg. 2011;146(3):254-255. 
 
2. Steele KE. Recent National Trends in the Use of Adolescent Inpatient Bariatric 
Surgery, 2000 through 2009. Why Isn’t Bariatric Surgery for Adolescents 
Catching On? JAMA Surg. 2013; 148(4): 314-315. 
 
 
Book Chapters  
 
1. Steele KE, Lidor AO, Laparoscopic Cholecystectomy. In Cameron JL, editor. Current 
Surgical Therapy 9th edition. Mosby; 2008: chapter-Minimally Invasive Surgery. 
 
2. Marohn MR, Steele KE, Lawler LP. Minimally Invasive Surgical and Image Guided 
Interventional Approaches to the Spleen. In Yeo CJ, editor. Shackleford’s Surgery of the 
Alimentary Tract. 5th edition. Chpt 127, pp 1780-1797. Saunders/Elsevier; 2007. 
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3. Steele KE, Wolfgang C. Nutrition. General Surgery Review, 2nd edition Makary MA, 
editor. Chpt 38, pp 461-471. Ladner-Drysdale: Washington D.C., 2006. 
 
4. Steele KE, Dackiw A. Adrenal Gland. General Surgery Review, 2nd edition, Makary 
MA, editor. Ladner-Drysdale: Chpt 19, pp 269-284. Washington D.C., 2006. 
 
5. Steele KE, Magnuson T, Schweitzer MA. Obesity and Bariatrics. General Surgery 
Review, 2nd edition Makary MA, editor. Chpt 14, pp 199-206. Ladner-Drysdale: 
Washington D.C., 2006. 
 
6. Steele KE, Lidor AO. Hasson Canula. The Sages Manual of Strategic Decision 
Making: Case Studies in Minimal Access Surgery. Ch1, pp5-7 Springer 2008. 
 
7. Steele, KE, Zeiger, MA Testosteronoma - Contemporary Endocrinology, A Cased-
Based Guide to Clinical Endocrinology. Part XVI, 489-497. Humana Press/Elsevier, 
2008. 
 
8. Vaidya V, Steele KE, Schweitzer M, Shermak M. Surgical Weight Loss for Obesity. 
Kaplan and Sadock's Synopsis of Psychiatry 9th Edition: Behavioral Sciences/Clinical 
Psychiatry. Sadock B, Sadock VA and Ruiz P, editor. Chpt 24.4, pp 2273-2289. 
Lippincott, Williams and Wilkins, 2009. 
 
9. Steele KE, The Stomach and Duodenum. Chapter 13. Lawrence Textbooks, 
Essentials of General Surgery 5th edition. Chpt 13. pp 244-273. Lippincott, Williams and 
Wilkins, 2013. 
 
10. Steele KE, Wolfgang C., De la paz E. Nutrition. General Surgery Review, 3rd edition 
Makary MA, editor. Ladner-Drysdale: Washington D.C., 2013. (in press) 
 
11. Steele KE, Magnuson T, Zuberi K. Obesity and Bariatrics. General Surgery Review, 





1. Steele KE, Burke A.  American College of Obstetricians and Gynecologists 
(ACOG) - Clinical Updates in Women's Health Care. Weight Loss Surgery and 




1. Steele KE, Schweitzer MA, Laparoscopic Revision of a Staple Line 
Dehiscence after Open Roux-en-Y Gastric Bypass. 2007 Video- Based 
Education Session accepted for presentation at American College of 
Surgeons on New Orleans 2007. 
 
2. Schweitzer MA, Mitchell M, Steele KE, Lynn-Sue J, Okolo P. Transoral 
endoscopic closure of a gastric fistula. American Society of Metabolic and 
Bariatric Surgeons, Video Session, Washington, DC, June 2008. 
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3. Nguyen H, Schweitzer MA, Steele KE, Lidor AO. Laparoscopic Truncal 
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1. 11/30/2008 to present, Mechanisms of sleep apnea in severe obesity.   
 Identification number - RO1HL050381 
 Sponsor- NIH 
 Total direct costs=$1,030,196. Current year direct costs=$247,613.  
 Principal Investigator- Alan R Schwartz, M.D., 
 Co-investigator – Kimberley E. Steele, M.D., percent effort - as needed. Active 
 recruitment 
 
2. 8/2009 to present, A pilot study to determine the feasibility of conducting a 
randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with 
enoxaparin (Lovenox) twice daily with respect to preventing 
venothromboembolism after bariatric surgery in obese patients. 
 Sponsor - Glaxo SmithKline Investigational Initiated Grant 
 Grant award=$348,936.00 
 Principal Investigator - Kimberley E. Steele, M.D.,percent effort - 4%. Active 
 recruitment. 
 
3. 05/2010 to present, Improving Diabetes through Lifestyle of Surgery (IDeaLs) 
Clinical Trial. Laparoscopic Roux-en Y Gastric Bypass, Laparoscopic Adjustable 
Gastric Banding or Diet Alone in the lower BMI of 30 to 35. 
 Identification number - 5KL2RR025006  
 Sponsor – NIH 
 Total direct costs= $250,000.  
 Principal Investigator - Jeanne Clark, M.D. 
 Co-investigator - Kimberley E. Steele, M.D., percent effort - as needed. Active 
 recruitment. 
 
4. 07/01/2011 to 05/30/2014, NIH Clinical Scholar Award (KL2): Institute for 
Clinical and Translational Research, The Johns Hopkins University.  
 Identification number - 5KL2RR025006.  
 Total award amount: $301,080. 
 Principal Investigator – Kimberley E. Steele, M.D., percent effort – 80%,   
 Presently, at the Johns Hopkins Bloomberg School of Public Health completing 
 my Ph.D. in Graduate Training and  Clinical Investigations. Scheduled to 
 graduate June 2014.  
 
5. 07/2013 to 06/2015, Serum Contraceptive Hormone Levels before and after 
gastric bypass surgery 
 Sponsor – Family Planning Association 
 Total award – $250,000 
 Principal Investigator – Ann Burke, M.D., M.P.H. 




6. 07/2013 to 6/30/2014, Neurochemical Changes Induced by Bariatric Surgery: 
The Gut-Brain Axis and its Relationship to Weight Loss 
 Sponsor – American Metabolic and Bariatric Society (ASMBS) 
 Total grant award - $ 49, 632. 





1. 10/2014 to 01/31/2018, Neurobiolgic Biologic Alterations in Bariatric Surgery: 
Taste response and weight loss (K23 application) 
 Sponsor – NIH, NIDDK 
 Total grant award – $742, 298. 
 Principal Investigator – Kimberley E. Steele, M.D., percent effort – 75%, to be  
 reviewed in June 2013.  
 Primary Mentor – Dr. Timothy Moran 
 
2.    07/2014 to 06/30/2015, Supplementary Funding for the K23 grant: Neurobiologic 
 Alterations in  Bariatric Surgery: Taste response and weight loss 
 Sponsor – The Johns Hopkins Bloomberg School of Public Health 2013: The 
 Bacon Field Chow  Memorial Fellowship Award 
 Total grant award - $23, 500 
 Principal Investigator – Kimberley E. Steele, M.D., percent effort – 1% 
 
3.  07/2014 to 06/2016, The Effect of Pre-operative Warm-up on Operative 
 Performance 
 Sponsor – Society of American Gastrointestinal and Endoscopic Surgeons 
 Total grant award – $29, 666 
 Principal Investigator – Kimberley E. Steele, M.D., percent effort – 5% 
 
4.  10/2014, Feasibility and Safety of the OverStitch Endoluminal Vertical Sleeve 
 Gastroplasty 
 Sponsor – NIH (R21) 
 Total award - $429, 752 
 Principal Investigator – Nisa Maruthur, M.D., M.P.H. 
 Co-Investigator – Kimberley E. Steele, M.D., percent effort – 1% 
 
5.  07/2014 to 07/2015, Metagenomic Analysis of the Human Gut Microbiome before 
 and after Bariatric Surgery: Comparison of Roux-en Y Gastric Bypass and  
 Sleeve Gastrectomy 
 Sponsor – Hopkins Digestive Diseases Basic Research Core Center Pilot Project 
 Total award – $25, 000 
 Principal Investigator – Jeanne Clark, M.D. 
 Co-Investigator – Kimberley E. Steele, M.D., percent effort 1% 
 
6.  12/01/2014 to 11/18/2019, Implementing behavioral treatment to reverse weight 
 gain after bariatric surgery 
 Sponsor – NIH subcontract with University of Pennsylvania 
 Total award - $1,678,270.00 
 Prinicipal Investigator – Janelle Coughlin, Ph.D. 
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 Co-Investigator – Kimberley E. Steele M.D., percent effort 5% 
 
7. 07/01/2014 to 06/30/2016, APB study – Apixaban Pharmacokinetics in Bariatric 
Patients: A study to determine the pharmokinetics and pharmodynamics of 
apixaban in obese patients who undergo bariatric surgery.  
 Sponsor- Pfizer 
 Total award - $100,000.00. 
 Prinicpal Investigator-Kimberley E. Steele M.D. 
 Co-investiagors-Brent Petty M.D., Michael Streiff M.D., Thomas Kickler M.D., 
 Charlie Flexner M.D., Michael Schweitzer M.D., Thomas Magnuson M.D. 
 
8. 07/01/2014 to 06/30/2016, The SAVIOR trial: Surgical Application of Vac 
dressings In Obese patients to Reduce wound complications. 
 Sponsor-KCI  
 Total award-$100,000.00. 
 Principal Investigator-Kimberley E. Steele M.D., Mahmood Malas M.D., M.P.H. 
 
9. 07/01/2014 to 06/30/2015, Educating the Bariatric Surgical Patient: A 
comprehensive educational video to enhance patient learning and improve 
patient safety and outcomes in the peri-operative period.  
 Sponsor- Hospital Relations Committee of The Women’s Board of Johns Hopkins 
 Total award-$15,455.00 
 Principal Investigator-Kimberley E. Steele M.D., Taylor Beauregard Kelamis, RN 





1. 8/2006 to 8/2007, Brain dopamine receptor activity in obese subjects before and 
after gastric bypass surgery. 
 Sponsor - The Association of Women Surgeons, 
 Grant award=$25,000 
 Principal Investigator - Kimberley E. Steele, M.D., percent effort - as needed. 
 Project completed and paper published. 
 
2. 07/2009 to 04/2010. An Agency for Healthcare Research and Quality 
(AHRQ)/Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) 
Network Grant Project. Bariatrics and diabetes.  
 Sponsor – AHRQ (DEcIDE) 
 Principal Investigator - Jody Segal, M.D. 
 Co-Investigator - Kimberley E. Steele M.D., percent effort=17%. Project 





1. 04/2/2007 to present, Association of Taq A1 allele with suboptimal weight loss in 
obese patients undergoing Roux-en Y gastric bypass.  
 Sponsor - The Johns Hopkins University School of Medicine Department of 
 Surgery 
 Total grant award=$20,000.  
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 Principal Investigator - Kimberley E. Steele, M.D., percent effort=as needed. 
 Active recruitment. 
 
2. 07/01/2013 to 06/30/2015, Clinician Scientist Award. 
 Sponsor – The Johns Hopkins University School of Medicine, Dean Rothman 
 Total grant award=$160,000. 




Research Program Building / Leadership 
 
07/2012 to present  Associate Director of The Center for Surgical Trials and  
    Outcomes Research (CSTOR), Department of Surgery,  
    JHSOM. In my capacity, I am responsible for supervising  
    (2 research coordinators and a research nurse) the day to  
    day operations, education and leadership of our faculty’s  
    clinical trials. 
 
07/2012 to present  Director of Surgical Research, Department of Surgery,  
    Johns Hopkins Bayview Medical Center. I supervise two  
    research coordinators and mentor medical students, pre- 
    med students, housestaff, MPH/graduate students/Ph.D.  
    students, PA’s, NPs and fellows in surgical research and  
    clinical trials.  





1997-1999  Tutorial Leader for Anatomy and Physical Diagnosis and Clinical  
   Medicine Ross University Year 2 Medical Students, Ross   
   University School of Medicine, Portsmouth, Dominica. 
 
04/2003   Third Year Medical Students Surgical Clerkship Penn State  
   College of Medicine, Instructor, Hershey, PA 
 
08/2003  Chest Tubes and Their Management In-service for Critical Care  
   Nursing/SICU, Instructor, Penn State College of Medicine   
   Hershey, PA 
 
05/25-26/2004  ATLS Course General Surgery Incoming Residents, Instructor,  
   Penn State College of Medicine Hershey, PA 
 
07/21-29/2004  The First Three Days in Surgery General Surgery Incoming  
   Residents, Instructor,  Penn State College of Medicine, Hershey,  
   PA 
 
09/2006 to 2011 Basic Surgical Clerkship for Medical Students, Preceptor (meet  
   once weekly for 1 to 2 hours), Johns Hopkins University Medical  
   School, Baltimore, MD 
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09/2006 to 2011 Student Surgical Clerkship Weekly Lecture Series, Associate  
   Director of the Surgical Clerkship, Johns Hopkins Bayview   
   Medical Center, Baltimore, MD 
 
07/2007, 2008, 2009 OSATS for the General Surgery Incoming Interns, Faculty, Blalock 
   12th floor, MISTC Johns Hopkins Hospital, Baltimore, MD 
  
09/2007 to 2011 Laparoscopic Simulation Curriculum for the Surgical Clerkship, 4 hour  
   lab/course given quarterly to all medical students years 2 to 4 in the  
   surgery clerkship, Faculty, Blalock 12th floor, MISTC Johns Hopkins  
   Hospital, Baltimore, MD 
 
01/31/08 to 2012 Basic and Complex Laparoscopic Skills Curriculum, responsible  
   for developing and teaching these modules to surgical interns and  
   residents, 3 hour labs every Thursday, Author and Faculty, The  
   Johns Hopkins Surgical Residency Program, Baltimore, MD 
 
 
08/2009 to 2012 General Surgery Skills (Chest Tubes, PETs, PEGs,   
   bronchoscopy, bowel  anastomoses, hernias, trauma, vascular  
   anastomoses), responsible for developing and teaching these  
   modules to surgical interns and residents, 3 hour labs every  
   Thursday, Author and Faculty, The Johns Hopkins Surgical  
   Residency Program, Baltimore, MD 
 
11/2008 to present Mock Orals, Faculty for surgical residents PGY 3-5, quarterly to  
   semi-annually, Johns Hopkins Department of Surgery, Baltimore,  
   MD.   
 
03/28/2010  PRECEDE Surgical Clerkship Lecture Series: Basic Radiology, 1 hour lecture, 
   Substitute Faculty, Blalock 12th floor MISTC, Johns Hopkins Hospital, Baltimore, 
   MD 
 
05/13/2010  Surgical Resident Lecture Series, Complications and Management of 
   Bariatric Patients, 1 hour lecture, Faculty, Blalock 12th floor MISTC, Baltimore,  
   MD 
 
05/18/2010  Surgical Boot Camp for Medical Students, Assistant Director and Faculty,  
   The Johns Hopkins University School of Medicine Surgical Clerkship,  
   Blalock 12th floor MISTC, Baltimore, MD. 
 
10/25/2010  PRECEDE Surgical Clerkship Lecture Series: Basic Radiology, 1 hour lecture, 
   Substitute Faculty, Blalock 12th floor MISTC, Johns Hopkins Hospital, Baltimore, 
   MD 
 
 
10/19/2010 to 10/22/2010 Intersession: Metabolism and Obesity, Small Work Group Leader  
    (Management  of Obesity via Surgery) and Debate (Adolescent  
    Bariatric Surgery), The Armstrong Building, Baltimore, MD 
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2/17, 2/24 and 3/3/2011 Transition to the Wards (TTW): Clinical History and Physical  
    Exams, Faculty (2nd year medical students 3hrs per session),  
    Johns Hopkins Hospital, Baltimore, MD 
 
3/3/2011   Surgical Management of Obesity, Faculty (1 hour lecture to the  
    surgical intern  class), Turner Auditorium, Baltimore, MD 
 
3/3/2011   Transition to the Wards (TTW): Examiner of medical students on  
    placement of intravenous catheter (two hour session), JHOC  
    Simulation Center, Baltimore, MD 
 
4/6/2011 and 5/18/2011 PRECEDE: Central Line Sterile Technique and Safe Placement,  
    didactic and technical skills lab, Faculty (15 medical students per  
    three hour session), JHOC Simulation Center, Baltimore, MD 
 
4/6/2011   PRECEDE: One hour lecture on GI Bleeding, Faculty, Blalock 12th 
    floor MISTC, Baltimore, MD 
 
5/20/2011   The Halsted: “New Hands” Surgical Send Off Camp for Medical  
    Students, Faculty, ( 2 hour session), The Johns Hopkins   
    University School of Medicine Surgical Clerkship, Blalock 12th floor 
    MISTC, Baltimore, MD. 
 
10/19/2011 to 10/20/2011 Intersession: Metabolism and Obesity. Small Work Group Leader  
    (Management of Obesity via Surgery) and Debate (Adolescent  
    Bariatric Surgery: Should It Be Done?), Faculty, the Armstrong  
    Building, Baltimore, MD 
 
12/14/2011   Health Promotion and Disease Prevention Course: Obesity and  
    Surgical Options (lecture for the first year medical students),  
    Faculty, The Armstrong Building, Baltimore, MD 
 
02/25/2013   Transition to the Wards(TTW 2013), Surgical Scrub and Gown  
    Practical Session, 9 to noon and Knot Tying and Suturing session, 
    1 to 5pm, Faculty, the Armstrong Building, Baltimore, MD 
 
02/26/2013   Transition to the Wards (TTW 2013), Nasogastric Tube Insertion  
    Practical Session, 1 to 5pm, Faculty, JHOC Simulation Center,  
    Baltimore, MD 
 
02/28/2013   Faculty for Transition to the Wards (TTW 2013), Examiner of  
    medical students on intravenous catheter placement technique, 1  
    to 3pm, JHOC Simulation Center, Baltimore, MD 
 
10/15 to 10/17/2013  Faculty for the Year 3 and 4 Metabolic Intersession 2013, One  
    hour lecture on Why bariatric surgery works and small group  
    sessions 1.5 hours x 2, The Johns Hopkins University School of  





05/8 to 9/2006   SAGES Advanced Foregut Resident Course, Invited  
    Faculty (16 hour instruction), Ethicon Endo-Surgery,  
    Cincinnati, Ohio 
 
05/21/2006   US Surgical Workshop: Endostitch and Intracorporeal  
    Suturing Training Course, Faculty, Blalock 12th floor  
    MISTC, Baltimore, MD. 
 
03/8 to 9/2007   SAGES Advanced Laparoscopic Hernia Surgery Resident  
    Course, Invited Faculty (16 hour instruction), US Surgical  
    Compound, Norwalk, CT 
 
06/18/2012   Laparoscopic Suturing and Skills Course, the Association of  
    Metabolic and Bariatric Surgery (ASMBS) Annual Conference  
    2012, Core Faculty, (4 hour course for International Surgeons),  
    University of San Diego, Minimally Invasive Simulation Labs, San  




03/21/2008              Perioperative Care of the Bariatric Patient: Surgical Nursing 
               In-service, Faculty, 6th Floor Surgery, Johns Hopkins Bavyiew Medical 
    Center, Baltimore, MD 
 
02/27/2009   Importance of Ambulation and Incentive Spirometry in the Bariatric 
    Patient, In-service Faculty, 6th Floor Surgery, Johns Hopkins Bayview 
    Medical Center, Baltimore, MD 
 
02/07/2012   Welch Center Journal Club/Seminar, The Johns Hopkins   
    Bloomberg School of  Public Health MPH and PhD program, noon  
    conference. Invited expert for article presented: Sjostrom L, et al.  
    Bariatric Surgery and Long-term Cardiovascular Events. JAMA  
    2012;307(1) 56-65., Whelton Conference Room, Welch Center,  
    The Johns Hopkins Bloomberg School of Public Health and  
    School of Medicine, Baltimore, MD. 
 
02/20/2012   Miller-Coulson Academy of Clinical Excellence (MCACE) and the  
    Residency Program Clinical Pathology Conference (CPC), invited  
    by Scott Wright MD, Director of Miller-Coulson Academy, Faculty  







07/2005 to present   Outpatient surgical service/clinic, surgical attending ½ to 1 session 
per week 
 
07/2005 to present  Inpatient surgical service/operating room, surgical attending, on  




2005 to present  I have mentored numerous medical students (The Johns Hopkins  
    University School of Medicine and international students including  
    students from Japan, Egypt, India and Greece), nurse   
    practitioners, engineers and surgical residents.  
 
Examples of student mentees: 
 Kendra Harris MD, MHS, Johns Hopkins SOM 2007-2008, went on to radiation oncology 
 residency at JHH. 
 Michael Brinkley, MD, Johns Hopkins SOM 2007-2008, mentored Michael and helped 
 him earn the Doris Duke Award and Fellowship. 
 Sam Hsieh, Royal College of Surgeons, Ireland, Ireland, 2008 to 2009, awarded MD 
 degree 
 Konstantinos Economopoulos, medical student from Greece, Dec. 2008, completed sub-
 internship rotation with me as his supervisor. 
 Hyaehwan Kim, Thomas Jefferson University, medical student, Feb. 2008, completed 
 sub-internship rotation with me as her supervisor. 
 Luis Carlos Cajas-Monson, MD, MPH, Johns Hopkins SOM 2010-2011, awarded MD 
 degree and went on to UCSD for surgical residency. 
 Katie Schlafer, Dickinson College, BSc. (pre-med), 2010-2011 
 Stephanie Baltch, Gaucher College, Baltimore, MD (pre-med program), 2012-2013 
 Elizabeth Goutha, Gaucher College, Baltimore, MD (pre-med program), 2013-2014 
 Anant Subramaniam, CBID Biomedical Engineering, Johns Hopkins University, 
 September 2013, provided mentorship on school team project - the need to prevent or 
 diagnose anastomotic dehiscence following GI/bariatric surgery 
 Gamal Abdalla, medical student from Ains Shams University, Egypt (completing a 3 
 month research elective with me), Jan.to April 2014  
 
2006 to present  The Johns Hopkins Minimally Invasive Surgical Fellowship;  
    training fellows in minimally invasive and bariatric surgery 
    Covidien and Ethicon Fellowship grant funded $75,000.  
    I have been involved in training and mentoring the following  
    fellows: 
 
    2006-2007: Molly Sebastian, MD 
    2007-2008: Hien Nguyen, MD 
    2008-2009: Jerome Lyn-Sue, MD 
    2009-2010: Hamilton Le MD, and Kevin Tymitz, MD 
    2010-2011: Marianne Franco MD, and Tejwant Datta, MD 
    2011-2012: Kathyrn Lamond, MD 
    2012-2013: Kashif Zuberi, MD 
    2013-2014: Erin Moran-Atkin, MD 
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2006 to present  Johns Hopkins Faculty-Instruction and mentoring of laparoscopic  
    approach to gastric bypass, adjustable gastric band, sleeve  
    gastrectomy, foregut surgery including Nissen Fundoplication and  
    Paraesophageal Hernia Repair, colon resection, hernia (ventral  
    and inguinal) repair and splenectomy, trauma call and   
    general surgery call. 
 
05/2010 to present  First year medical student shadowing, The Johns Hopkins first  
    year medical students elect to shadow a surgeon for a period of  
    time. Generally, 1 to 2 weeks. 
 
07/2012 to 06/30/2013 Estefania De La Paz Nicolau, MD, MPH, physician from Mexico  
    who completed her capstone MPH project under my supervision,  
    The Johns Hopkins Bloomberg School of Public Health. Do  
    Antibiotics Change the Microbiota of Bariatric Patients? 
 
09/2012 to present  Taylor Beauregard RN and Nicole Shacochis-Edwards RN, CUSP 
    Safety project initiated by the 6 Surgical Nursing Staff at Bayview  
    Medical Center: Mentoring the nursing staff on a bariatric safety  
    project. Perioperative Education Interventions for the Bariatric  
    Surgical Patient. Chosen by the Department of Surgery for the  
    Johns Hopkins Women’s Board Grant application submission this  
    year. 
 
Educational Program Building 
 
2007 to present  Developed and implemented surgical minimally invasive lab  
    curriculum for The Johns Hopkins Department of Surgery   
    residency program. 
 
2007 to present  Developed and implemented surgical minimally invasive lab  
    curriculum for The Johns Hopkins Surgical Clerkship for the  
    second to fourth year medical students. 
 
2009 to present  PRECEDE faculty- developed a curriculum for The Johns Hopkins 
    medical students clerkships. 
 
2008 to present  Instrumental in developing an hour long informational session for  
    The Johns Hopkins Center for Bariatrics. Website and in-person  
    based. (Goal is to educate potential patients who are interested in  
    bariatric surgery) 
 
01/2010 to present  Duke University surgical residency program utilizes the minimally  








2000 to 2005   Pennsylvania training license 
 




02/2006  American Board of Surgery Certificate #51053 
 
2002 to present Advanced Trauma Life Support Instructor 
 
1999 to present Advanced Cardiac Life Support  
 
1998 to present Basic Life Support 
 
2006 to present Fundamentals of Laparoscopic Surgery (FLS) 
 
Clinical Service Responsibilities 
 
Since 2005, I have taught medical students, general surgery residents and fellows at the 
Johns Hopkins University School of Medicine and surgery residents from Sinai Hospital 
of Baltimore. Teaching occurred on the surgical wards, conferences and in the operating 
room. 
 
Weekly surgical clinic, one and one-half days of operating/surgical procedures, on 
average one hour of rounding on the surgical floor, trauma and general surgery call. 
 
Clinical Program Building 
 
Since 2006, I have been involved in developing The Johns Hopkins Center for Bariatric 
Surgery program. 
 
Since 2009, I have been involved and on the committee for planning an Obesity and 
Metabolic Center at Johns Hopkins Institution. 
 
Since 2009, I have been Director and program builder of the Adolescent Bariatric 
Surgical Program at The Johns Hopkins Center for Bariatric Surgery.  
 
 
ORGANIZATIONAL ACTIVITIES:  
 
Institutional Administrative Appointments 
 
External Committees 
    
2004 to 2006   Resident Liaison, Executive Council for Central  
    Pennsylvania, American College of Surgeon  
    Keystone Chapter 
 
 
2007 to present                      Society of American Gastrointestinal Endoscopic Surgeons 
    membership committee 
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2008 to present  Association of Surgical Education- Surgical Simulation and 
    Education committee 
 
 
2009 to present                      American Society of Metabolic and Bariatric Surgery  




2000 to 2003   General Surgery Resident Class Representative   
    Committee, Penn State College of Medicine 
 
2007 to 2008   Data Safety Monitoring Board (DSMB) 
    Johns Hopkins University School of Medicine 
 
2008 to present   Surgical Resident Education Committee Johns Hopkins  
    University 
 
2009 to present  Johns Hopkins Bariatric Surgery Center of Excellence Committee 
 
2009 to 2010   PRECEDE Medical Student Curriculum Committee 
 
2009 to 2010   Operating Room Task Force Committee, Johns Hopkins  
    Bayview Medical Center. Promoting a better work   
    environment in the operating theater. 
 
2011 to 2012   Prevention of Venothromboembolism (VTE) at Johns  
    Hopkins Bayview Medical Center Working Committee. 
 
2011 to present  Data Safety Monitoring Board (DSMB). GSK Investigator  
    Initiated DVT Project. Johns Hopkins Bayview Medical  
    Center, Baltimore, MD.   
 
Journal Peer Review Activities 
 
05/2008 to present  Contemporary Surgery 
 
06/2008 to present  Surgical Obesity and Related Diseases (SOARD) 
 
04/2009 to present  Archives of Surgery 
 
05/2009 to present  Saudi Journal of Gastroenterology 
 
02/2010 to present  Brain Research  
 
05/2012 to present  Neuroscience Research 
 
06/2012 to present  JAMA & JAMA Surgery (Archives of Surgery) 
 




Advisory Committees and Review Groups 
 
04/09 to present  Association of Metabolic and Bariatric Surgery (ASMBS)  
    Grant Review Committee. Grant Reviewer 
 
02/17 to 19/2009  The Centers for Disease Control and Prevention (CDC),  
    US Medical Eligibility Criteria for Contraceptive Use.  
    Served as expert on panel, discussing recommendations  
    for bariatric patients and contraceptive methods. CDC,  
    Atlanta Georgia. 
 
10/14/2009   The American College of Surgeons Surgical Education I  
    Session- invited discussant. Intensive Laparoscopic  
    Training: The impact of a simplified pelvitrainer curriculum  
    on long term learning in surgical novices. Bonrath et al.  
    Chicago Illinois. 
 
October 18 2013  Requested to serve on NIH committee Special Emphasis  
    Panel (ZRG1 AARR-F(59)). José H Guerrier, Ph.D.  
    Scientific Review Officer, National Institutes of Health  
    Center for Scientific Review, Behavioral & Social   
    Science Approaches to Preventing HIV/AIDS, Rm 3190,  






2003 to 2007   Candidate, American College of Surgeons 
 
2004 to present  Association of Women Surgeons (AWS)  
 
2004 to present  Society of American Gastrointestinal Endoscopic Surgeons 
Candidate (SAGES) 
 
2006 to present  Association of Surgical Education (ASE) 
 
2006 to present  American Society of Metabolic and Bariatric Surgery 
(ASMBS) 
 
2007 to present  Fellow, American College of Surgeons (F.A.C.S) 
 
2007 to present  American Academy of Academic Surgeons (AAS) 
 
2010 to 2012   Liaison for the Academy of Academic Surgeons (AAS) to  
    the Association of Women Surgeons (AWS), invited by the  




Conference Organizers, Session Chair 
 
02/15/2012   The AAS/AWS conference luncheon and plenary session - 
    “Women in Surgical Leadership: Is there more to be  
    done?” Responsible for organizing and chairing the event  
    with invited speakers: Patricia A. Numann, MD (Past  
    President of ACS), Julie Ann Freischlag, MD (Chair Dept.  





Awards and Honors 
 
05/2000   Distinguished Scholar, Valedictorian, GPA 4.0 Ross  
    University School of Medicine. 
 
12/2001   Penn State Hershey Medical Center Peace Tree Book of  
    Honor  Award for Outstanding Patient Care by a Physician. 
 
 
07/2002   Resident Physician Humanitarian Award: in Memory of  
    Jane Witmer Kienle, M.D., Penn State Hershey Medical  
    Center (This was the first time the award was given to a  
    resident from the Department of Surgery) 
 
11/17/2002 to 11/24/2002 Penn State Pediatric Heart Surgical Team, Dr. John L.  
  Myers, Variety Children’s Lifeline Hospital de Ninos, Dr.  
  Roberto Gilbert E Quayaquil, Ecuador. (This was the first  
  time a 2nd year surgical resident was asked to accompany  
  Dr. Myers, in general he only  brings his cardiothoracic 2nd  
  year fellow) 
 
07/2003   Resident Case Study Challenge Winner  PGY3; Penn  
    State College of Medicine Surgical Residents 
 
07/2003 to 2006  AMA Physician Recognition Award in Continuing Medical  
    Education 
 
08/2006   Nominated for Association of Women Surgeons Female  
    Surgical Resident of the Year 2006. 
 
07/16/2008   Shining Star- Excellence in Clinical Care. Johns Hopkins  
    Bayview Medical Center. Baltimore, MD. 
 
06/22/2011   Outstanding Teaching Award, Faculty Teacher. The Basic  
    Surgery Clerkship for the 2010-2011 academic year, Johns 
    Hopkins University School of Medicine, Baltimore, MD. 
 
07/2012   Nominated and chosen to participate in the Office of  
    Women In Science and Medicine 2012 Leadership   
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    Program for Women Faculty (LPWF) Class of 2013, The  
    Johns Hopkins University School of Medicine.  
 
 
Invited Local Presentations 
 
11/10/2005  Guest lecturer - Essex Community College Paramedic Training  
   Graduate Course -Thoracoabdominal Trauma, Essex, MD. 
 
03/2007  Guest lecturer - Johns Hopkins Bayview Medical Center Research 
   Conference- Brain Dopamine Receptors and Obesity. Asthma and 
   Allergy Conference Hall, Johns Hopkins Bayview Medical   
   Campus, Baltimore, MD. 
 
10/20/2006  Guest lecturer - Nutritional Implications of Obesity and The  
   Disordered Eating Conference. Surgical Procedures for Obesity.  
   The Carroll Auditorium, The Johns Hopkins Bayview Medical  
   Center, Baltimore, MD. 
 
10/19/2007  Guest lecturer - Surgical Weight Loss Surgery. National Dietician  
   Interns Conference. Johns Hopkins Bayview Medical Center,  
   Baltimore, MD. 
 
10/28/2008  Guest lecturer - Obesity and Disordered Eating: Dietetic Internship 
   Joint Class Day. Surgical Management of Obesity. Presented to  
   Dietetic Interns from NIH, UMMS, UMd, VTech, NOVA and  
   Sodexo. Carroll Auditorium, Johns Hopkins  Bayview Medical  
   Center, Baltimore, MD. 
 
12/11/2009  Dietician Internship Joint Class Day - Obesity and Disordered  
   Eating. Bariatric Surgery and Nutrition Implications. Carroll  
   Auditorium, Johns Hopkins Bayview Medical Center, Baltimore,  
   MD. 
 
01/09/2010  Guest lecturer - Department of Surgery Annual Retreat 2010. An  
   Update on Research at Johns Hopkins Bayview Medical Center.  
   The Armstrong Medical School Building, Baltimore, MD. 
 
01/28/2010  Invited Speaker - The Johns Hopkins Community Physician  
   Pediatric Division Wyman Park. The Surgical Management of  
   Adolescent Obesity. Wyman Park Medical Plaza, Baltimore, MD. 
 
03/05/2010  Invited speaker -The Johns Hopkins Hospital 2nd Annual DVT  
   Awareness Symposium. The Prevention of Venous   
   Thromboembolism in the Bariatric Surgical Patient. Hurd Hall,  
   Johns Hopkins Hospital, Baltimore, MD. 
 
1/14/2011  Guest panelist - Women in Surgery, medical student meeting with  
   Dr. Julie Ann Freischlag and women faculty. Armstrong Building,  
   The Johns Hopkins University School of Medicine, Baltimore, MD. 
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5/8/2011  Invited panelist- The Johns Hopkins University Pre-Health   
   Leadership Conference. A Women’s Journey: on becoming a  
   surgeon. The Johns Hopkins  University, Glass Pavilion,   
   undergraduate campus, Baltimore, MD. 
 
9/8/2011  Invited speaker - Research Symposium. Halsted Society National  
   Meeting. Central dopamine and its relationship to obesity. The  
   Johns Hopkins Hospital-Hurd Hall, Baltimore, MD. 
 
12/5/2011  Dietician Internship Joint Class Day-Obesity and Disordered  
   Eating. The Surgical Management of Obesity. Asthma and Allergy  
   Auditorium, Johns Hopkins Bayview Medical Center, Baltimore,  
   MD. 
 
 
11/16/2012  Invited faculty and speaker: The Center for Clinical Trials (CCT)  
   and the Graduate Training Program in Clinical Investigation  
   (GTPCI) at the Bloomberg School of Public Health welcomes Dr.  
   Robert M. Califf as a visiting scholar. The Challenges of Clinical  
   Trials: from a clinician’s standpoint. The Johns Hopkins   
   Bloomberg School of Public Health, Baltimore, MD. 
 
12/10/2012  Invited lecturer, The 2012 Annual Dietetic Joint Intern Conference. 
   The Obesity Epidemic: When surgery is the only option. The  
   Asthma and Allergy Center, The Johns Hopkins Bayview Medical  
   Center, Baltimore, MD. 
  
Invited National Presentations 
 
09/06/01  Invited speaker-“Case Study:  Presacral cyst—iatrogenic   
   etiology?”, Visiting Professor Presentation for David Schoetz, Jr.,  
   Professor of Surgery, Tufts University School of Medicine, Division 
   of Colon and Rectal Surgery, Penn State College of Medicine,  
   Hershey, PA. 
 
11/19/2002  Invited speaker-“Case Study:  FAP, desmoid and adrenal   
   incidentaloma”, Visiting Professor Presentation for James   
   Fleshman, Washington University School of Medicine, Section  
   Chief, Colorectal Surgery Division of Colon and Rectal Surgery,  
   Penn State College of Medicine, Hershey,     
   PA. 
 
09/11/2003  Invited speaker- “Case Study: Recurrent GI Bleed Secondary to  
   Jejunal Diverticulum”, Visiting Professor Presentation for Zane  
   Cohen, Division Chair, University of Toronto, Division of Colon  
   and Rectal Surgery, Penn State College of Medicine, Hershey,  
   PA. 
 
12/03/2003  Invited speaker-“Squamous Cell Carcinoma Case Presentation:   
   An Incidental Finding within a Hemorrhoid” GI/Endoscopy Rounds, 
   Penn State Hershey Medical Center, Hershey, PA. 
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05/15/2005  Nursing Grand Rounds -“Critical Care Nursing Update” Trauma  
    Critical Care Module for Nurses in Training. Holy Spirit Hospital,  
   Camp Hill, PA. 
 
05/06/2006  Invited speaker - Cleveland Clinic International Video Web   
   Teleconference: Laparoscopic Morgagni Hernia Repair. Presented 
   from The Minimally Invasive Surgical Center at Johns Hopkins  
   Hospital, Baltimore,MD. 
 
10/30/2007  Guest lecturer - Adolescent Obesity: Tools to help clinicians  
   evaluate and treat, CME: Frederick Maryland. 
 
04/2008  Guest lecturer - Safe Access and Trocar Placement in the   
   Previously Operated Abdomen. American College of Surgeons  
   Conference- Minimally Invasive Surgery Course, San Francisco,  
   California. 
 
12/05/2009  Guest lecturer - Pri-med 2010 Conference Plenary Session -  
   Harvard Medical School and The Johns Hopkins University School 
   of Medicine. The Surgical Management of Obesity. The Baltimore  
   Convention Center, Baltimore, MD. 
 
05/05/2010  Meet the Professor-55th Annual Philip A. Tumulty Topics in Clinical 
   Medicine Course. Case presentations/Question and Answer  
   seminiar on bariatric patients. Turner Auditorium, The Johns  
   Hopkins University School of Medicine, Baltimore Maryland. 
 
05/05/2010  Invited speaker - 55th Annual Philip A. Tumulty Topics in Clinical  
   Medicine. Weight loss Surgery 101: for the primary care physician. 
   Turner Auditorium, The Johns Hopkins University School of  
   Medicine, Baltimore Maryland. 
 
5/4/2011  Meet the Professor-56th Annual Philip A. Tumulty Topics in Clinical 
   Medicine Course. Seminar on what every primary care physician  
   needs to know about bariatric patients. Turner Auditorium, The  
   Johns Hopkins University School of Medicine, Baltimore Maryland. 
 
02/15/2012  Moderator for Association of Women Surgeons Luncheon-Women 
   in Surgical Leadership: Is there more to be done? Organized the  
   event with invited speakers including Drs. Patricia J Numann  
   (President of the American College of Surgeons), Julie Ann  
   Freischlag and Amalia Cochran. The Association of   
   Academic Surgeons (AAS) Annual Surgical Conference Feb. 13- 
   17 2012, Las Vegas, ND. 
 
5/10/2012  Meet the Professor - 57th Annual Philip A. Tumulty Topics in  
   Clinical Medicine Course. A Question and Answer Session - A  
   Primer on Bariatric Surgery for the Primary Care Physician. The  
   Johns Hopkins University School of Medicine, Baltimore Maryland. 
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10/05/2012  Invited speaker at the plenary session for the 2012 Annual   
   Meeting of The North American Menopause Society (NAMS).  
   Obesity: When surgery is the only option. Gaylord Palms   
   Convention Center, Orlando Florida. 
 
10/05/2012  Meet The Professor for the 2012 Annual Meeting of The North  
   American Menopause Society (NAMS). Obesity Surgery: A primer 
   for the primary care physician. Gaylord Palms Convention Center,  
   Orlando Florida. 
 
11/12/2013  ASMBS 2013 Obesity Week – Bariatric Research – Faculty.  
   Research Assessment Methods – How They Differ from What is  




Invited International Presentations 
 
3/19/08  Johns Hopkins International Lecture Series: Bariatric Surgery- 
   Procedures and Complications. Presented to Al  Mishari Hospital  
   in Riyadh, Saudi Arabia Teleconference, Johns Hopkins Medicine  
   Telehealth. Johns Hopkins Hospital, Baltimore, MD. 
 
3/17/09 to 3/20/09 Invited lecturer- Gastroenterology and Hepatology Viva La Vida  
   Conference. Lecturing on 2 subjects: a) The Management of  
   Bariatric Patients and b) The  Surgical Management of Crohn’s  
   Disease. The Ritz Carlton Convention Center, San Juan, Puerto  
   Rico. 
 
6/1/2012  3rd Annual International Women in Surgery Career Symposium.  
   Faculty for the medical students and resident plenary session.  
   Pregnancy in Surgical Residency: how to make it work. Hyatt  




03/18/2008  Grand Rounds, Johns Hopkins Community Physicians: Surgical 
Weight Loss for     the Primary Care Physician: What we need 
to know. Presented to Johns Hopkins    Community Physician Group, 
Burton Pavilion, Johns Hopkins Bayview Medical     Center, 
Baltimore, MD 
 
06/04/2010  Internal Medicine/Multidisciplinary Grand Rounds, Harbor 
Hospital: The Surgical     Management of Obesity: What the 
primary care physician needs to know, Harbor    Hospital, Baltimore, 
MD. 
 
6/10/2011  Internal Medicine Grand Rounds: Surgical Weight Loss   
   Complications, Harbor Hospital, Baltimore, MD. 
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12/5/2011  Sleep Medicine Grand Rounds: Weight Loss Surgery and the  
   Effects on Sleep Apnea, Asthma and Allergy, Rm4B44   
   Conference Hall, The Johns Hopkins Bayview Medical Center,  
   Baltimore MD. 
 
09/28/2012  Pediatric Grand Rounds at Mercy Medical Center: Childhood  
   Obesity: When is surgical intervention an option? Mercy Medical  
   Center, Baltimore, MD 
 
12/07/2012  Grand Rounds, Department of Surgery: Childhood Obesity: When  
   is surgical weight loss appropriate? The Johns Hopkins Bayview  
   Medical Center Department of Surgery, Baltimore, MD 
 
05/22/2013  Grand Rounds: Bariatric Mini-Symposium, Department of   
   Endocrinology, Central Dopamine and the Effect of Weight loss  
   and Taste/ Appetite, Marburg Conference Room, The Johns  








1994 to 1995  Note taker for students with disabilities University of Toronto  
   Volunteer Service for the Department of Special Services,   
   Toronto, Ontario, Canada 
  
January 1995  Special Guest: Ice Skating Performance for the Canadian   
   Association of  Muscular Dystrophy, Maple Leaf Gardens, Toronto, 
   Ontario, Canada 
 
2009 to 2010  Washington Hill Community Board Member, citizens in the   
   community cleaning-up Washington Hill, Improving our city,  






1983 to 1990:   Member of the Canadian National Ice Dance Center and Granite  
   Figure Skating Club, National Competitor, Toronto, Ontario,  
   Canada. 
 
1991 to 1992  German National Bavarian Ice Dance Champion, Oberstdorf,  
   Germany 
 
1992 to 1994  International Carded Athlete, member of the German National  
   Figure Skating Team (Ice Dancing). Olympic Team Member 1994 
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D. Brief Biosketch 
 
 
Dr. Steele was born in Oakville, Ontario Canada. She remained in Ontario throughout her 
elementary and high school years. She then attended the University of Toronto to obtain 
her Bachelor of Science degree with High Honors.  
Early Years 
As a young adult, Dr. Steele never really imagined that she would choose surgery as her 
career. For most of her 20s, she was competing full-time on an international level as an 
ice dancer. An ice dancer attains perfection of movement and form through countless 
hours of practice on the ice. The shift to medicine came after an injury ended her skating 
career. She since found that medicine, and surgery in particular, shares a great deal with 
competitive skating. The dedication, determination and persistence required to be an elite 
athlete carried forward as she pursued a career in medicine. She took an unorthodox 
approach to medicine and returned to her academic studies to earn her MD degree as a 
distinguished scholar and valedictorian from Ross University School of Medicine in 
2000. Despite the parallels that in retrospect seem obvious, she was not drawn to surgery 
at first. Indeed, her initial impression of surgeons was that they were technically skilled 
but somewhat cold, and not especially interested in research or spending time one-on-one 
with the non-anesthetized patient. Her impressions were changed, however, by her 
surgical teacher and mentor in medical school, Dr. Anna Kobylecky. Dr. Kobylecky did 
it all. In the O.R. she was in control: confident, calm, meticulous, and technically astute. 
She was a dedicated teacher who expected a high level of performance from everyone, 
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and for whom complete knowledge of the patient and procedure was an essential 
prerequisite to operating. Most importantly she encouraged Dr. Steele to ask questions 
and be curious about the causes and consequences of disease. It was her mentoring that 
inspired Dr. Steele to pursue an academic career path where she could make a difference 
clinically, by teaching and through research. Dr. Steele completed her general surgery 
residency training at Penn State University School of Medicine in Hershey Pennsylvania 
from 2000 to 2005 and was the first surgical resident to earn the prestigious Kienle 
Humanitarian Award for outstanding clinical skills and compassionate care of her 
patients. She was nominated by the faculty for the Association of Women Surgeons 
Female Surgical Resident of the Year, and had the rare opportunity as a second year 
resident to travel to Ecuador, where she accompanied the chief of pediatric cardiothoracic 
surgery to perform delicate and complicated pediatric heart procedures. From 2005 to 
2006 she completed a minimally invasive and bariatric surgery fellowship at the Johns 
Hopkins Hospital and Johns Hopkins Bayview Medical Center. After completing her 
fellowship, she was actively recruited to The Johns Hopkins Center of Bariatric Surgery 
where she has established a busy surgical practice. In 2009, after having been in practice 
only two years, she was asked to serve as a national expert on the effect of bariatric 
surgical procedures on contraception at the Centers for Disease Control and Prevention 
(CDC) in Atlanta, GA. That same year, she was named Director of the Adolescent 
Bariatric Surgical Program, taking on the task of developing the only program in 
Maryland to offer safe surgical options for the morbidly obese adolescent. In establishing 
this center, she assembled a multidisciplinary team involving faculty and staff from 
pediatric gastroenterology, psychiatry, nutrition and the Mount Washington Weigh Smart 
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Program and together they have obtained IRB approval for a longitudinal study of 
bariatric surgical outcomes in adolescents. She has also played a key role in the 
development of the internationally recognized Johns Hopkins Center for Bariatric 
Surgery Adult Program. 
In her first year as faculty, despite being clinically busy, she volunteered to precept the 
medical students who were completing their surgical clerkship. She was so well received 
by the students and the program director that she was asked to take on the role of 
Associate Director of the Surgical Clerkship in the same year, 2006. Not only did she 
teach various components within the surgical clerkship including labs, didactic sessions 
and in the operating room, she helped with administrative duties, mentored medical 
students (both from Hopkins and abroad) that went on to become surgical residents, took 
on sub-interns, developed and taught a laparoscopic curriculum that continues to be 
utilized today and helped develop and teach the PRECEDE medical student surgical 
curriculum and the surgical resident minimally invasive curriculum having authored 8 
modules that have been used in Duke Universities surgical curriculum. In 2011, she 
received the Outstanding Teachers Award for the Surgical Clerkship. Dr. Steele is 
presently working on an educational study involving students and trainees, evaluating the 
importance of warm-up prior to going to the operating room to perform a surgical 
procedure. In addition to making a large contribution to teaching within the institution, 
she has accumulated an impressive amount of educational scholarship outside the 
institution. She is committed to the education of medical students and serves on the 
Association of Surgical Educations medical student education committee. She has 
authored numerous book chapters, been invited faculty to numerous SAGES national 
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courses and most recently was faculty at a laparoscopic suturing course at the annual 
ASMBS meeting, where she had the privilege of teaching surgeons from around the 
world.  
Inspiration to become a surgeon scientist 
Although, Dr. Steele very much enjoys her clinical work and teaching, she now 
understands that she cannot make scientific contributions unless she can devote her 
professional time towards developing a research career. This became abundantly clear 
three years ago when she received the KL2 award and more recently the Clinician 
Scientist Award in 2013. The KL2 has provided Dr. Steele with the academic basis of 
scientific and research knowledge, and allowed her to explore many of her unanswered 
questions about her patient population – namely morbidly obese surgical patients, the 
prevention and treatment of blood clot formation. As well, the academic environment at 
Johns Hopkins has inspired her to move from clinician to clinician researcher, actively 
seeking answers and explanations to the causes and consequences of blood clot formation 
in the obese surgical patient. Bariatric surgical patients present us with a uniquely 
valuable resource to determine many of our questions regarding DVT prophylaxis, 
prevention and treatment.  
Taken together, Dr. Steele’s ongoing clinical studies, education, and passion regarding 
bariatric research have motivated her aims for this thesis project. 
Opportunities 
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Enrollment in the PhD program has given her the opportunity to do much collaboration 
with accomplished researchers including Mechanisms of Sleep Apnea in Severe Obesity 
(R01 HL050381), Principle Investigator Alan Schwartz, M.D. and Improving Diabetes 
through Lifestyle and Surgery (IDeaLS) (R01 DK089557-01), Principal Investigator 
Jeanne Clark, M.D. As well, she is a co-investigator on numerous multidisciplinary 
projects investigating obesity related topics, involving investigators from psychiatry, 
obstetrics and gynecology, pulmonology, urology, gastroenterology, radiology and 
pediatrics.  Her overarching career goal is to use her training and experience in clinical 
research to earn a position as an independently funded clinical investigator with the 
intention of being a leader in obesity research and weight loss surgery. 
Final Thoughts 
On a personal note: Dr. Steele could not have completed this this work without the love, 
support and extreme patience from her amazing husband Greg Prokopowicz and their two 
sons Michael and Matthew.  
